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 PREFACE 
 
Europe is the oldest continent in the world, being a quarter of the entire 
population more than 60 years old. This “demographic explosion” makes important to 
identify factors (biological and not biological) involved in aging, with the main goal of 
increasing the number of elderly persons in good health. 
The present study is part of the Integrated European Project “GEHA - GEnetics of 
Healthy Aging” (Franceschi et al. 2007), whose aim is to identify genes involved in 
healthy aging and longevity, which allow individuals to survive to advanced age in good 
cognitive and physical conditions and in absence of the major age-related diseases. 
To achieve this aim, it was important to: (1) collect information on health status 
and DNA from 2192 long-lived sibpairs (90+) and an equal number of ethnically-
matched younger controls from the 11 European countries; (2) perform a genome-wide 
linkage scanning in all the sibpairs and a LD mapping (linkage disequilibrium) of the 
candidate chromosomal region; (3) analyse three chromosomal regions (region 
D4S1564 in chromosome 4, region 11.p15.5 in chromosome 11, APO-E in chromosome 
19), which were previously seen to be associated with longevity; (4) genotype all 
recruited subjects for APOE polymorphisms; (5) genotype all the recruited subjects for 
mtDNA haplogroups; (6) sequence a subset of the mtDNAs in order to evaluate the 
genetic and epigenetic variability. 
In this context, the purpose of the Project is to examine the association of 
haplogroups with healthy aging and to sequence the entire mitochondrial genome in 
order to study new mutations and polymorphisms related to aging. 
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Chapter 1 
 
INTRODUCTION 
 
1. The aging process and mortality deceleration 
Aging may be considered as the most common disease affecting inexorably 100% 
of the animal world and is the accumulation of changes in an organism over time. Aging 
can be defined as a multifactorial phenomenon characterized by a time-dependent 
decline in physiological function. The individual age can be defined with three 
parameters: chronological ageing, referring to how old a person is, is arguably the 
most straightforward definition of ageing and may be distinguished from "social 
ageing" (society's expectations of how people should act as they grow older) and 
"biological ageing" (an organism's physical state as it ages).  
Differences are sometimes made between populations of elderly people. Divisions 
are sometimes made between the young old (65–74), the middle old (75–84) and the 
oldest old (85+). However, problematic in this is that chronological age does not 
correlate perfectly with functional age, i.e. two people may be of the same chronologic 
age, but differ in their mental and physical capacities, so they have extremely different 
biological age.  
It is very difficult to define when ageing starts, because it is deeply influenced by 
culture, society, economic well-being and by the society self. Moreover, it is natural to 
associate aging with degenerative pathologies: some presents a mental decay, others 
only inferior articulation weakness or in particular one sensorial organ. From 
biomedical point of view, aging is a universal and progressive change which leads to a 
loss of individual capacity of adapting in the environment in which it lives. This event 
inexorably leads the organism to a major susceptibility condition against disease; 
consequently mortality arises in an age-dependent way. 
Senescence is the state or process of aging. In particular cellular senescence is a 
phenomenon where isolated cells demonstrate a limitated ability to divide in culture 
(discovered by Hayflick in 1961) while organismal senescence is the aging of organisms. 
This senescence is characterized by a declining ability to respond to stress, increasing 
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homeostatic imbalance and increased risk of disease. Today, it is still not discovered one 
single aging biomarker. In Humans, this phenomenon is characterized by an enormous 
heterogeneity which appear not only among different organisms, but also in the single 
organism: tissue age in different way, producing a proliferative mosaic (Franceschi et al., 
1999), where also single cells have different replicative potential. One example of 
cellular senescence has been attributed to the shortening, in vitro, of telomeres with 
each cell cycle in peripheral blood leucocyte and not in centenarians fibroblast; when 
telomeres become too short, the cells die. The length of telomeres is therefore the 
"molecular clock," predicted by Hayflick. 
From a demographic view, in the latest one hundred years, and in particular from 
the second half of XX century and in industrialized countries, a demographic transition 
has happened, characterized by  a drastic decrease of infant mortality and a rising of 
aging rate. 
In the world, Europe is the area with the highest aging rate: a quarter of the 
entire European population has more than 60 years of age and it is estimated that it 
could reach a third in the next 30 years. 
So, far from being fixed, the mortality of people over 80 years decrease 
dramatically since 1950, especially since 1970 in developed countries. The mortality 
curve was represented by Gompertz in 1825: it shows a semi-logarithmic scale in which 
death rate is in function with Age (years) and it explains why mortality rates increase 
exponentially with age (the Gompertz law) in many species, by taking into account the 
initial flaws (defects) in newly formed systems. He also suggested that it is a feature of 
all organisms but this could be true at his time, when people’s lifespan was 80 years 
maximum. The Gompertz–Makeham law of mortality describes the age dynamics of 
human mortality rather accurately in the age window from about 30 to 80 years of age. 
At more advanced ages, death rates do not increase as fast as predicted by this mortality 
law – a phenomenon known as the late-life mortality deceleration. Now people can 
reach the venerable age of 100 and “real” data appreciably differ from Gompertz curve 
(in blue in fig.1). Vaupel et al (1998) tested the hypothesis that mortality accelerates 
with age as reproduction declines, estimating age trajectories of death rates for Humans 
and other organisms. As Fig. 1.1 shows, death rates increase at a slowing rate after age 
80. A logistic curve (in blue), that fits the data well from age 80 to 105, indicates that 
death rates may reach a plateau. A quadratic curve (in green) fit to the data at ages 105+ 
suggests a decline in mortality after age 110. The red line is the aggregation of 14 
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countries (Japan and 13 Western European countries) with reliable data, over the period 
from 1950 to 1990 for ages 80 to 109 and to 1997 for ages 110 and over. 
(A) (B) 
Fig. 1.1:  (A)  Figure inspired by Gavrilov and Gavrilova. It represents the Gompetz law and the real data 
trend. After 90 years, the mortality rate decreases. (B)  Age trajectories of death rates from 80 to 122 
years for females. The logistic curve (in blue) fits the data well from age 80 to 105 and it indicates that 
death rates may reach a plateau. A quadratic curve (in green) fits  the data at ages 105+ suggesting a 
decline in mortality after age 110. The red line is the aggregation of 14 countries (Japan and 13 Western 
European countries) with reliable data, over the period from 1950 to 1990 for ages 80 to 109 and to 1997 
for ages 110 and over (Source: Vaupel et al. 1998) 
 
Mortality deceleration was observed not only in humans, but also in organisms, 
such as Ceratitis capitata (the Mediterranean fruit fly), Anastrepha ludens, Anastrepha 
obliqua, and Anastrepha serpentina (three other species of true fruit fly), 
Diachasmimorpha longiacaudtis (a parasitoid wasp), Drosophila melanogaster, 
Caenorhabditis elegans (a nematode worm), and Saccharomyces cerevisiae (baker’s 
yeast) (Vaupel et al., 1998). 
There is not still a clear explanation for this phenomenon, but this exponential 
rising of old persons could be attributable to changes at the individual level on the one 
hand and to changes in the composition of the surviving cohort on the other. In 2000, 69 
million people world wide were aged 80 or over. By 2050, the 80+ year-old people are 
projected to be more than 370 million, representing 4,4% of the entire population. 
Similarly, the number of nonagenarians will reach 63 million by 2050, and centenarians 
will reach 5.3 million. These improvements in life expectancy came as the consequence 
of rising standard quality of life, environment hygiene, alimentation (both quality and 
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total caloric introduction of food), public health interventions, and medical 
developments that reduced death from infectious diseases. 
The increase in life expectancy in developed countries leads to one hand  
extremely complicated demographic phenomenon, and on the other hand new problems 
regarding the allocation of resources for old age pensions and care for the elderly. In 
order to provide a suitable health care support, it is necessary a better comprehension 
of factors (biological and non-biological) involved in aging devoid of major diseases and 
disabilities, contributing to a much more well-being status. 
The aging phenomenon is very complicate and it requires an integrated approach, 
or rather to combine biological studies with social sciences, demographic, historic and 
anthropological studies (Franceschi et al., 2000a). Accordingly the term “successful 
aging” identifies a multidimensional phenomenon, encompassing the avoidance of 
disease and disability, the maintenance of high physical and cognitive function, and 
sustained engagement in social and productive activities. Successful ageing may be 
viewed an interdisciplinary concept, spanning both psychology and sociology, where it is 
seen as the transaction between society and individuals across the life span with specific 
focus on the later years of life (Fentleman et al. 1990) 
In this perspective, it is presumed that reaching an old age free from the most 
common pathologies is possible. Following studies have tried to separate the concept of 
“successful aging” from “pathological status” and “functional decline” (Rowe e Kahn, 
2004). Thus, aging can not be determined only by genetic control (30%) but also by 
environmental and social-sanitary factors (social problems, stress, poor-feeding, 
pathologies in general). All these factors may modify every individual vulnerability with 
a consequent loss of adaptability (Motta et al., 2005; Perls et al., 2002).  
Style of life seems to have an important role for aging as it is demonstrated by 
longitudinal studies; one of that was the European longitudinal study HALE (Knopps et 
al., 2004) conducted on subjects with a range age of 70-90 years, and a second study was 
conducted on subjects with a mean age of 80 years (Woo et al., 2002). The first has 
demonstrated that an optimal diet (Mediterranean diet) leads to a drastic decreasing of 
50% of mortality; the second that an intense physical activity and a major consumption 
of fish, associated with less cigarette and alcohol, dramatically reduce mortality. 
Day by day it has understood that “successful aging” studies could be the key to 
understand the difficult, and till now not completely clear, process of  senescence. Today 
we speak about longevity. 
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2. The extreme longevity 
Longevity is a multifactorial process in which genetic and environmental factors, 
as well epigenetic and stochastic element, seem to interact and each making variable 
contribution to the overall presentation of the phenotype (Candore et al., 2006).  
 
L = En + S + G + Ep  
(Longevity = Environment + Genetics + Epigenetics + Stochasticity) 
 
1) Environment: the environment represents about 20 to 30 percent of 
longevity, meaning non genetic survival attributes that are fixed for individuals by the 
time they are 30 years old (Vaupel et al., 1998). Among these non genetic fixed factors 
are healthy conditions early in life, socio-economic conditions in childhood, the socio-
economic position a person attained at about age 30, and physical environment 
(personality, intelligence, health behavior and everyday activities, mental and physical 
health), each contributing to attain longevity. Several studies in medicine and 
epidemiology, like Elo et al. (1992), and Evans et al. (2005), show that environmental 
quality is a very important factor affecting health and morbidity: air and water pollution, 
depletion of natural resources, are all capable of increasing human mortality. In today’s 
western world, many illnesses today emerge from poor eating habits, lack of exercise, 
poor sleeping habits, and bad habits such as excessive drinking, drugs and nicotine. 
Declining cigarette smoking as well as changes in diet habits may be important factors in 
rising life expectancy, at least in some countries. It has been widely reported that 
environment plays an important role during pregnancy and during the first year, 
because in this period neuron’s number and a lot of parameters are established. Barker’s 
(1992) “fetal-origins hypothesis” suggests that nourishment and infections in utero 
and during infancy program the development of risk factors for several important 
diseases of middle and old age.  Longevity may in part be determined by conditions in 
early childhood and perhaps before birth (Kanaka-Gantenbein, 2010). 
Another important trait is the psychological and dispositions towards life. A 
higher longevity makes people more sympathetic to future generations and/or their 
future selves. Therefore, if someone expects to live longer, they should be willing to 
invest more in environmental quality. Lower cognitive functioning was consistently 
associated with an increased mortality risk across a number of studies (Small and 
 9 
Backman, 1999). There is also some evidence that aspects of subjective positive and 
happiness are related to a longer life, while psychological distress and depression may 
increase the risk of death (Huppert and Whittington, 1995). 
2) Stochasticity: another aspect to be taken into account is the stochasticity, 
meaning the wide variation of life span of genetically identical organisms even if reared 
in a constant environment. Kirkwood (2005) has shown that an isogenic population of 
the nematode C.Elegans has a striking intrinsic variability of life span (from 8 to 32 days, 
depending also on the strain). The whole process depend on chance and these stochastic 
events are absolutely random. 
3) Genetic and epigenetic: studies on twins estimate that unexpectedly less than 
10 % of individual variation in life expectancy after 30 years of age, depend on early 
event (intrauterine life and infancy), while the 65 %  on late event, happened after 30 
years of age. Thus, the same studies on twins indicate that 25-30% of longevity 
variability depends on  genetic-epigenetic pool as quantitative multifactorial trait. 
Epigenetic refers to phenotypic changes caused by mechanisms that are 
unrelated to changes in the underlying DNA sequence, most notably chromatin 
remodeling driven by histone modifications, and DNA methylation. An increasing body 
of evidence supports a role for epigenetic changes in the etiology of aging and its 
associated disease sequelae (Silvia Gravina and Jan Vijg, 2010). While epigenetic changes 
are essential for development and differentiation, they can also arise later in life either 
by non-random mechanisms, such as responses to environmental change, or through 
stochastic errors in maintaining fixed patterns of DNA or histone modification. 
What is the theoric end of human life? A French woman has reached 122 years 
and surely it will not be an isolated case. The aging rate and the maximum life span are 
extremely variable, in fact genetic factors control long survival (90 years and more) 
explaining why nonagenarians and centenarians are numerous in the same family 
(cluster). Stocasticity seems to be important during the first years of life, while genetic 
gives its contribute after sixty years. 
Interestingly, the aspect of sex differences in longevity must be analyzed. 
Oksuzyan et al. (2008) examined sex differences in health and survival, with a focus on 
Nordic countries, finding that men are physically stronger with fewer disabilities, but 
have substantially higher mortality rate at all ages compared with women. It is clearly a 
male-female health-survival paradox. It is probably due to multiple causes that include 
fundamental biological differences (immune factors and responses, hormones, and 
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disease patterns), behavioural differences (for example risk-taking, reluctance to seek 
and comply with medical treatment) and a methodological bias (such as selective non-
participation and under-reporting of health problems, and delayed seeking of treatment 
by men) between sexes. 
In recent decades the research on aging has expanded quickly, probably as a 
consequence of the lengthening of the average human life span and the increasing 
percentage of elderly population. There is a huge number of hypothesis and theories, 
divided according to the basic idea of aging being a programmed process or not, as the 
table shows (Tab. 1.1). 
 
 
Tab. 1.1 Classification of the most important theories of ageing (Source: Weinert and Timiras, 
2003) 
 
3. The evolutionary theories 
Before the theory of evolution, the process of aging was conceived in the same way 
that all things deteriorate slowly over time. The first evolutionary theory by Charles 
Darwin was based on the concept that random and heritable variation of biological traits 
(caused by mutations) will lead to natural selection for preferential reproduction of 
those individuals who are particularly fit in a given environment. After the development 
of the theory of evolution, scientists began to wonder why evolution had produced such 
complex and well-adapted creatures that were so successful at surviving from 
conception through to adulthood, but which then fell into decay and died. August 
Weismann in 1891 developed the theory of programmed death which proposed that 
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aging evolved to the advantage of the species, not the individual, and that there just be 
an evolutionary advantage to having only a limited lifespan. 
But contemporary theories propose two models for how aging can evolve: one is 
the theory of mutation accumulation and the second is the antagonistic pleiotropy 
hypothesis. The mutation accumulation theory of aging was proposed by Medawar in 
1952 and considers aging as a bio product of natural selection. Aging in fact has no 
adaptive traits because natural selection does not occur in long lived animals and 
provides little additional contribution to offspring numbers. It means that old age is not 
under selective pressure per se. On the other hand the antagonistic pleiotropy theory 
proposed by Williams in 1957 says that some genes are beneficial at earlier ages but 
harmful at later ages (the genes with age related opposite effects are called pleiotropic 
genes).  
There were attempts to define better the antagonistic pleiotropy theory; the 
disposable soma theory proposed by Kirkwood and Holliday (2005) predict that aging 
occurs due to the accumulation of damage during life and that failures of defensive or 
repair mechanisms contribute to aging. It postulated a special class of gene mutations 
with antagonistic pleiotropic effects in which hypothetical mutations save energy for 
reproduction (positive effect) by partially disabling molecular proofreading and other 
accuracy promoting devices in somatic cells (negative effect). In other words, given 
finite resources, the more an animal expends on bodily maintenance, the less it can 
expend on reproduction, and vice versa. The distinction between somatic and 
reproductive tissues is therefore important because the reproductive cell lineage, or 
germ line, must be maintained at a level that preserves viability across the generations, 
whereas the soma needs only to support the survival of a single generation. According to 
Kirkwood aging is a sort of strategy prefixed by natural selection in order to preserve 
energy (Fig.1.2). Organisms’ life, who live in wild conditions (in a not protected 
environment), is drastically reduced by extrinsic phenomena (incidents, starvation, cold, 
predation, infection, and so on) and in consequence they die before aging. In a protected 
environment, organism can reproduce but it does not die, experiencing the aging 
process. In conclusion, senescence is not programmed because it hits only individuals 
who live long. 
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Fig. 1.2 In a not protected environment, organisms’ life is drastically reduced by extrinsic phenomena. In a 
protected environment organisms can experience aging. 
 
4. The network theory 
In 1989 Franceschi proposed a general theory of aging suggesting that this 
process is controlled by a network of cellular and molecular defence mechanisms 
(Franceschi, 1989). Among molecular and cellular defence network there are (Fig. 1.3): 
 DNA repair mechanisms 
 Antioxidant defence system, enzymatic or not 
 Production of heat shock protein (HSPs) 
 Activation of poly(ADP-ribose)polymerase (PARP) 
 Apoptosis, an ancestral process which permit to eliminate damaged cells, 
mutated, or transformed (Franceschi et al.,1995a). 
These mechanisms cope with such a variety of potentially harmful agents, such 
as internal or external stressors, dangerous for the maintenance of cell functional 
integrity, physical stressors (UV, gamma radiation, heat), chemical stressors (oxygen 
free radicals and reducing sugars), biological agents (Bacteria and viruses). 
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Fig. 1.3: The network of cellular and molecular system anti-aging (Original fugure modified by “Inflamm-aging. 
An evolutionary perspective on immunosenescence”, Franceschi et al., 2000) 
 
The aim of the network theory is to combine evolutionary theories of aging 
proposed by Kirkwood (1977) with molecular biology data. An alteration of this defence 
system leads to a homeostasis loss and in consequence to senescence determined by 
physiological modification. 
The way that every single mechanism contribute to network and how it is 
organized are still not clear, in particular in superior organisms. Some of the necessary 
functions involved in stressors defence were conserved during evolution, making an 
improvement and expansion of mechanisms, producing new and higher levels of 
organization (Franceschi et al., 2000b).  
 
5. The remodelling theory 
The necessity to conceptualize studies on human immunosenescence and the 
new model of healthy centenarians has lead to the elaboration of remodelling theory in 
aging (Franceschi et al. 1995, Franceschi and Cossarizza, 1995); the main question was 
to evaluate which was the contributor of the immune system to longevity. 
In this approach only centenarians in good health, without principal pathologies 
and physic and cognitive disability were considered as a model of successful aging and 
successful physiological immunosenescence. Healthy centenarians are quite rare, so the 
assessment of their health status is methodologically difficult. Franceschi et al. (2000a) 
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studied 382 centenarians and found that 22 % of them were in good health status and 
they were compared with healthy people of different ages obtaining that some immune 
responses were unexpectedly well conserved in centenarians and that immune 
responses were differently affected by the aging process. Immunosenescence could be 
the result of continuous remodelling or adaptation of the entire system to the 
deteriorative changes occurring over time. In consequence, healthy centenarians are 
those who have the capacity of adapting their body to damaging agents and to 
immunological stressors as well. From an immunological point of view, centenarians are 
not “the best” but the “best adapted” to environment. From an evolutionary point of 
view, we have to consider that the human immunological system were programmed to 
survive till reproductive age and then to reach senescence. 
The increasing percentage of 80-20 years people and the fact that environment 
conditions are in rapidly changing, in which the probability to encounter new antigens is 
relatively higher than last centuries, force the immune system to operate in new 
conditions, not planned by evolution and thus to modify itself in a still not clear way. 
 
6. The replicative senescence  
A telomere is a region of repetitive DNA at the end of a chromosome, which 
protects the end of the chromosome from deterioration, and of some non coding genes. 
In Humans, the repetitive sequence in telomeres is constituted by six nucleotides 
TTAGGG, repeated for a total length of 3-20 kb. There are also additional 100-300 kb 
between telomere and the rest of chromosome. 
Telomere length is maintained in immortal cells by the telomerase enzyme. In 
laboratory, mortal cell lines can be immortalized by the activation of their telomerase 
gene, present in all cells but active in few cell types. What is the connection between 
telomere and aging process? Telomeres can be defined “molecular clock”: as a 
consequence of cellular replication, their length reduce dramatically till when they can 
not perform their protective function for chromosomes. Cells can not reproduce 
correctly because the telomerase enzyme, an inverse transcriptase, is not able to 
regenerate the telomere till the end and its structure reduces every time cell divides 
itself. It means that each DNA replication leads to an important loss of genetic 
information, causing cell death.  
To keep the same length of telomeres means confer eternity to cells. Joeng at al. 
(2004) conducted a study with two groups of worms belonging to C.Elegans and with 
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two different telomeric length. The research has demonstrated that the group with 
longer telomeres lived with a life expectancy more than 20%. But keeping the same 
telomere length means produce abnormal cells, leading to cancer. 
 
7. MtDNA damage and the mitochondrial theory of aging 
Among all aging theories, the free radical theory is one of the most gained, 
proposed for the first time by Harman in 1957. It explains how aging is strictly 
associated with high level of free radicals, which are chemical species with a free 
electron in their external orbital and, for this reason, they are extremely reactive and 
instable. Different conditions related to oxidative stress could interact with aging: an 
increasing speed of producing reactive oxygen species (ROS), a decline of antioxidant 
defense system and a low efficiency in repairing damaged molecules. 
Although the available evidence strongly suggests that mitochondria play a role in 
this process, there appears to be a wide range of opinions as to the exact nature of the 
involvement of mitochondria in aging. The mitochondrial theory, proposed by Miquel 
in 1980, is considered an extension of the free radical theory.  As it is commonly known, 
nDNA is protected by histone proteins and various repair enzymes, which minimizes 
damage to nDNA from free radicals/oxidants. mtDNA has no histone protection or 
significant enzymes repair systems to offer free radical protection. Therefore, mtDNA is 
far more subject to free radical damage than nDNA. The commonest form of free radical 
damage to mtDNA molecules is the production of 80HdG, an oxidized guanine base. Even 
in young (3 month old) rats, the level of 80HdG is already 16 times higher in mtDNA 
than nDNA (Richter et al. 1995). As mtDNA damage accumulates over the lifetime of an 
individual, the functionality of the ETC enzyme complexes that produce ATP, and are 
encoded for (in part) by mtDNA, decreases dramatically and gradually produces a 
cellular energy crisis. The system is not capable to keep the equilibrium and it leads to 
cellular aging first, organism aging then. The dramatic mutation increasing causes 
defective structures formation in the respiratory chain and in consequence a defective 
functionality which creates a rising in ROS production. The mitochondrial theory of 
aging is based around the idea of a vicious cycle, in which somatic mutation of mtDNA 
engenders respiratory chain dysfunction, enhancing the production of DNA-damaging 
oxygen radicals. 
The mtDNA has a very high mutation rate due to its chronic exposure to mitochondrial 
ROS. When a new mtDNA mutation arises in a cell, a mixed intracellular population of 
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mtDNAs is generated (wild-type and mutated mtDNAS), a state known as eteroplasmy. 
The mutant and normal molecules are randomly distributed into the daughter cells and 
as a consequence of this replicative segregation, the proportion of mutant and normal 
mtDNAs can drift toward an homoplasmic condition (all mutant or all wild type).  
Furthermore, it has seen that in order to compensate the energy deficiency, mtDNAs 
have been found to be preferentially, clonally, amplified within cells (Coskun et al. 
2003).  
Therefore, cells with defective mitochondria are preferentially stimulated to replicate 
their mitochondria and mtDNAs, the mitochondrial energetic output declines, ROS 
production increases, and the propensity for apoptosis increases. Thus the accumulation 
of mutant mtDNA creates the aging clock (Fig. 1.4). 
 
 
Fig. 1.4: Aging model. The dot line shows the minimum number of cells for the tissue to function normally. 
In black are died cells in a mitochondrial-mediate process. In green cells with optimal function. 
 
 
8. The genetics of Human Longevity 
A recent research conducted in Boston has revealed genetic profile of persons 
predispose to reach 100 years or more even if till now, a unique variant related to 
longevity has not been discovered but Family studies of exceptional longevity can 
potentially identify genetic and other factors contributing to long life and healthy aging. 
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The two main concepts arisen from recent studies on the genetics of human 
longevity are the following: 
1) Human longevity clusters in families 
2) Long-living siblings are likely enriched in longevity genes 
Sebastiani (Science, 2010) has analyzed genetic profiles of centenarians and she 
has discovered 19 variants shared by people with similar characteristic, i.e. survival age, 
delay in developing Alzheimer disease, cardiovascular diseases and hypertension.  
Therefore, natural selection does not select aging genes but aging is the result of 
pleiotropic effect of genes that operate in other areas. It is very interested that 
numerous studies have evidenced how life span is due to ipomorphic or nullomorphic 
mutations; the “wild-type” genes seem to codify processes with negative effect on 
longevity, thus defined “gerontogenes”. The overwhelming majority of gerontogenes 
mutations increase the capacity of coping with stress and specifically with oxidative 
stress and caloric restriction (Christensen et al., 2006). 
So, longevity is under genetic control (nuclear and mitochondrial), suggesting a 
substantial hereditability of healthy aging, in a complex interaction with a great variety 
of environmental factors (life style, nutrition and culture as well): 
 
1. Studies on evolutionistic biology indicate that life span is species-specific and 
has a strong genetic basis. There are also mutations in specific genes which are 
able to increase life span, being involved in some principle metabolic ways 
(resistance to oxidative stress, insulin way, energetic metabolism). We talk about 
“major genes”, genes conserved during the evolution and that control life span 
(Tatar et al., 2003). 
1. Studies on long-lived families and sibpairs have evidenced that the survival 
rates of siblings of centenarians and siblings of a similar birth cohort, who died in 
their early seventies, had a four times greater chance of surviving to their early 
nineties (Perls et al., 1998). The same group in 2002 discovered that males 
sibling of centenarians, comparing with a cohort of 1900, had a seventeen times 
greater change to reach 100 years, while sisters had a probability eight times 
greater (Perls et al., 2002).  
2. A great number of association studies have been conducted on candidate genes 
of centenarians. Some genes like ApoE, ApoB, ApoA1, H-Ras, IL-6, IL-10, IFNγ, 
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PON1, Tyrosine Hydroxylase, INS, IGF2, IGF-1R, Glutathione transferase (GSTT1) 
SIRT3 seem to play an important role in healthy aging and longevity (De 
Benedictis et al., 2001; Bonafè et al., 2003; Rose et al., 2003, Bellizzi et al. 2005, 
Glatt et al. 2007) (Fig. 1.5).  In particular, studies on -174 C/G polymorphism of 
IL-6 promoter in male centenarians has revealed a significant increasing of 
person carrying mutation CG or CC (Franceschi et al., 2000; Bonafè et al., 2001). 
Probably the presence of this mutation could be surviving favorable in the last 
part of life, since significative differences among classes of inferior ages have not 
been observed. 
Moreover, a relationship between plasmatic concentration of IL-6 and 
susceptibility to principal age-related pathologies, such as Alzheimer disease 
(Franceschi et al., 2001), diabetes (Fernandez-Real et al., 2000), osteoporosis 
(Ferrari et al., 2001; McLean, 2009) and cardiovascular pathologies (Basso et al., 
2002) has come out. 
Another study was conducted on PON1 gene (Paraoxonase1), a major anti-
atherosclerotic component of high-density lipoprotein (HDL), responsible for 
hydrolyising organophosphate pesticides and nerve gasses. Studies on two 
polymorphisms of PON1 gene (one in codon 55 and one in 192) evidenced that allele 
B frequency in codon 192 is higher in centenarians than in controls and that B+ 
subjects are carrying the M allele in codon 55 (Bonafè et al., 2003; Rea et al., 2004).   
It has also been evidenced that the presence of allelic variant ε4 of ApoE gene 
(ApoE4) plays a negative role in reaching longevity: biomedical researchers have 
demonstrated how ε4 frequency in Italian and French centenarians is 
significantly lower than in younger controls. Moreover, it has been noticed that 
subjects affected by Alzheimer disease have a higher frequencies of ε4 allele, 
demonstrating that this allelic variant represents a high risk for the pathology 
(Carrieri et al., 2001; Blanchè et al., 2001).  
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Fig. 1.5: Candidate genes in association studies related to longevity (from “The genetics of human 
longevity”, Capri et al., 2006) 
 
3. Studies on chromosome 4: a genome wide scan, with “Affected Sibpairs 
Analysis” (ASP), has been performed on 308 individuals belonging to 137 
sibships demonstrating exceptional longevity and a significantly statistical 
association (P=0.044) between longevity and the genetic marker D4S1564 
microsatellite on chromosome 4, that is underrepresented among long-living 
individuals when compared with younger controls (Puca et al., 2001). In order to 
identify gene variants affecting life span, the same group performed an 
haplotype-based fine-mapping study of the fragment. What they found was a 
haplotype marker within microsomal transfer protein (MTP) as a modifier of 
human life span. Nebel et al. (2005) performed a study on 1039 unrelated 
subjects of German ancestry with a mean age of 98 years, 373 of them were 
centenarians. They found that the MTP haplotype was over-represented only in 
controls, in comparison with studies reported in the literature. 
Beekman et al. (2006) investigated the linkage to 4q25 in 164 nonagenarian 
sibships of Leiden Longevity Study (LLS), comparing the MTP -493G/T and Q95H 
allele and haplotype frequencies in the Leiden Longevity Study (379 
nonagenarians, 525 of their offspring, and 251 partners of their offspring) and in 
the Leiden 85+ Study (655 octogenarians and 244 young controls). This study 
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population was followed for at least 7 years, providing the opportunity to 
perform also prospective analyses using the longitudinal data. They found neither 
evidence for linkage at 4q25 nor association of the MTP locus with longevity in 
nonagenarian individuals. After a meta-analysis of all previous studies the 
authors concluded that the association in U.S. Caucasians may have its source in 
admixture of the U.S. control population rather than in the genetic effect of the 
locus on exceptional longevity. 
4. Studies on chromosome 11: it is becoming more and more evident that 
chromosome 11 could be involved in human longevity because several studies 
have shown a large number of variants in such a region. The 11p15.5 
chromosomal region, about 2.8 Mb, is of particular interest as it encloses five 
genes (HRAS1, SIRT3, TH, INS and IGF2) and its variability of which was found to 
be associated with life extension by association studies. These genes are 
homologous of genes that modulate lifespan in model organisms (De Benedictis 
et al., 1998; De Luca et a., 2002; Bonafè et al. 2002, Rose et al., 2003; De Rango et 
al., 2008). A recent study was perfomed by Lescai et al. (2009) who scanned the 
area in four European sample groups for a total of 1321 centenarians and 1140 
younger subjects, matched for ethnicity and geographical origin, with a set of 239 
SNPs. They didn’t confirm the earlier findings of the literature because no 
significant results (P<0.05) have been found on the earlier associated loci (ie, TH, 
IGF2, INS and HRAS1). They performed a meta-analysis on the SIRT3 SNP data 
and the other 229 markers including 2461 samples. For SIRT3 no positive 
association was found except for one SNP having a significant effect (rs939915); 
for the other 229 markers, six SNPs have been found significant for the frequent 
genotype (rs4073591, DEAF1-rs4073590, KRTAP5-6-rs11040489, rs4930001, 
TSPAN32-rs800140 and rs16928120).  
5. Studies on European centenarians suggest an association between hereditable 
variants of mitochondrial DNA (mtDNA) and longevity. In particular the group 
leaded by De Benedictis (De Benedictis et al., 1999) collected and analysed 
individuals selected for successful aging and longevity (212 subjects older than 
100 years and in good clinical condition) and a sample of 275 younger 
individuals (median age 38 years) carefully matched as to sex and geographic 
origin (northern and southern Italy). They carried out that mtDNA haplogroup 
frequency distribution was different between centenarians and younger 
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individuals (P=0.017); and that the frequency of the J haplogroup was notably 
higher in centenarians than in younger individuals (P=0.0052). Further data 
showed that this distribution is population-specific, being also present in long-
lived subjects from Ireland (Ross et al., 2001) and from Finland (Niemi et al., 
2003), but not in subjects coming from southern Italy (Dato et al., 2004). 
Morever, a C150T mutation in mtDNA is much more frequent in centenarians 
than in younger subjects. This mutation is so important because it causes a 
remodelling of the replication origin at position 151, instead of 149 and can be 
inherited (as polymorphism) or acquired during life (mutation) (Rose et al, 
2007). 
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Chapter 2 
 
THE MITOCHONDRIAL GENOME 
 
1. Mitochondrial genetics 
Mitochondria are semi-autonomously functioning organelles, harbouring some 
life important cellular process, like apoptosis, regulation of cell cycle, lipidic metabolism, 
the citric acid cycle, the respiratory chain and the oxidative phosphorylation (OXPHOS), 
the last one generates approximately 90% of cellular adenosine triphosphate (ATP) 
(Wallace, 1997). 
Mitochondria are involved in aging process and, as nucleous, contain  a resident 
genome having unique genetic features, in fact it is independently replicated, translated 
and transcribed, is maternally inherited, because the cytoplasmic location of 
mitochondria, does not recombine and undergoes replicative segregation during both 
mitosis and meiosis (Anderson et al, 1981; Taanman, 1999). MtDNA comprise 0,1-1.0% 
of the total DNA in most mammalian cells, each organelle contains 2-10 copies of mtDNA 
molecules and each cell contain several mitochondria, so each human cell contains more 
than 1000 copies of mtDNA (Penta et al, 2001).  
Another characteristic is that the human mtDNA is a supercoiled, double-
stranded circular molecule of 16,569 base pairs (bp) composed of a control region or D-
loop (displacement loop) and a coding region. Introns and intergenic sequences are 
absent so genes overlap. MtDNA contains 37 genes coding for 13 polypeptides of the 
mitochondrial electron respiratory chain, 22 tRNAs and 2 rRNAs.  
The mitochondrial proteome consists of 1500 polypeptides, whose only 13 
codified directly by mtDNA, and in particular by mitochondrial ribosome or 
mitoribosome.  
The 13 mtDNA-encoded polypeptide genes are translated on mitochondrial 
ribosomes and all are structural subunits of OXPHOS enzyme complexes. These include 
7 (ND1, 2, 3, 4L, 4, 5, 6) of the 46 polypeptides of complex I (NADH dehydrogenase), one 
(cytochrome b, cytb) of the 11 polypeptides of complex III (bc1 complex), 3 (COI, II, III) 
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of the 13 polypeptides of complex IV (cytochrome c oxidase), and 2 (ATP 6 and 8) of the 
16 proteins of complex V (ATP 
synthetase). The nDNA codes for all other mitochondrial proteins including all four 
subunits of complex II (succinate dehydrogenase), the mitochondrial DNA polymerase γ 
(POLG) subunits, the mitochondrial RNA polymerase components, the mitochondrial 
transcription factor (mtTFA), the mitochondrial ribosomal proteins and elongation 
factors, and the mitochondrial metabolic enzymes. These factors are recognized thanks 
to a leader sequence in the N-term and then transported in the mitochondrion. 
MtDNA undergoes replication utilizing a different origin for each of the two DNA 
strands, the purine abundant heavy strand (H-strand), and the pyrimidine abundant 
light strand (L-strand). In addition to its mRNA, rRNA, and tRNA genes, the mtDNA 
comprises  a 1,121-np control region (CR), also called displacement loop (D-loop, nt 
16024-576) (Taanman, 1999). This CR includes the L- and H-strand promoters (PL and 
PH); their mitochondrial transcription factor A (mtTFA) binding sites; the downstream 
conserved sequence blocks (CSB) I, II, and III; and the origins of H-strand replication 
(OH1 and OH2) (Shadel and Clayton, 1997) (Fig. 2.1). 
 
 
Unlike nuclear DNA, mtDNA may replicate more than once during each cell cycle, 
or not at all, and may undergo replication in non-dividing cells. 
Fig. 2.1: Scheme of the mitochondrial DNA molecole organization. ND1, ND2, ND3, ND4, ND4L, ND5, ND6 
are subunits of complex I; COI, COII, COIII are subunits of complex IV; cyt b is the complex III; genes 
codifying tRNAs are defyined with a single letter of the corrispondine amminoacid. 
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The human mtDNAs are strictly maternally inherited, thus the offspring mtDNA is 
identical to maternal mtDNA (except some mutations). When a mutation arises in an 
mtDNA, it creates a mixed population of normal and mutant type of mtDNAs, a state 
known as heteroplasmy. When a heteroplasmic cell divides, the two types of mtDNAs 
are randomly distributed into the daughter cells, which drifts toward either pure mutant 
or wild type. Over time, this replicative segregation results in segregation of the mutant 
mtDNAs into pure mutant or into normal population, this event is called homoplasmy 
(Wallace, 2007). 
However, there are highly conserved regions, while other regions show a very high 
variability. 
The overall mutation rate is ten to twenty times higher than the nuclear genome 
and most of the replacements that have been found in mitochondrial DNA are point 
mutations, with a strong preponderance of transitions (substitutions purine → purine or 
pirimidine → pirimidine) respect to transvertions (sostitutions purine → pirimidine or 
vice versa).  
It has a very high mutation rate, due to the lack of histones and to an inefficient 
repair system. Moreover mtDNA is located in the mitochondrial matrix, near the 
mitochondrial respiratory chain, that is a potent source of DNA damaging free radicals. 
Particularly, the 1121 nucleotides of D-loop region, are the most sensitive to 
mutagenesis (Chinnery et al, 1999). In addition, mtDNA has a high mutation fixation 
rate, which explains the high level of mtDNA substitutions. 
As a direct consequence of these mtDNA features, there are two levels of mtDNA 
variability: an hereditary or inter-individual variability, and a somatic or intra-individual 
variability. 
Because of strict maternal inheritance, mtDNAs can only evolve by the sequential 
accumulation of mutations along radiating maternal lineages and the number of 
mutation, that differentiate the mtDNA of an individual from that of his ancestor, can be 
used as a molecular clock, providing a useful and thorny tool to the phylogenetic 
reconstruction. 
This means that the human mtDNA is a molecular archive of the history and 
migration of women who have passed on to subsequent generations. If a mtDNA 
mutation arises that is beneficial in a particular environment, it and its descendants will 
increase in frequency in that environment. Thus, different subsets of the variation in 
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mtDNA tend to be confined to different regions and different human populations 
(Torroni, 2006). 
 
2. The D-loop 
The mtDNA comprises  a 1,121-np control region (CR), also called displacement 
loop (D-loop, nt 16024-576) (Taanman, 1999). This CR includes the L- and H-strand 
promoters (PL and PH); their mitochondrial transcription factor A (mtTFA) binding sites; 
the downstream conserved sequence blocks (CSB) I, II, and III; and the origins of H-
strand replication (OH1 and OH2) (Shadel and Clayton, 1997) (Fig. 2.2). In this particular 
trait three hypervariable sequences are present, called HVSI, HVSII and HVSIII, 
characterized by a high level of mutation, higher than mtDNA variability, showing a high 
number of hotspot (Malyarchuk and Rogozin, 2004).  
 
 
 
Fig. 2.2: Schematic representation of the D-loop region. HV1 and HV2 are 
hypervariable regions, OH is the origino f replication of the heavy chain and P are 
promoters of transcription. 
 
Particularly, the 1121 nucleotides of D-loop region, are the most sensitive to 
mutagenesis (Chinnery et al, 1999). In addition, mtDNA has a high mutation fixation 
rate, and the high level of mtDNA substitutions and their relative stability make the d-
loop the ideal candidate for the identification and classification of mitochondrial 
haplogroups (Kivisild et al, 2005; Torroni et al, 2006). 
 
3. Using of mitochondrial DNA in a population’s study   
The uniparental inheritance is one of the greatest advantages of this marker 
because it allows us to trace the ancestral information in the DNA of a population based 
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solely on the maternal contribution and eliminating the effects of recombination, which 
characterize the nuclear DNA. The phylogenetic trees constructed on the casis of 
mitochondrial DNA data can therefore be interpreted as genealogies that trace the 
history of a species and/or a population by female lineage. 
The first completely sequenced mitochondrial DNA was obtained in 1981 by 
Anderson and still we use it as a reference sequence (Cambridge Reference Sequence, 
CRS; Anderson et al., 1981; subsequently recise and corrected by Andrews et al., 1999).  
The analysis of mitochondrial DNA variability in human populations is expressed 
at three levels: 
• Analysis of D-loop sequenze; 
• Analysis of restriction sites polymorphisms (RFLPs) in the coding region; 
• Sequencing of the entire genome. 
 
4. MtDNA inherited variability: the haplogroups 
Testing mutations of the coding region, it is possible to attribute to individuals or 
people the belonging to specific haplogroups, i.e. monophyletic lines defined by the 
presence or absence of restriction sites in specific locations of the genome. The members 
of a haplogroup are descended from a single common female ancestor who first had this 
particular set of polymorphisms. Haplogroups can be thought as the arms of the family 
tree that correspond to various human migrations made by people during the expansion 
in the world. 
The mitochondrial genome inherited variability has been studied for many years in 
relation to human history, on the assumption that the polymorphic inherited variants 
were neutral from the  selection point of view and the populationistic arrangement of 
human mitochondrial genomes derived solely from the phenomena drift. And now it is 
established that the polymorphic variants of the mtDNA, that is mitochondrial 
haplogroups, are not neutral and therefore mitochondrial types have different 
efficiencies on different functional basic characters. In particular it was noted that there 
is a correlation between haplogroups and diseases, haplogroups and longevity. 
To perform a detailed and thorough study, which can provide not only the 
variability of the oldest but also the most recent, it is necessary to dissect haplogroups in 
subhaplogroups, i.e. smaller phylogenetic entities. 
All the information necessary to the reconstruction of phylogenetic trees, today in 
our possession, were found by sequencing a large number of samples; this analysis has 
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gone through a number of technological and methodological stages and is now in the era 
of complete sequence. 
Even during the nineties emerged a defined phylogenetic picture of the mtDNA 
thanks to the mtDNA digestion with specific restriction enzymes and the study of the 
length of the fragments obtained after enzymatic cleavage (restriction fragment length 
polymorphism-enzyme, RFLP). 
This method was applied for the first time by Wallace revealing that the mtDNAs 
can be classified into small monophyletic lines, i.e. haplogroups. More recent studies 
have been conducted by Torroni (Torroni et al. 1994) whose studies on  175 European 
American individuals mtDNAs revealed 117 haplotypes (different sequences). More 
related haplotypes were grouped into four haplogroups, referred to by capital letters (H, 
I, J, K). 
Summarizing the data obtained from restriction, the main RFLP markers that 
define the major haplogroups observed in Europe are the following:
 
• Haplogroup J: presence of NlaIII site at position 4216, presence of DdeI 
site at position 10394 and absence of BstI and HinfI site, respectively at positions 
13704 and 16065. 
• Haplogroup H: absence of AluI site at position 7025, absence of DdeI site 
at  position 10394 and absence of MseI site at position 14766. 
•  Haplogroup I: absence of DdeI site at position 1715, absence of HaeII site 
at  position 4529, simultaneous presence of AvaII site at position 8249 and 
absence of  HaeIII site at 8250, presence of AluI site at 10032, presence of DdeI 
site at 10394, simultaneous presence of BamHI/MboI sites at position 16389 and 
absence of AvaII site at position 16390. 
•  Haplogroup K: simultaneous presence of HaeII site at 9052 and HhaI at 
9053, presence of DdeI site at position 10394, presence of HinfI site at position 
12308. 
 
The RFLP analysis of 49 Finns, 37 Swedes and 48 Tuscans mtDNAs has revealed 
the presence of additional European haplogroups that have been called T, U, V, W and X 
(Torroni et al. 1996): 
• Haplogroup T: presence of NlaIII site at position 4216, presence of BfaI 
site at position 4917, absence of DdeI site at 10394, simultaneous presence of 
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BamHI  site at 13366, MboI at 13367 and absence of AvaII site at 13367, MspI at 
15925 and presence of AluI site at 15606. 
• Haplogroup U: absence of DdeI site at position 10394, presence of HinfI 
at position 12308. 
•  Haplogroup V: absence of NlaIII site at position 4577, DdeI at 10394, 
MseI at 14766. 
•  Haplogroup W: simultaneous presence of AvaII site at position 8249 and 
absence of HaeIII at  8250 and 8994, DdeI at 10394. 
•  Haplogroup X: absence of DdeI site at 1715 e 10394, presence of AccI 
site at  position 14465. 
 
So the nine haplogroups listed above, along with a few representatives L African 
haplogroup and M Asian haplogroup, collect almost all of the variation of mtDNA in 
Europe. 
Until recently three African haplogroups (L1, L2, L3), seven Asian (A, B, C, D, E, F, 
G) and nine in Europe (H, T, U, V, W, X, J, I, K) (Torroni et al, 1996) were identified, but 
now great strides are made in the phylogenetic analysis of mitochondrial haplogroups 
whose studies have provided a variation of the internal monophyletic haplogroups by 
dividing them into smaller subsets called subhaplogroups (Kivisild et al. 1999, 
Macaulay et al, 1999, Torroni et al. 2001). 
The latest studies are examples of the ability of genetics to make inferences about 
the origin of humans and studies of evolutionary biology. These analysis show us that 
the data provided by mtDNA can be used not only to evaluate models based on direct 
inquiry of ancient material offered by other disciplines, but also to identify relationships 
previously never assumed among very different populations and different geographical 
areas. Thus, human genetics can now directly promote the development of new areas of 
research in paleontological, archaeological, linguistic and historical areas, not to 
mention the important discoveries in medicine, which led to relate the mitochondrion 
and its functions to multiple diseases and disorders. 
Alongside the increased phylogenetic definition, even the nomenclature of the 
various haplogroups was amended and supplemented: haplogroup R0 replaced the pre-
HV, pre-V replaced the HV0  and HV0a gathers everything that is not V, and all that is in 
HV0 branch (Torroni et al, 2006). 
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5. The phylogenetic trees 
MtDNA variations studies in human populations have identified peculiar 
mutations that are neutral or near neutral, avoid elimination by selection and may thus 
become prevalent through genetic drift. 
Hence, mutations which occurred tens thousands of years ago will nowadays be 
present in high frequency, population and continent specific mtDNA polymorphisms, 
creating groups of related mtDNA haplotypes, or haplogroups sharing a specific set of 
stable polymorphic restriction sites (Torroni and Wallace, 1994; Wallace 1995; Wallace, 
1994). The classification of mtDNA haplogroups is based on information gained from 
RFLP analysis of the coding region and from the nucleotide sequence of the 
hypervariable segments I (HVSI) in the control region (Torroni et al., 1996).  
In all the studies and construction of phylogenetic trees it is considered a mutation 
all the differences between the sequence to be analyzed and the sequence of Cambridge, 
and thanks to these mutations it is possible to identify the haplogroup and its subclass. 
Haplogroups are coded with capital letters and subclusters with a running number 
(Ballinger et al., 1992; Torroni et al., 1996). 
According to the most recent classification, the phylogenetic tree of mitochondrial 
DNA originated in Africa about 150-200 thousand years ago (Fig. 2.3); African 
haplogroups are the oldest and fall into four main haplogroups: L0 (the oldest), L1, L2 and 
L3 (the younger). L0, L1 and L2 represent about 76% of all mtDNA sub-Saharan Africa and 
are defined by the HpaII restriction site in position 3592. All non-Africans mtDNAs are 
descended from the branch L3 and they are divided into the superfamilies M and N about 
65,000 years ago.
 
 
Fig. 2.3: Representation of the most important haplogroups. It is noticed the diramation of European 
haplogroups M and N from L3.  
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Haplogroups H, I, J, N1b, T, U, V, W are characteristic of  populations of European 
descent, while macrohaplogroups A, B, C, D are present in the New World and Asia; G, Y, 
and Z are mainly present in Siberia (Mishmar et al., 2003) and the haplogroup X present 
with low frequency in northern Africa, western and central Asia, Europe and North 
America (Reidla et al, 2003). 
The eight most common European haplogroups (H, U - which also includes K - J, T, 
V, X, I, W) all originate from the branch N. In Asia there is a multitude of different 
haplogroups, which includes more than thirty subdivisions, most of which belong to 
class M. N originated from haplogroups A, B and F while C, D and G separated from M 
haplogroup (Fig. 2.4). Of all these haplogroups, A, C and D were the first to overcome the 
Bering Strait about 20-30 thousand years ago, followed by haplogroup X 15,000 years 
ago and B 14,000 years ago. 
 
 
 
Fig. 2.4: Diagram outlining the migratory history of female mtDNA haplogroups. All mtDNAs arose in Africa 
with the first L0 branch, followed by lineages L1, L2 and L3. In the North L3 gave origine to M and N, which 
succeeded in leaving Africa and colonizing Eurasia. In Europe, N gave rise to the H, I, J, Uk, T, U, V,W, and X 
haplogroups. In Asia, M and N gave rise to a diverse range of mtDNA lineages including A, B, and F from N 
and C, D, and G from M.  
 
Also today it was recognized that H and V, as well as J and T, form lines sisters 
(Umetsu et al., 2005) and K is a subgroup dell'aplogruppo U (UK). 
 
6. Geographic selection theory 
The geographic selection theory is the most recent theory that seeks to explain the 
origin of the various polymorphisms and their distribution;  it hypothesizes that the 
polymorphisms, and therefore the protein variants, have been selected by climate 
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adaptation (Mishmar et al., 2003) and confer a genetic advantage for survival. In fact, in 
the case of efficient respiratory chain, most of the proton gradient developed by the 
various mitochondrial complexes is converted in ATP, whereas in the case that some 
mutation makes this process less effective, the proton gradient is dissipated, producing 
heat. Such mutations would be a selective advantage for populations living in cold 
climate regions (Wallace, 2005). 
Other researchers (Kivisild et al., 2006) assume that if a polymorphism has an 
adaptive function, then it must be placed in a more ancient tree of mtDNA. On the 
contrary an excess of non synonymous mutations is characteristic of a younger line of 
the phylogenetic tree. 
Studies about proteins encoded by mitochondrial DNA have shown, in favor of this 
thesis, that the amino acid sequence of the ATP6 gene is highly variable in the Arctic and 
it is highly conserved in the tropics and temperate zones; cytb is hypervariable and 
conserved in temperate in the tropics and the Arctic; COI is variable in tropical while it is 
kept in temperate zones and in the Arctic (Wallace, 2005; Raule et al, 2007). 
These polymorphisms are therefore widely used to identify the race an individual 
belong and with the maternity test in forensic medicine, thanks to the unique features of 
mitochondrial DNA: maternal transmission, a high number of copies per cell, high- 
mutation and the absence of recombination (Yuasa and Umetsu, 2005). 
 
7. The importance of “Mitochondrial Eve” 
A comparison of mitochondrial DNA belonging to human races of different 
ethnicities and regions suggests that these DNA sequences have evolved molecularly 
from the sequence of a common ancestor. On the assumption that an individual inherits 
mitochondria only from his mother, this finding implies that all human beings have a 
female descent deriving from a female that researchers have named Mitochondrial Eve. 
Based on the molecular clock technique, which correlates over time with genetic 
drift observed, it is believed that Eve has lived about 150,000 years ago. Although the 
name suggests the biblical Eve, the mitochondrial Eve was not the only female of her 
time in fact it is assumed that there were more than 20,000 individuals of the species of 
Eve. Only Eva gave rise to a single unbroken line of daughters that persists today. Thus 
considering how many and which mutations characterize an individual, it can be traced 
back to the genetic history of her female ancestors: the number of mutations separating 
the two individuals is indicative of the temporal distance between them and the 
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common ancestor, while the analysis of haplogroups allows us to reconstruct 
displacements of ancient men, or better women, across continents and regions of the 
world.
 
The phylogeny suggests that the first woman lived in Africa and that living beings, 
whose mitochondrial lineages branched first, are those of indigenous Africans. All other 
indigenous peoples of other continents have branched from the African. 
All descended from Africans, some of them migrated out of Africa to populate the 
rest of the world. Because the mitochondrial Eve represents the root of the 
mitochondrial family tree, she must have lived in Africa before the exodus. Both 
archaeological discoveries, and anthropological examinations on the skull, as well the 
latest information generated by DNA research, confirms the theory of “Out of Africa”. 
Obviously, the mutations accumulated in hundreds of thousands of years, represent the 
key to the reconstruction of our genetic history and the identification of mitochondrial 
lineages. 
From the historical point of view the genetic data suggest that modern man's 
passage from East Africa to Asia probably occurred in two ways. One route took him to 
India and South-east Asia and from there further splits:  to south, ie Australia, and to 
north, ie China and Japan. 
The northern route took him through the Middle East, Persia, Central Asia and 
from there expanded in several directions: towards west (Europe) and to the east and 
north-east (Siberia and America, no later than 15,000 years ago, through Beringia, strip 
of land covering the present Bering Strait).  
Population growth was a bit slow, also affected by the alternation of more or less 
favorable climatic junctures. The end of the last glacial period, about 14,000 years ago, 
was followed by a period of climatic stability. From 13 to 10,000 years ago in various 
parts of the world agriculture and pastoralism began to grow, providing significant new 
sources of food to groups of men devoted to hunting and gathering wild fruits. The 
emergence of agriculture involved a considerable development of new tools, the 
emergence of a new era in human history, the Neolithic Age. 
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8. Correlation between haplogroups and longevity, haplogroups and 
pathologies  
The analysis of mtDNA haplogroups is currently providing new insights into the 
role of mtDNA-inherited variability in several complex traits like aging and 
neurodegenerative disease. It was observed that in Italian centenarians mtDNA 
haplogroup J was overexpressed (De Benedictis et al., 1999), suggesting a protective role 
for this mtDNA variant against aging and this observation was confirmed in a study on 
Finnish (Niemi et al., 2003). Other studies refute this association (Dato et al, 2004 and 
Ross et al, 2001). In Japanese centenarians a sublineage of haplogroup D was more 
frequent (Tanaka et., al 1998; Tanaka et al., 2000).  
We have previously argued that mitochondrial DNA has a high rate of mutation 
which leads not only to the accumulation of a wide range of sequence polymorphisms 
that define haplogroups and subhaplogroups, but also to mutations that cause diseases. 
These diseases arise particularly in tissues and organs with high energy demand: the 
central nervous system, heart, skeletal muscle and heart, just to name a few. In addition 
to a wide spectrum of pathological changes, there are many other mtDNA 
polymorphisms that, alone or in combination with other polymorphisms appear to 
modulate the risk of complex diseases. Mutations characterizing haplogroups and 
subhaplogroups and considered "neutral" may instead play a role in some complex 
diseases.  
It seems that certain polymorphisms are associated with one or more haplogroups 
and that they confer a protection against the onset of these neurodegenerative diseases, 
while others seem to facilitate their development (Santoro et al, 2006, Reeve et al, 
2008). For example, some studies have shown that the J haplogroup could affect the 
expression of Leber's optic neuropathy (LHON) (Chinney et al, 2001) and in particular 
that some polymorphisms characteristic of J may increase the penetrance of pathogenic 
mutations (Torroni et al. 1997) such as, diabetes (Mohlke et al, 2005), and optic neuritis 
(Reynier et al, 1999).  
It has been proposed that J haplogroup can have two different aspects: on one 
hand it can lead to longevity by minimizing the ROS production and it can favour a 
decoupling situation as Fig. 2.5 shows. In fact some authors suggested that this OXPHOS 
uncoupling characteristic was an ancient mitochondrial adaptation to the cold, as it 
promoted heat production (Wallace et al, 1999). The same authors suggested that this 
condition would reduce ROS production, decreasing the gradual mitochondria 
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degradation thus favouring aging. This could explain the overrepresentation of J among 
populations of people over 100 years. 
On the other hand, J has a general low ATP production that, in addition to 
environmental factors, causes ah higher proportion of diabetes patients. Furthermore it 
seems to amplificate some pathologies, as happens in LHON patients, in association with 
11778 mutation. 
 
 
Fig. 2.5:  Hypothetical mechanism of the “J paradox”. The figure summarizes the impact of J on the OXPOS 
level, the implications on an individual level and the impact on the distribution of populations studied 
within the phylogeny. 
 
Other associations were studied: haplogroups J and K are underrepresented in 
Parkinson’s disease (van der Walt et al., 2003), and haplogroup T is underrepresentedin 
AD patients (Chagnon et al., 1999). Hence, it is likely to think that the different mtDNA 
lineages are qualitatively different from each other, bearing mutations able to improve 
the OXPHOS efficiency, and consequentely reducing the risk of some pathologies. 
Furthermore, it has been reported by Ruiz Pesini et al., that haplogroups H and T 
displayed a significant difference in the activity of complex I and IV of OXPHOS (Ruiz 
Pesini et al., 2000). 
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9. Point mutation of mtDNA 
The mitochondrial theory of aging (Hamilton et al., 2001) proposes that 
accumulation of mutations in mtDNA and consequent mitochondrial dysfunction are the 
major contributors to aging and age-related neurodegenerative disease. 
The polymorphisms and single base mutations in mtDNA are very probable 
because of the proximity of a source of ROS and the limited ability to correct from the 
enzyme deputy to the replication of mtDNA, polymerase γ (Kaguni 2004, Kujoth et al. 
2005, Johnson et al. 2001). 
Recently, somatic mutations in the Control Region (CR) of the mtDNA have been 
associated with aging (Coskun et al., 2003). The A189G and T408A CR mutations 
accumulate with age in skeletal muscle (Wang et al., 2001), and a T150C mutation 
accumulates in white blood cells (Zhang et al., 2003). 
The C150T mutation (where a cytosine (C) is replaced with a thymine (T) in 
position 150 of the control region CR) is of particular interest in the study of aging. 
It has been identified not only in skin fibroblasts but also in lymphocytes and 
granulocytes of peripheral blood in centenarians and twins. This led to hypothesize a 
link between mutation and longevity, and between mutation and resistance to stress-
induced ROS production (Coskun et al. 2003). 
The C150T mutation seems to promote longevity causing the displacement of the 
origin of replication from 151 to 149 in the control region (Zhang et al. 2003). In fact, the 
C150T is located near one of the main origins of replication of the H strand of mtDNA 
(Fig. 2.6). 
 
Fig. 2.6: Position of the C150T mutation in the D-loop and other specific tissue mutations age-dependent. 
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Zhang et al. (2003) argue that the somatic event in or near the 150 position could 
lead to a general remodeling of the entire system of replication, probably controlled by 
the nucleus. Therefore this remodeling could accelerate mtDNA replication, to 
compensate the oxidative damage of the same DNA and its functional deterioration 
occurring in old age. The age-dependent accumulation of point mutations with age, the 
previously identified in fibroblasts and skeletal muscle in critical sites for mtDNA 
replication, can be considered part of the remodeling. 
The data also showed that C150T variant causes a remodelling of the replication 
origin at position 151 and can be either inherited (polymorphism) or somatically 
acquired (mutation).It also may cause an activity decreasing. Coskun et al. (2003) 
suggested that mtDNA haplogroups are likely not neutral and that C150T variant 
associated with haplogroup J (De Benedictis et al, 1999) might have changed oxidative 
phosphorylation efficiency (OXPHOS) by reducing the activity. Moreover J haplogroup is 
associated to the presence of at least four mutation near the replication origin, C150T 
included (Niemi et al., 2005).  
How might C150T and/or haplogroup J contribute to longevity? The C150T variant 
or a linked polymorphism in haplogroup J might change OXPHOS efficiency and thus ROS 
production, reducing oxidation stress and increasing longevity. In fact human mtDNAs 
radiated out of Africa and colonized the world through successive accumulation of 
sequential mutations along radiating maternal linage, from mother to daughter. 
Transitions in mtDNA types between Africa and Eurasia and north and south seem to 
correlate with latitude indicating that mtDNA diversity has been subjected to climatic 
selection (Mishmar et al., 2003). This means that mitochondria burn calories to make 
ATP to do work, and generate heat to maintain the inside body temperature. The balance 
between these two mutually exclusive processes is determined by the OXPHOS efficiency. 
Highly efficient OXPHOS generates ATP with little waste heat. Less efficient OXPHOS 
generates more heat producing the same amount of ATP. The most efficient activity is 
preferable in the tropics, whereas the less would be critical for survival in the arctic. 
What is more in the arctic area  the amino acid sequence of the human mtDNA ATP6 
protein is hypervariable, implying that mutations in this mtDNA gene have been 
important for human adaptation to extreme cold. A reduction in OXPHOS efficiency 
would also burn more calories. As a result, fewer reducing electrons are introduced from 
the diet to make ROS. A life-long reduction in mitochondrial ROS stress would, in turn, 
decrease apoptosis and increase longevity.  
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Rather frequent is heteroplasmic somatic mutation T414G (fig. 2.6), a transversion 
at position 414 in the D-loop region of the mitochondrial genome, normally present in 
high proportions (more than 50%) in cultured fibroblasts of individuals with age over 
65 years (Michikawa et al., 1999).  
Wang et al. (2001), conducting studies on skeletal muscle, discovered that while 
the 414G mutation is absent, there are two other heteroplasmic mutations, A189G and 
T408A. Unlike somatic T414G, A189G and T408A polymorphisms are transmitted by 
germline and thus associated with specific mitochondrial haplogroups (Rose et al., 
2002).  
These muscle-specific mutations accumulate with age in the mitochondrial genome 
(Wang et al., 2001, Del Bo et al., 2002), particularly in the control region, which is 
important for replication. Another interesting observation is that the A189G is located in 
a position very close to one of the main origins of replication for the heavy chain H 
(position 191). It is curious to note that two of the main origins of replication have been 
identified as sites of accumulation of age-related mutations. 
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Chapter 3 
 
The GEHA Project – Genetic of Healthy Aging 
 
1. The GEHA Project 
Europe is the oldest continent and in the last decade the number of people aged 
more than 90 years is rapidly rising. The actual proportion of people with more than 90 
years is about 50% of the total population. There is a small proportion of elders that 
apparently undergoes an aging process and they surprisingly appear deprived of the 
most common age-related disease (cardiovascular disease, stroke, type II diabetes, 
cancer and dementia). In this scenario it is important to study causes and mechanisms of 
the aging, that in 2001 the 5-year European Union Integrated Project GEnetics of 
Healthy Aging (GEHA) born. The most important aim of this study is to identify genes 
involved in healthy aging and longevity, which allows individuals to reach advanced old 
age in good cognitive and physical conditions, without the major age-related diseases.  
The GEHA Project represents the strongest and the most competitive consortium 
ever realized in Europe to investigate genetic bases of human aging process, capable of 
reaching results that is impossible to obtain in a single European country. 
The 5-year GEHA Project was supported through Priority 1 (Life Sciences, 
Genomics and Biotechnology for Health) of EU’s FP6 (Project Number LSHM-CT-2004-
503270) and approved by European Commission. The project started on May 1, 2004 
and ended ion April 30, 2010 (with a 1-year delay). 
The Project can be divided in several steps: 
1) Standardization of all procedures: two Informed Consent Form (one for 90+ 
sibpairs and one for the younger controls), three Questionnaires (for 90+ 
sibpairs, for the younger control and for the family of the 90+ sibpair, in the 
National language and in English), phenotypic, genetic database plus a database 
for mtDNA, set up a collection of biological material (blood samples and cheek 
swab), a protocol for extraction and for APOE genotyping; 
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2) the recruitment of subjects, divided in 90+ sibpairs and an equal number of 
controls (TRIOS is composed of at least two 90+ sibs and 1 younger ethnically-
matched control subject); 
3) the DNA extraction, the quality control and shipment to the GEHA Partners in 
order to conduct genetic analysis (nuclear and mitochondrial genomes); 
4) Genetic analysis on nuclear and mitochondrial DNA 
5) Statistical analysis of the collected data with mathematical methods. 
The GEHA Project is the largest international collaborative research group for the 
theoretical and sperimental capacity in the biogerontology and genetic are of aging. 
 
2. The objectives of the GEHA Project 
The most important objective of the Project is to identify gene which influence 
healthy aging and longevity, and that protect individuals from major age-related 
diseases. Accordingly the major goals of the Project are the following: 
1. To overcome the fragmentation of the research on the genetics of aging in 
Europe; 
2. to set up a coherent, tightly integrated program of research that unites 
demographers, geriatricians, geneticists, epidemiologists, molecular biologists, 
bioinformaticians and statisticians; 
3. to recruit an unprecedented number of long-living sibpairs (2192) were 
both members are aged 90 years of age and more from 11 Euperan countries in 
15 geographic areas; 
4. to perform a genome-wide scan on the DNA of all the recruited subjects (ASP, 
Affected Sibpairs analysis, or Linkage Analysis); 
5. to recruit 2192 etnically-mached control subjects (mean age 50-75 years) 
from the same geographic area in order to fine-map the chromosomal regions 
identified by Linkage analysis and the three candidate chromosomal regions 
(see n.8); 
6. to perform bioinformatics, functionale genomics, proteomics and 
molecular biology studies on the putative longevity genes and gene variants 
resulting from ASP and LD mapping; 
7. to test whether ethnically different European population (including Sardinia 
and Finland) share the same genes involved in aging and longevity; 
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8. to study the role played in human longevity by nuclear regions (D4S1564 in 
chromosome 4, 11p15.5 in chromosome 11, and ApoE in chromosome 19); 
9. to study the role of mitochondrial DNA through the analysis of germline 
variants (haplogroups) and mutations (C150T) in human longevity; 
10. to identify gender-specificity genes associated with longevity; 
11. to stratify the samples according to APOE genotype; 
12. to develop innovative analytical strategies (based on statistical and 
mathematical models) capable of combining all the collected data; 
13. to perform a short longitudinal study to evaluate the importance of genetic 
factors on the mortality of the recruited 90+ sibpairs; 
14. to organize activities for young researchers and to disseminate the results of 
the GEHA activity, discussing ethical implications. 
 
3. The GEHA consortium and its bodies 
The GEHA consortium is composed of 25 partners of 12 European Countries (Italy, 
France, Germany, Denmark, Finland, Greece, England, North Ireland, Belgium, 
Nertherlands, Poland and Ukraina) and 1 Partner from China, who collaborates in an 
interdisciplinary study (Fig. 3.1).  
 
 
 
Fig. 3.1: representation of the 25 Partners who collaborates in the GEHA project 
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All these countries have different laws and traditions about privacy, ethical 
recommendation, access to demographic source, IPR (Intellectual Property Rules) rules, 
among others. The GEHA project regarding the genetics of human longevity requires the 
recruitment of very old sibpairs and the donation of blood or other biological material 
on which carry out the genetic analysis. Moreover, GEHA deals with sensitive issues, 
which requires attention and care as much as possible. For these reasons it was 
necessary to standardize all the tools and the fulfilment or ethical requirements both 
essential to start the first phase of the Project, i.e. the recruitment of 90+ sibpairs and 
younger controls. 
In order to fulfil all the scientific, ethical, financial and IPR requirements, and 
following the guidelines of the EU, the GEHA project was endowed with a complex 
organization structure composed by the following bodies: 
• Coordinator (Professor Claudio Franceschi),  
• Project Manager (Dr. Alessandra Malavolta),  
• Scientific Manager (Dr. Silvana Valensin),  
• General Assembly composed of 25 members (i.e. all the Principal 
Investigator, one person from each Partner) 
• Steering Committee composed of 9 members (i.e. the leaders of the 12 
WPs), 
• Ethics Steering Group composed of 3 internal members and 2 external 
member, 
• External Advisory and Gender Board composed of eminent scientist 
from United States and Europe 
• Financial Management Board composed of 5 members, 
• Legal and IPR Board composed of 3 members. 
 
The GEHA Consortium was composed as following:  
• PARTNER 1: UNIBO (GEHA Project Coordinator) University of Bologna, Italy, 
PI: Prof. C. Franceschi 
• PARTNER 2: CRLC, University of Montpellier, France, I: Prof. J.M. Robine 
• PARTNER 3: CAU, Kiel Centre for Functional Genomics, Germany, PI: Prof. S. 
Schreiber 
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• PARTNER 4: CEPH, Foundation Jean Dausset, France, PI: Dr. H. Blanché 
• PARTNER 5: ISS, Istituto Superiore di Sanità, Italy, PI: Dr. A. Stazi 
• PARTNER 6: LUMC, Leiden University Medical Centre, LUMC, The Netherlands 
PI: Prof. E. Slagboom 
• PARTNER 7: MPIDR, Max Planck Institute for Demographic Research, Germany, 
PI: Prof. J. Vaupel 
• PARTNER 8: NHRF, National Hellenic Researcher Foundation, Greece, PI: Dr. E. 
Gonos 
• PARTNER 9: KTL, Tampere School of Public Health, Finland, PI: Prof. A. 
Hervonen 
• PARTNER 10: NENCKI, Nencki Istitute for Experimental Biology, Poland, PI: Prof. 
E. Sikora 
• PARTNER 11: QUB, Queen’s University of Belfast, UK, PI: Prof. I. M. Rea 
• PARTNER 12: UNICAL, University of Calabria, Italy, PI: Prof. G.De Benedictis 
• PARTNER 13: IFOM, Institute of Milan, Italy, PI: Prof. G. Pelicci 
• PARTNER 14: UNISS, University of Sassari, Italy, PI: Prof. L. Deiana 
• PARTNER 15: UCL, Catholic University of Louvain, Belgium, PI: Prof. M. Poulain 
• PARTNER 16 : FUNDP, Facultes Universitaire Notre Dame de la Paix, Belgium, PI: 
Prof. O. Toussaint 
• PARTNER 17: UNEW, University of Newcastle, UK, PI: Prof. T. Kirkwood 
• PARTNER 18: SDU, University of Southern Denmark, Denmark, PI: Prof. B. Jeune 
• PARTNER 19: TAMPERE, National Public Health Institute, Finland, PI: Prof. L. 
Peltonen 
• PARTNER 20: R&I, Research Innovation s.r.l., Italy, PI: Dr. A. Leon 
• PARTNER 21: INRCA, Italian National Research Centre on Aging, Italy, PI: Dr. L. 
Spazzafumo 
• PARTNER 22: UAAR, University of Aarhus, Denmark, PI: Dr. P. Kristensen 
• PARTNER 23: BGI, Bejing Genomics Institute, BGI, China, PI: Prof. L. Bolund  
• PARTNER 24: EAT, Eppendorf Array Technologies, Belgium, PI:  Prof. J. Remacle 
• PARTNER 25: IG, Institute of Gerontology, Kiev, Ukraine,PI: Professor V.V. 
Bezrukov 
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4. GEHA databases 
In order to ensure data privacy to the participant subjects and at the same time 
ensures full availability of samples, phenotypes and molecular data to all the Partners, 
GEHA envisages a peculiar centralization of the different types of data collected. The 
GEHA consortium set up three main databases: 
• The Phenotypic Database containing clinical and demographic data on the 
basis of GEHA questionnaires (Odense, Denmark); 
• The Genotypic Database containing genotyping data (Kiel, Germany); 
• mtDNA Database containing data related to studies on mtDNA (Tampere, 
Finland). It allows to assign haplogroups automatically, to recognize 
aminoacidic variations automatically and to obtain all the references 
related to a polimorphism automatically (www.mitomap.org). 
Even if these three databases are physically separated, they are strictly 
interconnected, allowing to all GEHA Partner to perform all types of analysis and 
protecting privacy of participants. It gives the possibility to introduce independent 
projects and treat data separately, connecting with the other GEHA databases in 
progress. 
 
5. Genetic analysis (nuclear and mitochondrial genome) 
 
Nuclear genome 
In the last few years an enormous quantity of data are presented about human 
genome on millions of new single polymorphism (SNPs) variants. The main goal of GEHA 
is to perform Linkage analysis but surprising data were obtained with association 
studies (Fig. 3.2). After a preliminary investigation, the scan of the 11p15.5 region was 
performed, using DNA from centenarians and younger controls. A density of 1 SNP per 
10.037 bp was obtained in the 2.4 Mb region. A variation in a gene already implicated in 
longevity was replicated in the German samples, and other three genes gave positive 
signals in both German and Central Italians, which render these genes important 
candidates gehe involved in longevity. Also the Linkage analysis was performed 
including 15 centers together and separate. Only at chromosome 19 they observed a 
borderline significant linkage result. Linkage analysis looks for co-inheritance of 
chromosomal regions with the trai in families. It is not only more powerful than 
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association studies for identifying rare-risk disease alleles but also it is not influenced by 
population admixture. 
 
Fig. 3.2: graphic representation of the GEHA design. Linkage analysis (1) and association studies (2) were 
conducted on all recruited samples. 
 
Mitochondrial DNA 
About the study of mitochondrial DNA, the main activities were: 
1. mtDNA resequencing. Different approaches were developed by the GEHA 
consortium in order to obtain complete sequences. The first methods uses 3 sets of 
primers producing fragments of about 6kb, sequenced with 39 primers, the second 
method uses 55 primers for each strand and a kit provided by APPLERA and 
standardized in the lab of Partner n.1 (UNIBO), and the productes are sequenced by  a 
single universal primers. GEHA sample belong to the specific population of Southern 
Italy and Greece (sequenced by partner n.1), Finland and Denmark (sequenced by 
Partner n.23) for a total of 1000 mtDNAs. In particular Partner n. 1 should sequence 660 
subjects, divided in 300 nonagenarians (90+) and 330 younger controls. 
2. All other GEHA samples are genotyped for mtDNA haplogroups and 
subhaplogroups, using a protocol based on PCR amplification and sequencing of the 
mtDNA D-loop.  
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Results are showed in this thesis. The list of GEHA TRIOS (each constituted by two 
90+ sibpairs and one younger ethnically matched control, Tab. 3.1 and Fig. 3.3) is the 
following: 
 
 
Tab. 3.1: list of all recruited samples coming from all Europe. The GEHA center, country and the number 
of trios are reported. 
 
 
 
GEHA center Country 
2 sibs and 
one control 
3 sibs and 
one control 
4 sibs and 
one control 
5 sibs and 
one control 
UNIBO Italy 182 23 6 1 
CRLC France 241 29 3 1 
CAU Germany 93 5   
ISS Italy 73 2   
LUMC Netherland 148 14 2  
SDU DK 392 46 5  
NENKI Poland 133 4   
NHRF Greece 95 3   
UNICAL Italy 185 7 1  
UNISS Italy 50 2   
UCL Belgium 79 1   
QUB Ireland 58 4 2  
UNEW UK 100 1   
TAMPERE Finland 127 24 1 1 
INST.GERONT Ukraine 46 2   
TOTAL  2002 167 20 3 
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% Trios with 2, 3, 4 and 5 sibs (all Countries)
% Trios with 3 sibs
8,1%
% Trios with 4 sibs
1,1%
% Trios with 2 sibs
90,7%
% Trios with 5 sibs
0,1%
% Trios with 2 sibs % Trios with 3 sibs
% Trios with 4 sibs % Trios with 5 sibs
 
Fig. 3.3: a trios is formed by at least two 90+ sibpairs and one younger ethnically matched control. In our 
data sibships with two sibs are 90.7%, sibships with more than two sibs are 9.3%. 
 
3. Analysis of heteroplasmy. A new protocol to highlight the heteroplasmy of the 
C150T point mutation by DHPLC technology has been developed and standardized. The 
results show that a correlation between heteroplasmy levels and longevity exists and is 
highly significant (Partner n.12). 
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Chapter 4 
 
AIM OF THE STUDY 
 
 
In the present study, we investigate the association of haplogroups, mitochondrial 
polymorphisms and mutation with longevity. It has been discovered that longevity is 
essentially a familiar characteristic: centenarians offspring lived more than others, 
centenarians offsprings are presumed to reach aging in physical and cognitive 
conditions better than their coetaneous. In this scenario, mitochondrial DNA and its 
variability plays an important role. 
The aim of the Project GEHA is to identify genes involved in healthy aging and 
longevity, allowing individuals to survive to advanced old age in good cognitive and 
physical function and in the absence of major age-related diseases, such as type II 
diabetes, neurodegenerative diseases, cardiovascular diseases and osteoporosis. 
The principal aim of this study is to analyse molecular markers that could play a 
role in healthy aging, proposing: 
1. Amplification of control region and RFLP in order to study haplogroups and 
the relationship with longevity. The technique is applied on subjects coming 
from 11 European countries adherent to the Project; 
2. Standardization of the entire methodology used to analyze mtDNAs, thanks 
to robotized platform Hamilton MicroLab Star; 
3. Statistical analysis of obtained results and research of polymorphisms and 
mutations associated with longevity and healthy aging; 
4. Analysis of complete sequences 
5. Cluster analysis and Network analysis 
 
The 2192 recruited candidates represent a great number of subjects, allowing to 
obtain sufficient data for statistical analysis. Moreover the extension of the recruitment 
area allow not to limit the analysis to a very restricted haplogroup numbers, exceeding 
all the geographic problems (because mtDNA is localized in limited geographic area).  
 48 
Chapter 5 
 
MATHERIALS AND METHODS  
 
 
1. Samples 
The available DNA samples belong to subjects that are divided in two groups: 
probands and controls.  Proband is the oldest sibling of the sibship that was recruited, 
should have 90 years or more and should have at least one sibling of the same surname 
and an age above 90. The control subject is ethnically-matched with proband and should 
be aged 50-75 years. Subjects come from 11 countries, corresponding to 15 different 
geographic areas. Since the two members of the sibpair must have the same mtDNA due 
to maternal inheritance, the Project decided that only the oldest of the sibpairs must be 
genotyped for mtDNA haplogroup. Our sample is divided as follows: 
 
ANALYSIS SIBS CONTROLS TOT 
Complete sequencing 637 655 1,292 
D-loop sequencing 1449 1498 2,947 
TOT 2,086 2,153 4,239 
 
All subject’s DNA has been extracted with an automate and standardized 
procedure (Gentra) in order to guarantee the uniformity of all concentrations by one 
Partner of the Project (KTL - Helsinki, Finland). For our analysis, 4 µg of genomic DNA 
have been provided by KTL. 
 
2. General protocol 
The general plan for the definition of mtDNA subhaplogroups is first the 
amplification and then the sequencing of D-loop fragment. Then we are able to assign a 
preliminary haplogroups which must be confirmed by amplification of a specific trait in 
the coding region, and a digestion with a specific enzyme.  
The general scheme of the protocol is as follows: 
- Amplification of the D-loop region (about 1500 bp)  
- Agarose gel electrophoresis 
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- PCR clean-up reaction using ExoSAP-IT® 
- Sequencing reaction 
- Sequence analysis with SeqScape software in order to attribute a 
preliminary subhaplogroup 
- Amplification of a coding region trait specific for each haplogroup 
- Digestion using specific restriction enzymes 
- To confirm or not the predicted subhaplogroup 
 
PCR amplification  
A pair of primers were used for Dloop amplification reaction: 15877F 
(CAAATGGGCCTGTCCTTGTA) and 770R (GCTGCGTGCTTGATG CTTGT) which are 
specific for the interested segment of mtDNA (the D-loop, about 1500 bp).  
Amplification was performed in a 25 µl volume. Each amplification will contain at 
final concentration: 
 
REAGENTS [STOCK] [FINAL] VOLUME 
Buffer 10X 
 (Invitrogen) 
 200 mM Tris-HCl 
(pH8) 
 500 mM KCl 
20 mM Tris-
HCl (pH8) 
50 mM KCl 
2.5 µl 
MgCl2 
(Invitrogen) 
50 mM 1 mM 0.5 µl 
dNTP 
(Invitrogen) 
100 mM 16 µM 4 µl 
Taq 
(Invitrogen) 
5 U/µl 0.04 U/µl 0.3 µl 
Primers: 
15877F, 770R 
10 µM 0.4 µM 1 µl 
DNA 60 ng/µl 0.72 ng/µl 2 µl 
Water / / 13.55 µl 
Final volume 25 µl 
 
The PCR cycling profile (using T1 Thermocycler Biometria) is as follows:  
 
Temperature  Cycle number 
95°C 5 min 1 
95°C 
68°C 
72°C 
40 sec 
40 sec 
2 min 
35 
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72°C 12 min 1 
 
Agarose gel electrophoresis 
It is very important to verify the amplification on a agarose gel 1.5%. Materials we 
need are:  
 1.5 agarose gel made up with standard 0.5X TBE (see APPENDIX) 
 Ethidium Bromide solution if this has not been pre-incorporated into the 
gel 
 Tracking dye (Bromophenol Blue and/or xylene cyanol + glycerol) 
In each well pipet 1.2 μl of the cleaned-up PCR reactions and 8.8 μl (6.2 μl H2O and 
2.6 μl BF6X) to reach a volume of 10 μl. Load in a well a marker which contains a mix of 
known fragments and used to compare our bands. Run the gel at 150 V for half an hour. 
 
PCR clean-up 
The clean-up reaction is important because it purify PCR products from primers or 
nucleotides not incorporated. For PCR clean-up add 2 μl of Exosap-IT (directly to PCR 
product) each 5 μl of PCR product (Fig. 5.1). We experimented that only 1 μl of ExoSAP 
each 25 μl PCR product is sufficient and it allows to reduce costs. ExoSAP-IT® (USB, PN 
78200) is a mix containing two enzymes: an exonuclease (ExoI) degrades residual single-
stranded primers and any extraneous single-stranded DNA produced by PCR, and a 
shrimp alkaline phosphates (SAP) hydrolyzes remaining dNTPs from the PCR mixture 
which could interfere with the sequencing reaction. 
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Fig. 5.1: PCR clean-up 
The PCR cycling profile (using T1 Thermocycler Biometria) is as follows:  
1. activation of enzyme at 37°C per 30 minutes 
2. inactivation at 80°C per 15’ 
 
Sequencing reaction 
The sequencing technique has been developed by Torroni’s lab of University of 
Pavia. He has provided us a list of the most used primers to be tested on our samples. To 
execute the sequencing reaction, we have used three primers, each at concentration of  
3.2 pmol/µl. 
 
 
 
 
 
 
The d-loop is sequenced in three different fragments, partially overlapping.  
The reaction was performed in a 10 ul volume. Each reaction will contain at final 
concentration: 
 
 
 
Primers  Sequence Lenght (bp) Tm 
15973 For AACTCCACCATTAGCACCCA 20 60.38 
16522 For TAAAGCCTAAATAGCCCACA 20 55.27 
13 For ATCACCCTATTAACCACTCACG 22 58.01 
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REAGENTS [STOCK] [FINAL] VOLUME 
Buffer 5X 
(Applied 
Biosystems) 
5X 0.8X 1.6 µl 
Big Dye 
Terminator 
v.3.1 
(Applied 
Biosystems) 
8 µl in a total volume 
of 20 µl 
per reaction  
1 µl 0.8 µl 
Primers: 
13F, 
15973F,16522F 
10 µM 0.32 µM 1 µl 
Cleaned-up PCR 
product 
/ / 2 µl 
Water / / 4,6 µl 
Final volume 10 µl 
 
The thermal profile is as follows: 
 
Temperature  Cycle number 
96°C 1 min 1 
96°C 
50°C 
60°C 
10 sec 
5 sec 
4 min 
25 
 
The BigDye Terminator reagent contains a mix of nucleotide. Free bases that 
match the template sequence can attach to the new strand's growing (3') end, but among 
all the free bases swimming in the solution, there are a few having a chemical 
fluorescent part, i.e. dye. When the coloured bases attach to the growing strand, the 
extra chemical part keeps the new DNA strand from growing any further. A different 
coloured dye is attached to each of the four kinds of bases. 
A completed sequencing reaction contains an array of coloured DNA fragments. 
The shortest are the length of the primer plus one coloured base. The longest fragments 
are usually between 500 and 800 bases long, which is when the sequencing reaction 
runs out of steam. 
 
Sequencing clean-up reaction 
To perform the sequencing clean-up reaction, it is important to add in each well 
the following reagents: 
• 2.0 µl of sodium acetate (NaAc); 
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• 30 µl Ethanol 100% stored at –20°C, in order to precipitate  sequenced 
fragments; 
• Incubate at room temperature for 10 min; 
• Spin the plate at 1100 xg for 42 min; 
• Remove cover and invert onto paper towel and spin at 100xg for no more 
than 1 min 
• 70 µl ethanol 70% stored at –20°C  
• Spin at 1100 xg for 14 min; 
• Remove cover and invert onto paper towel and spin at 100xg for no more 
than 1 min; 
• Store the plate at 37°C for at least 1h in order to evaporate all the ethanol; 
• Resuspend all wells with 10µl Hi Di Formamide (denaturing agent which 
allows to maintain a denaturing state for capillary elechtrophoresis); 
• Denaturing at 95°C for 2 min. 
 
3. Analysis at ABI3730 sequencer   
The sample are then loaded on the automatic sequencer (ABI 3730, 48 capillaries). 
Inside the sequencer the division of the fragment depends on their molecular weight and 
are separated by a process called capillary electrophoresis. The sequencing machine sets 
up an electric field; all the DNA moves down through a porous gel toward the positive 
charge. Shorter fragments of DNA move more quickly through the matrix of the gel than 
larger fragments do (Fig. 5.2). 
In the sequencing machine, a laser excites the fluorescent dyes, and a camera 
detects the lights that the excited dyes emit. One by one, the sequencing machine reads 
the DNA molecules passing down the gel, and sends the information to a computer. Each 
nucleotide have a different  emission spectrum allowing to identify different bases. 
A computer program helps integrate the information from individual sequencing 
reactions. It spots where fragments overlap, to puzzle the pieces back together.  
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Fig. 5.2: principle of sequenze function. The sequencing fragments obtained (a) pass through a laser (b), 
while a system provides to record the Energy emitted by the excited fluorescent molecole 
 
Many overlapping sequencing reads are needed to reveal the uninterrupted 
sequence of the original stretch of DNA. On average, every base pair of human DNA will 
be sequenced nine times. Some stretches of DNA are easier to read and need to be 
sequenced a little less often to get high-quality sequence. Some stretches need to be 
analyzed more exhaustively to get finished high-quality sequence. 
The sequencer gives data in electropherogram form, through a file (.ab1) that 
shows four different peaks (green for adenine, red for timine, blue for cytosine and black 
for guanosine) and the height of each peak depends on the detected intensity. 
Now, we are able to read file .ab1 with the software SeqScape v2.1.1 (Applied 
Biosystems) which allows the alignment, the assembling of the overlapping fragments 
and a comparison with the Reference Sequence of Cambridge (Fig. 5.3). 
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Fig. 5.3: Image of an analysis with Seqscape. The Cambridge reference sequence is in brown, 
coloured peak represent all the four nitrogenous bases and the green bars indicates the quality of 
the peak relative to the background noise. 
 
4. Preliminary assignment of subhaplogroups 
After having compared our sequences with the reference one, it is indispensable to 
define every single subhaplogroups to use specific phylogenetic trees. 
The position 73 is the most ancient and whose transition A/G (adenine/guanosine) 
allows to distinguish between HV branch and U, JT and N branches. 
If in position 73 there is an A (equal to Cambridge sequence), our interest is direct 
to HV branch, if there is a G we will take into account U, JT and N branches (for 
phylogenetic trees see ADDENDUM). 
All mutations must be researched in its specific phylogenetic tree, till it is possible 
to obtain a more detailed description. Then a specific enzymatic digestion is needed.  
The following table summarize the most important position of each 
subhaplogroup. 
 
 
Branch H-V: 
Subhaplogroup Mutational sites 
V 72, 16298, 4580 
Pre*V2 72,16298, 15904 
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Pre*V1 72, 16298, 14766 
HV1 16067, 14766 
PreHV1 16126, 16362, 11719 
HV* 16168 
H 7025 
         H1 3010 
         H3 6776 
         H5 456-16304 
         H6 239-16362-16482 
 
Branch U 
Subhaplogroup Mutational sites 
U1 16249, 285, 13104 
         U1a 16183, 16189, 4991 
U2  
         U2e 16051, 16129, 16189,16362 
U3 16343, 14139 
        U3a 16390 
U4 16356, 499, 4646 
U5 16270 
        U5a 16256, 14793 
        U5b 150, 14182 
U6 16172, 3348 
U7 16318, 5360 
U8  
       K 16244, 16311, 9055 
       U8b 16311, 16234, 9055 
U9 6386, 12308 
 
Branch JT 
Subhaplogroup Mutational sites 
JT 16126 
J 16069 
       J1 3010 
       J2 7476 
T 16294 
       T1 16163, 16189, 12633 
       T2 16296, 14233 
Branch N 
 
Subhaplogroup Mutational sites 
N 16233 
       X 16189, 16278, 153, 14470 
       I 16129, 16392, 199, 204, 250, 
10034 
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       W 16292, 189, 195, 204, 8994 
       N1b 16145, 16176G, 11362 
 
Amplification of coding region trait 
Once each subhaplogroup was hypothesed, it is indispensable to confirm this 
hypothesis trough the presence of particular polymorphisms in the coding region. 
Amplification was performed in a 25 ul volume. Each amplification will contain at 
final concentration: 
 
REAGENTS [STOCK] [FINAL] VOLUME 
Buffer 10X 
 (Invitrogen) 
 200 mM Tris-HCl 
(pH8) 
 500 mM KCl 
20 mM Tris-
HCl (pH8) 
50 mM KCl 
2.5 µl 
MgCl2 
(Invitrogen) 
50 mM 1.5 mM 0.75 µl 
dNTP 
(Invitrogen) 
100 mM 16 µM 4 µl 
Taq 
(Invitrogen) 
5 U/µl 0.04 U/µl 0.2 µl 
Specific 
primers(*) 
10 µM specific specific 
DNA 60 ng/µl 0.72 ng/µl 2 µl 
water / / variable 
Final volume 25 µl 
 
The thermal profile is as follows: 
Temperature  Cycle number 
93°C 30 sec 1 
93°C 
T°C 
72°C 
15 sec 
20 sec 
1 min 
35 
72°C 12 min 1 
 
The following table (Tab.5.1) reports all the pair of primers necessary to produce 
the amplification, with the relative annealing temperature and the amplificated 
fragment length. Only for U4 and J2 haplogroups the cycle number of annealing is 44 
instead of 35. 
 
Subhapl Primers and their sequence Tann Length 
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H 6892F: GCAATATGAAATGATCTGCTGC                                                     
7860R: TCGTTGACCTCGTCTGTTATGT    
54,5°C 242 bp  
H1 
2988F: CGATGTTGGATCAGGACATCTC                                                   
3235R: CTTAACAAACCCTGTTCTTGGG  
60°C 248 bp 
H3 
6637F: TTCTTATCCTACCAGGCTTCG                                                      
6807R: GTGTGTCTACGTCTATTCCTACTGTAAACA 
62°C 170 bp  
R0a 
11491F: ACGCCTCACACTCATTCTCA                                                    
11750R: TGCTAGGCAGAATAGTAATGAGGATGTAGG 
64°C 260 bp  
V 
4381F: ACCTATCACACCCCATCCTAAA                                      
4683R: TTAGAAGGATTATGGATGCGGT 
57°C 302 bp  
HV1-
HV0* 
14676F: TTCTCGCACGGACTACAACC                                                   
14996R: CGTGAAGGTAGCGGATGATT 
55°C 321 bp  
HV0a 
15796F: GGACAAGTAGCATCCGTACT                                                    
16439R: GCACTCTTGTGCGGGATATT 
55°C 643 bp  
U1 
12744F: CCTATTCCAACTGTTCATCG                                                      
13192R: GAGTGGTGATAGCGCCTAAG 
55°C 448 bp  
U1a 
4381F: ACCTATCACACCCCATCCTAAA                                                          
5210R: GGTGGATGGAATTAAGGGTGTT   
59°C 829 bp  
U2e 
13134F: AGCAGAAAATAGCCCACTAA                                                  
13829R: AGTCCTAGGAAAGTGACAGCGA  
56°C 695 bp  
U3 
14103F: CTCTTTCTTCTTCCCACTCA                                                    
14996R: CGTGAAGGTAGCGGATGATT 
53°C 893 bp  
U4 
4381F: ACCTATCACACCCCATCCTAAA                                                     
5073R: TGGTTATGTTAGGGTTGTACGG 
59°C 656 bp  
U5a 
14676F: TTCTCGCACGGACTACAACC                                                      
14996R: CGTGAAGGTAGCGGATGATT 
55°C 321 bp  
U5b 
14158F: CCGAGCAATCTCAATTACAATATG                                                                      
14996R: CGTGAAGGTAGCGGATGATT 
57°C 835 bp  
U6 
3085F: ATCCAGGTCGGTTTCTATCT                                                        
3693R: CAGGGCGTAGTTTGAGTTTGA 
54°C 608 bp  
U7 
5199F: ATTCCATCCACCCTCCTCTC                                                           
5607R: AGTGGGGTTTTGCAGTCCTT 
56°C 409 bp  
U8b-K 
8829F: CCTAGCCATGGCCATCC                                  
9184R: GGCTTACTAGAAGTGTGAAAAC 
50°C 356 bp  
U9 
6120F: ATCATAATCGGAGGCTTTGG                            
6455R: GAAGAGGGGCGTTTGGTATT 
54°C 335 bp  
TJ 
4142F: GATTCCGCTACGACCAACTC                             
4365R: GGATTCTCAGGGATGGGTTC   
57°C 224 bp  
T1 
12014F: CTCACCCACCACATTAACAACA                     
13829R: AGTCCTAGGAAAGTGACAGCGA  
60°C 1816 bp  
T2 
13957F: GGCCTTCTTACGAGCCAAAA                        
14257R: TATTGGTGCGGGGGCTTTGTATAA  
60°C 300 bp  
J1 
2988F: CGATGTTGGATCAGGACATCTC                        
3235R: CTTAACAAACCCTGTTCTTGGG 
60°C 248 bp  
J2 
7239F: GCATACACCACATGAAACATCC                       
7860R: TCGTTGACCTCGTCTGTTATGT    
59°C 622 bp  
I 
9893F: CAAACATCACTTTGGCTTCG                           
10280R: GGGTAAAAGGAGGGCAATTT 
53°C 388 bp  
X 
14379F: CCATCGCTAACCCCACTAAA                                                                      
14996R: CGTGAAGGTAGCGGATGATT 
54°C 618 bp  
W 
8910F: CTTACCACAAGGCACACCTACA                       
9230R: ATAGGCATGTGATTGGTGGG 
58°C 320 bp  
M1 
10147F: ACATAGAAAAATCCACCCCT                           
10569R: CTAGGCATAGTAGGGAGGAT 
53°C 422 bp  
 59 
N1b 
10457F: TCATATTTACCAAATGCCCCTC                      
11750R: TGCTAGGCAGAATAGTAATGAGGATGTAGG 
64°C 1294 bp  
L 10498F: TAGCATTTACCATCTCACTTCT                       
10930R: GGAAAAGGTTGGGGAACAGC 
56°C 433 bp  
Tab. 5.1: primers and related sequences, annealing temperature and length of each fragment. 
 
Enzymatic digestion reaction 
The reaction has a final quantity of 25 µl composed of 7 µl of PCR product, 1 U of 
enzyme (New England) and related buffer 1X, and for a few enzyme also BSA 0.6X.  
The list of all enzyme is reported in Tab. 5.2, with information about their 
temperature, the dimension of digested and not digested fragments.  
 
 
Sub-hapl Enzyme Temp Digested fragments Not digested fragments Cut 
H AluI 37°C 137-75-30 167-75 - 
H1, J1 TaqI 65°C 228-20 248 - 
H3 NlaIII + BSA 37°C 139-31 170 + 
R0a HaeIII 37°C 228-32 260 + 
HV1-HV0* MseI + BSA 37°C 209-90-17-4 209-107-4 - 
HV0a MseI + BSA 37°C 430-175-142-108 430-108-67-38 + 
U1 HinfI 37°C 287-89-72 287-161 - 
U1a AluI 37°C 305-186-116 491-116 - 
U2e HinfI 37°C 462-134-99-86 561-134 + 
U3 MboI 37°C 610-127-120-36 610-156-27 + 
U4 RsaI 37°C 411-179-83-19 590-83-19 + 
U5a BsrbI 37°C 205-115 321 + 
U5b RsaI+AluI 37°C 700-123-23 700-146 - 
U6 MboI 37°C 311-263-34 574-34 + 
U7 Tsp509I 65°C 158-82-76-57-35 240-76-57-35 + 
U8b-K HaeII + BSA 37°C 224-132 356 - 
U9 HaeIII 37°C 140-123-72 195-140 - 
TJ NlaIII + BSA 37°C 149-74 224 + 
T1 AvaII 37°C 1200-615 o 738-615-462 1816 - 
T2 Tsp509I 65°C 85-73-62-54-26 88-85-73-54 - 
J2 AluI 37°C 235-219-167 409-219 - 
I AluI 37°C 200-139-48 339-48 + 
V NlaIII + BSA 37°C 269-163 432 - 
X AccI 37°C 531-86 618 + 
W HaeIII 37°C 205-84-31 205-115 - 
M1 AluI 37°C 172-165-85 343-85 + 
L MnlI + BSA 37°C 243-61-58 301-61 - 
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N1b AluI 37°C 441-313-215-142-106-70 441-313-227-142-106-70 - 
Tab. 5.2: list of haplogroups and their specific enzymes. Incubation temperature and fragments digested 
or not are reported. 
 
The digested product are visualized on agarose gel 2.5%, only T1 and T2 
subhaplogroups need particolar conditions: 
• Agarose gel 0,8% for T1 subhaplogroup (because of the great dimension of 
fragments) 
• agarose gel 4% for T2 subhaplogroup (because of the little dimension of 
fragments). 
If the first digestion does not confirm the hypotesis, it is necessari to revaluate the 
sequence, to suppose other subhaplogroup and digest the fragment with other enzyme. 
 
5. Automated procedure 
We also have automated the amplification and sequencing reaction with the 
MICROLAB STAR workstation, equipped with 16 channels and able to arrenge all the 
operation, reducing time and manual errors. The platform can prepare reactions for 96 
different samples, can distribute the reagent mix (manually prepared) in each well and 
96 different DNAs both stored in plates and in 2 ml tubes. The latest must be collocated 
in specific adaptor with the barcode turned to laser (Fig. 5.4). 
 
Fig. 5.4: robotic platform and the localization of all components and reagents. 
Blue plate  (-20°) + 
BioPlastic (96) plate 
4     5     6 
adapters for 1,5 
eppendorf 
1 
32 
33 
64 
65 
96 
B 
White plate (+4°) + 
Eppendorf 2 ml 
1 
7 
13 
19 
Green plate + BioPlastic 
(96) x DNA plate 
Filter Tips 
300  
Tips 300  
Filter Tips  
10  
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The MICROLAB STAR workstation also allows to perform the sequencing reaction 
(Fig. 5.5). As this reaction is performed with three primers for each sample, all the 96 samples 
are divided in three plates, each carrying 32 samples as follows: 
 
A1 A2 A3 A4 A1 A2 A3 A4 A1 A2 A3 A4
B1 B2 B3 B4 B1 B2 B3 B4 B1 B2 B3 B4
C1 C2 C3 C4 C1 C2 C3 C4 C1 C2 C3 C4
D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
E1 E2 E3 E4 E1 E2 E3 E4 E1 E2 E3 E4
F1 F2 F3 F4 F1 F2 F3 F4 F1 F2 F3 F4
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
H1 H2 H3 H4 H1 H2 H3 H4 H1 H2 H3 H4
Primer 1 Primer 2 Primer 3
  
Samples 1-32 
 
 
Fig. 5.5: robotic platform and the localization of all components and reagents for sequencing. 
 
6. Example of RFLP for H haplogroup 
In order to analyze the mtDNA genetic variability in our population and their 
relationship with longevity, different diagnostic sites has been identyfied through 
restriction analysis of the mtDNA coding region. This restriction allowed attributing at a 
single sample one specific haplogroup. 
Tips 300  
Filter Tips 10  
3 mix Plate     ABI 1 (1-32) 
Plate    BioPlastic 
(PCR) 
Plate     ABI 2 
(33-64) 
Plate     ABI 3 
(65-96) 
1 
7
1 13 
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An example of H haplogroup analysis (attributed with a first preliminary analysis 
by SeqScape) is reported. 
 
DNA amplification 
As expected, the agarose gel shows an amplified band of 242 bp (Fig. 5.6). The PCR 
program is the same used for D-loop amplification, only annealing temperature has been 
modified, because it depends on primers. 
 
 
Fig. 5.6: Amplification of a coding region fragment specific for H haplogroup. 
 
Digestion of amplified fragments 
The digestion of amplified regions is performed using AluI enzyme (specific for the 
H haplogroup identification) (Fig. 5.7). 
 
 
  Fig. 5.7: AluI digestion of specific amplificated traits for H haplogroup.  
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It is known that AluI must not cut in 7025 position to confirm the H haplogroup 
hypothesis. The 242 bp fragment can be cut: 
1) In only two fragments (one in 167 bp, and the other in 75 bp) if the enzyme has 
not digested in 7025 position; 
2) In three fragments (on in 137 bp, one in 75 bp  and in 30 bp) if the enzyme has 
digested in 7025 position; 
The overwhelming majority is not digested confirming our hypothesis and so it is 
necessary to continue with other amplifications and digestion with specific enzyme for 
H1 and H3. Samples which show 137 bp and 75 bp bands do not belong to H haplogroup, 
but to V haplogroup for example, which presents in position 73 the A nucleotide. 
Sample marked with (*) in Fig. 5.2 has probably endured a contamination; it is 
advisable to repeat the digestion. 
 
7. Statistical analysis 
The analysis of the sequences to determine haplogroups and somatic mtDNA 
variability was carried out by SeqScape software v 2.1.1 (Applied Biosystem). 
Mitochondrial sub-haplogroups, genotype frequencies and gender were compared 
between 90+ subjects and their ethnically-matched controls using the χ2 with Pearson 
correction or Fisher-exact test. 
The mitochondrial subhaplogroups variability envisages at least 80 
subhaplogroups, which have been further grouped into 27 subgroups considering their 
frequencies and phylogenetic relationship. The comparison between each of the 27 
mtDNA subhaplogroups in 90+ cases and younger ethnically-matched controls have 
been computed by applying Pearson's Chi-squared test with Yates' continuity correction. 
All analyses were performed separately for women and men, as well as for the 
total group. Tests for statistical significance were two-sided with = 0.05; we performed 
also a logistic regression to generate odds ratio (OR) with their associated 95% 
confidence intervals (CI), to asses odds of carrying each mtDNA haplogroups in cases 
compared with controls. R statistical software was used for all statistical analyses. 
The phylogenetic relation and the distribution of haplogroup J were represented 
by mathematical method of Median-Joining Network (Bandelt et al., 1999). This 
method combines two algorithms, one is Kruskal to calculate the minimum spanning 
trees and one is Farris euristic to calculate the maximum parsimony. The first was used 
to construct all the phylogenetic trees minimizing the sum of distances among 
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haplotypes, the latter to create median vectors which allow to group trees. We can 
consider median vectors as eventual haplotype not sampled or ancestral haplotype 
become extinct. Phylogenetic networks were constructed with Network 4.1.1.1 
program (http://www.ﬂuxus-engineering.com). Polymorphisms were divided into 4 
classes according to their rate of evolution (Hasegawa et al. 1993; Malyarchuk and 
Derenko 2001; Allard et al. 2002). Fast positions (16093, 16129, 16189, 16311, 16362) 
were weighted by one, intermediate positions (16051, 16126, 16145, 16168, 16172, 
16184, 16192, 16209, 16218, 16223, 16256, 16261, 16278, 16291, 16293, 16294, 
16304, 16320, 16325) by 2, and slow positions (all other transitions between 16024 and 
16383 as well as 16482) by 4.  
Multidimensional scaling (MDS) is a set of related statistical techniques used in 
information visualization for exploring similarities or dissimilarities in data. In general, 
the goal of the analysis is to detect meaningful underlying dimensions that allow to 
explain observed similarities or dissimilarities (distances) between the investigated 
objects. The distances used in MDS need not be metric, as non-metric distances such as 
ranking can be used and the output coordinates are in the standard Euclidean space of 
the user-chosen dimension. The program used to obtain the distribution gives “stress” 
values, related to the good quality of distances data. The lower is the stress value, better 
is the adaptation of the reproduced distance matrix. Conventionally, a map is considered 
acceptable if the stress value is less than 0.1. In this thesis, the not metric MDS analysis 
was implemented in the sammon function in MASS library of R program.  
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Chapter 6 
 
RESULTS 
 
 
1. Distribution of samples 
In this study it has been applied a high resolution analysis, through sequencing of 
d-loop and restriction analysis of specific markers in the coding region of mtDNA. We 
explore the mitochondriale haplogroups and the possible association between mtDNA-
inherited sequence variation and longevity in a total of 4,239 samples. In 1,292 it has 
been conducted the entire sequencing, in 2,947 it has been performed the RFLP analysis.  
The distribution between the sinlings and controls is shown in the table below. 
The Tab. 6.1 shows males/females proportion with its associated percentage. The 
haplogroup analysis is conducted on all our subjects and includes also samples whose 
mtDNA was completely sequenced. In particular our sample are divided as follows:  
 
ANALYSIS SIBS CONTROLS TOT 
Complete sequencing 637 655 1,292 
Dloop sequencing 1449 1498 2,947 
TOT 2,086 2,153 4,239 
 
In particular, the 1,292 samples are divided in 1,167 sequenced by the Chinese 
Partner (BGI) and 125 sequences analyzed in UNIBO. 
In our total sample, there is a higher proportion of female (69%) subjects but, in 
both categories (male and female), proportion is equilibrate (about 50% cases and 
controls). 
Moreover, subjects who can reach 100 years are higher in female than in male 
(respectively 4.8% e 2.7%). One possible reason is that males are under a much more 
stronger selection than females, so males can hardly reach the same female ages. This 
consideration reflects the general proportion in the population.  
 
 
 
 
 66 
 Males (N = 1,327)  Females (N = 2,860) 
 90+ (%) Controls (%)  90+ (%) Controls (%) 
N 628 (47) 699 (53)  1458 (50) 1454 (50) 
Mean Range 94.1 ± 2.5 61.7 ± 6.2  94.5 ± 2.6 61.7 ± 6.2 
Age range 89-103 43-79  88-107 49-83 
 17>100 years   70> 100 years  
Tab. 6.1: sample distribution and general characteristic of the study participants. 
 
 
All the analyzed samples come from European countries and from different 
geographic areas. For example Italy is represented by Bologna, Rome, Sassari and from 
Calabria region. 
It is extremely important for statistical analysis to balance the number of 90+ 
subjects with their matched controls as reported in Table 6.2 and Fig. 6.1. 
 
 
Country Center name No. siblings No. younger controls 
Belfast QUB 64 64 
Belgium UCL 80 88 
Bologna UNIBO 213 214 
Germany CAU 94 96 
Finland  TAMPERE 153 145 
Montpellier CRLC 274 275 
Newcastle  UNEW 99 100 
Denmark SDU 428 441 
Netherland LUMC 162 167 
Poland NENKI 129 132 
Roma ISS 75 75 
Sassari UNISS 47 52 
Ukraina INST GERONT 49 49 
Calabria UNICAL 125 152 
Greece NHRF 94 103 
Total  2,086 2,153 
 
Table 6.2: distribution of samples and their different countries. 
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Fig. 6.1: Graphic distribution of 90+ subjects and controls as reported in Tab.1. 
They are correctedly bilanced. 
 
1.1 Sex distribution of the participants 
As we observed previously, females are more numerous than males, except for 
Greece where more males than females were recruited. The total number of males and 
females divided per country is reported in Tab. 6.3 and in the following figures. 
 
 Sibs Controls 
 Male Female Male Female 
Belfast 16 48 15 49 
Belgium 25 55 26 62 
Bologna 55 158 54 160 
Calabria 41 84 66 86 
Denmark 138 290 141 300 
Finland 40 113 46 99 
Germany 31 63 30 66 
Greece 67 27 72 31 
Montpellier 75 199 77 198 
Netherland 52 110 74 93 
Newcastle 21 78 25 75 
Poland 24 105 26 106 
Roma 25 50 27 48 
Sassari 11 36 12 40 
Ukraina 7 42 8 41 
 
Tab. 6.3: Sex distribution (in %) 
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Fig. 6.2 : Sex distribution in each countries in all 90+ subjects (in %) 
 
 
 
 
Figure 6.3 : Sex distribution in each countries in all control subjects (in %) 
 69 
1.2 Age Distribution 
The following tables (Tab. 6.4 and Tab 6.5) summaries the minimum, median, and 
maximum age of the older siblings and controls, separately for females and males.  
 
 Female Male 
 Min Median Max Min Median Max 
Belfast 89 96.5 104 89 93.5 98 
Belgium 90 95.5 101 91 94 97 
Bologna 90 96 102 91 97 103 
Calabria 90 96 102 91 97 103 
Denmark 90 96.5 103 90 95 100 
Finland 88 95 102 89 96 103 
Germany 91 96.5 102 90 96 102 
Greece 91 99 107 90 96 102 
Montpellier 90 97.5 105 91 95.5 100 
Netherland 90 96 102 91 97 103 
Newcastle 90 96.5 103 91 95.5 100 
Poland 91 96.5 102 91 95 99 
Roma 91 95.5 100 91 95.5 100 
Sassari 91 96 101 91 94.5 98 
Ukraina 92 98 104 92 94.5 97 
 
Tab 6.4: Summary of age-distribution for old siblings by sex and country (age in years) 
 
Fig. 6.4: Age distribution boxplot of female siblings by countries 
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Fig. 6.5: Age distribution boxplot of male siblings by countries 
 
 Female Male 
 Min Median Max Min Median Max 
Belfast 50 62.5 75 56 65 74 
Belgium 50 61.5 73 50 62.5 75 
Bologna 50 62.5 75 51 62 73 
Calabria 50 62.5 75 50 62.5 75 
Denmark 50 66.5 83 43 61 79 
Finland 50 62.5 75 50 61.5 73 
Germany 53 64 75 51 61.5 72 
Greece 50 62.5 75 50 63 76 
Montpellier 50 62 74 50 63 76 
Netherland 50 65 80 51 63.5 76 
Newcastle 50 62.5 75 51 63.5 76 
Poland 49 61 73 49 61.5 74 
Roma 50 61.5 73 52 60.5 69 
Sassari 54 65 76 61 64.5 68 
Ukraina 56 66 76 61 64.5 68 
 
Tab. 6.5: Summary of age-distribution for the controls by sex and country (age in years) 
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Fig. 6.6: Age distribution boxplot of female controls by countries. 
 
Fig. 6.7: Age distribution boxplot of male controls by countries. 
 
The red bars in the figures above indicate the general average age and we can 
observe that, specially among 90+ males, dividing in geographical areas, Bologna, 
Calabria, Rome and Greece (which belong to Mediterranean area) and Germany, Finland 
and Netherland (to the northern areas) have an higher average age than other countries 
and other subjects. 
  
2. Distribution of haplogroups 
Among our total samples (4,239 samples), the hierarchical survey of diagnostic 
markers, present in the coding region, allowed the classification of mtDNA from 90+ and 
controls into more than 40 haplogroups and sub-haplogroups. Most of these are typical 
of modern European population, but a few percentage of East Asian (M1a, D5a), sub-
Saharian African (L1b1) and North American (A4, C1d) mtDNAs has been also detected. 
This latter finding is not so unexpected because in Europe, East Asian and in particular 
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African haplogroups are quite common. We decided to group all the sub-haplogroups 
with frequencies lower than 1.5%, thus reducing the overall number of categories from 
85 (see Tab.1 in the Appendix) to 22 (Tab. 6.6 and Fig. 6.8). 
 
90+ sibpair (n=2,086)  controls (n=2,153) 
sub-haplogroups N % SE  sub-haplogroups N % SE 
H* (1) 402 19.27 0.0086  H* (1) 381 17.70 0.0082 
H1 292 14.00 0.0076  H1 325 15.10 0.0077 
H2 42 2.01 0.0031  H2 23 1.07 0.0022 
H3 71 3.40 0.0040  H3 85 3.95 0.0042 
H5 68 3.26 0.0039  H5 63 2.93 0.0036 
H6 52 2.49 0.0034  H6 47 2.18 0.0031 
HV0* (2) 83 3.98 0.0043  HV0* (2) 68 3.16 0.0038 
HV* 42 2.01 0.0031  HV* 50 2.32 0.0032 
I 46 2.21 0.0032  I 44 2.04 0.0030 
J1 144 6.90 0.0056  J1 153 7.11 0.0055 
J2 39 1.87 0.0030  J2 57 2.65 0.0035 
K1 117 5.61 0.0050  K1 140 6.50 0.0053 
T1 43 2.06 0.0000  T1 53 2.46 0.0033 
T2 174 8.34 0.0061  T2 152 7.06 0.0055 
U (3) 59 2.83 0.0036  U (3) 61 2.83 0.0036 
U2 38 1.82 0.0029  U2 39 1.81 0.0029 
U4 34 1.63 0.0028  U4 48 2.23 0.0032 
U5a 90 4.31 0.0044  U5a 109 5.06 0.0047 
U5b 51 2.44 0.0034  U5b 56 2.60 0.0034 
W 51 2.44 0.0034  W 39 1.81 0.0029 
X 42 2.01 0.0031  X 41 1.90 0.0029 
OTHER (4) 106 5.08 0.0048  OTHER (4) 119 5.53 0.0049 
 
Tab. 6.6: list of sub-haplogroups with the related frequencies and Standard Error (SE). (1) H* includes all 
mtDNAs belonging to H, except those classified as H1, H3, H5 and H6. (2) HV0* includes HV0a, (3) U 
includes U1, U3, U6, U7, U8, (4) OTHER includes K, K2, T, R0, R0a, R1, R2, HV1, HV2, N1a, N1b, N1c,N9a, 
A4, D5, C1d, M1, L1b1, with frequencies lower than 1,5%. 
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Fig. 6.8: Distribution of the most important haplogroups. 
 
No significant difference was found between cases and controls distribution in 
mtDNAs classification. 
Comparing our frequencies with those previously reported in literature Tab. 6.7 
(Richards et al. 2000), we verified that our results correspond with a good 
approximation to the reference values referred to populations. 
 
Haplogroup  90+ subjects  Controls  Reference (*)  
HV   51.7%  48.3%  50.4-54.1%  
 H  44.4%  42.9%  44.5-48.2%  
 V  1.3%  1.5%  3.9-5.4%  
J   8.7%  9.7%  8.3-10.4%  
T   10.6%  9.8%  7.2-9.2%  
U   13.0%  14.5%  20.1-23.2%  
K   6.5%  7.4%  4.9-6.6%  
I   2.2%  2.0%  1.6-2.7%  
W   2.4%  1.8%  1.5-2.5%  
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X   2.0%  1.9%  1.2-2.0%  
(*) Richards et al. 2000    
Tab. 6.7: The table shows the haplogrops’ frequencies compared with those reported by Richards et al. 
2000. 
 
In general, frequencies are similar to those reported in literature except for 
frequencies of V, T and U haplogroups that are more distant from Richards data. In 
particular haplogroup HV resulted to be the most frequent, present in 51.7% 
nonagenarians and 48.3% controls in agreement to previous studies (Torroni et al. 
1996). Haplogroup T has a  higher frequency both in 90+ subjects and controls than in 
reference population, while haplogroups V and U have an opposite trend. Probably, it 
could be due to the fact that we have studied new population previously never explored.  
It is also extremely important to perform analysis data divided for gender. The 
sub-haplogroups, the frequencies, the Standard Error and the comparison between male 
and female are shown in Tab. 6.8 and Tab. 6.9 (and respectively in Fig. 6.9 and Fig. 
6.10). 
 
Males (N = 1327) 
  90+ subjects (N=628)   Controls (N= 699) 
 N % SE  N % SE 
H* (1) 134 21.3 0.0163   135 19.3 0.0149 
H1 75 11.9 0.0129  108 15.5 0.0137 
H2 10 1.6 0.0050   11 1.6 0.0047 
H3 18 2.9 0.0067  16 2.3 0.0057 
H5 24 3.8 0.0077   20 2.9 0.0063 
H6 19 3.0 0.0068  16 2.3 0.0057 
HV0* (2) 24 3.8 0.0077   24 3.4 0.0069 
HV* 14 2.2 0.0059  17 2.4 0.0058 
I 7 1.1 0.0042   13 1.9 0.0051 
J1 40 6.4 0.0097  44 6.3 0.0092 
J2 6 1.0 0.0039   22 3.1 0.0066 
K1 47 7.5 0.0105  46 6.6 0.0094 
T1 11 1.8 0.0052   11 1.6 0.0047 
T2 46 7.3 0.0104  54 7.7 0.0101 
U (3) 21 3.3 0.0072   20 2.9 0.0063 
U2 12 1.9 0.0055  13 1.9 0.0051 
U4 13 2.1 0.0057   13 1.9 0.0051 
U5a 24 3.8 0.0077  30 4.3 0.0077 
U5b 18 2.9 0.0067   17 2.4 0.0058 
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W 13 2.1 0.0057  16 2.3 0.0057 
X 18 2.9 0.0067   19 2.7 0.0062 
OTHER (4) 34 5.4 0.0090  34 4.9 0.0081 
 
 
Tab. 6.8: frequencies of male mtDNA sub-haplogroups of 628 90+subjects and 699 controls from all 
European countries. SE=Standard Error; Sub-haplogroups with frequencies lower than 1.5% were 
grouped. (1) H* includes all mtDNAs belonging to H, except those classified as H1, H3, H5 and H6. (2) HV0* 
includes HV0a, (3) U includes U1, U3, U6, U7, U8, (4) OTHER includes K, K2, T, R0, R0a, R1, R2, HV1, HV2, 
N1a, N1b, N1c,N9a, A4, D5, C1d, M1, L1b1, with frequencies lower than 1.5%. 
 
 
 
Fig. 6.9: Haplogroup distribution of frequencies in males. 
 
The Pearson chi-squared test has demonstrated that haplogroup distribution in 
males is not significant (X-squared = 22.6211, p-value = 0.6543). 
 
Females (N = 2912) 
  90+ subjects (N= 1458)   Controls (N= 1454) 
 N % SE  N % SE 
H* 268 18.4 0.0101   246 16.9 0.0098 
H1 217 14.9 0.0093  217 14.9 0.0093 
H2 32 2.2 0.0038   12 0.8 0.0024 
H3 53 3.6 0.0049  69 4.7 0.0056 
H5 44 3.0 0.0045   43 3.0 0.0044 
H6 33 2.3 0.0039  31 2.1 0.0038 
HV0* 59 4.0 0.0052   44 3.0 0.0045 
HV* 28 1.9 0.0036  33 2.3 0.0039 
I 39 2.7 0.0042   31 2.1 0.0038 
J1 104 7.1 0.0067  109 7.5 0.0069 
J2 33 2.3 0.0039   35 2.4 0.0040 
K1 70 4.8 0.0056  94 6.5 0.0064 
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T1 32 2.2 0.0038   42 2.9 0.0044 
T2 128 8.8 0.0074  98 6.7 0.0066 
U 38 2.6 0.0042   41 2.8 0.0043 
U2 26 1.8 0.0035  26 1.8 0.0035 
U4 21 1.4 0.0031   35 2.4 0.0040 
U5a 66 4.5 0.0054  79 5.4 0.0059 
U5b 33 2.3 0.0039   39 2.7 0.0042 
W 38 2.6 0.0042  23 1.6 0.0033 
X 24 1.6 0.0033   22 1.5 0.0032 
OTHER 72 4.9 0.0057  85 5.8 0.0062 
 
Tab. 6.9: frequencies of female mtDNA sub-haplogroups in 1458 90+ subjects and 1,454 controls from 11 
European countries. SE=Standard Error; Sub-haplogroups with frequencies lower than 1.5% were grouped. 
H* includes all mtDNAs belonging to haplogroup H, except those further classified (H1, H3, H5 and H6). 
The same rationale has been used for HV0*, U and Other. 
 
 
Fig. 6.10: HaplogroupS’ distribution of frequencies in females. 
 
The Pearson chi-squared test has demonstrated that haplogroup distribution in 
females is slightly statistical significant (X-squared = 39.5362, p-value = 0.04329). Also a 
XY conditioning plot analysis was conducted: thit is a plot of two variables conditional 
on the value of a third variable (called the conditioning variable). The conditioning 
variable may be either a variable that takes on only a few discrete values or a continuous 
variable that is divided into a limited number of subsets. In the graph below (Fig. 6.11) 
it is possible to notice that for both cases and controls the majority of haplogroup 
frequencies are around the 5%, only a few are near 10% and two are more than 15%. 
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Fig. 6.11: a XY conditioning plot divided in Females and Males. On the ordinate there are the haplogroup 
frequencies of 90+ subjects, on the x-axis the controls frequencies (there are 26 dots, each corresponding 
to an haplogroup). On the x-axis the frequency of controls is reported, on the y-axis the frequency of 
siblings. 
 
3. Associations between haplogroups and longevity 
As no difference has been revealed from the distribution between 90+ cases and 
controls even when frequencies were compared separately for gender, we further 
proceeded with statistical analysis performing an association test (Fisher test) between 
cases/controls and gender (Tab. 6.10) for each subhaplogroup (high resolution 
analysis), to identify the potential sub-haplogroup associated with healthy aging and 
longevity.  
Subhaplogroups OR 95% CI 
Fisher exact test 
p value 
H 0.874 0.71 - 1.06 0.1938 
H1 0.695 0.48 - 0.99 0.0427 
H3 1.461 0.63 - 3.38 0.3379 
H5 1.171 0.53 - 2.59 0.7137 
H6 1.114 0.45 - 2.77 0.8357 
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HV 0.971 0.37 - 2.52 1 
HV0* 0.884 0.47 - 1.64 0.7665 
I 0.484 0.08 - 2.45 0.4748 
I1 0.392 0.006 - 6.09 0.6030 
I3 0.367 0.02 - 3.41 0.3707 
J1 0.953 0.55 - 1.62 0.8978 
J2 0.293 0.08 - 0.86 0.0214 
K 0.403 0.060 - 2.31 0.2761 
K1 1.370 0.79 - 2.36 0.2425 
K2 0.102 0.001 - 1.73 0.1026 
N 3 0.078 - 234.45 1 
N1 0.728 0.13 - 3.64 0.7311 
R0 4.156 0.34 - 232.12 0.3333 
T 1.886 0.12 - 37.90 1 
T1 1.309 0.45 - 3.80 0.6303 
T2 0.653 0.39 - 1.07 0.0918 
U1 1.137 0.17 - 7.49 1 
U2 0.924 0.31 - 2.66 1 
U3 2.023 0.28 - 24.13 0.6800 
U4 1.656 0.58 - 4.72 0.3392 
U5 1.060 0.62 - 1.78 0.9000 
U6 3.237 0.29 - 51.96 0.3348 
U8 2.307 0.33 - 17.92 0.4136 
W 0.724 0.20 - 2.53 0.5843 
W5 0.141 0.0014 - 4.93 0.2262 
X 1.570 0.25 - 10.38 0.6951 
X2 0.577 0.17 - 1.87 0.4210 
 
Tab. 6.10: Fisher test (p-value), Odds ratio (OR) and 95% Confidence Intervals (95%CI) for 
subhaplogroups in the entire sample. 
 
In Tab. 6.10 only the principal subhaplogroups are reported, the other are too few 
to give a significative result (for example A4, C, D, L, M, N, R1, R2, U7, U9, W1, W4, W6 
and X1). 
Of all haplogroups, only H1 and J2 resulted significant. 
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Fig. 6.12: distribution of males and females, cases and controls belonging to H1 haplogroup. 
 
Among all males, H1 is more represented in controls than cases, while among 
females the frequency is similar. The p value is slightly significant (p=0.0427) (Fig. 
6.12). 
As regard haplogroup J2,  differences between cases and controls resulted 
significant (p=0.0214). If we take into account gender considering the distribution 
among males shows that more than 80% are cases, as Fig. 6.13 reports, while among 
females the frequency is equally distributed. 
 
 
Fig. 6.13:  distribution of male and female belonging to J2 haplogroup. It is represented with a high 
frequency among male controls. 
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These percentages mean that haplogroup J2 has an higher frequency among male 
controls than cases and that we cannot observe any difference between the cases and 
controls among females. 
 
4. H1 and J2 distribution in countries 
We also analyzed the distribution of H1 and J2 haplogroup in the 11 European 
countries in order to investigate the possible association with one or more countries. By 
applying a Pearson's Chi-squared test to each country in the H1 distribution (Tab. 6.11 
and Fig. 6.14), without taking into account gender, we verified that H1 is significantly 
associated with control  belonging to Greece (p=0.0455), Poland (p=0.01631) and highly 
associated with Newcastle (p=0.00604). But H1 inverts its trend in Belfast, Belgium, 
Montpellier, Finland and Sassari even if they are not significant (being more represented 
in 90+ subjects of different countries than controls). If we stratify for gender, we could 
find that H1 in Greece, Poland and Newcastle, is significantly associated with male 
controls confirming this association (data not reported). 
 
 90+  controls 
 N % SE  N % SE 
Belfast 12 4.1 0.0150  8 2.5 0.0126 
Belgium 17 5.8 0.0178  15 4.6 0.0170 
Bologna 20 6.8 0.0191  29 8.9 0.0231 
Calabria 9 3.1 0.0131  14 4.3 0.0165 
Denmark 75 25.7 0.0331  81 24.9 0.0351 
Finland 25 8.6 0.0212  22 6.8 0.0204 
Germany 13 4.5 0.0156  14 4.3 0.0165 
Greece 4 1.4 0.0088  12 3.7 0.0153 
Montpellier 48 16.4 0.0281  44 13.5 0.0278 
Netherland 19 6.5 0.0187  21 6.5 0.0199 
Newcastle 6 2.1 0.0108  20 6.2 0.0195 
Poland 12 4.1 0.0150  27 8.3 0.0224 
Roma 9 3.1 0.0131  4 1.2 0.0089 
Sassari 16 5.5 0.0173  7 2.2 0.0118 
Ukraina 7 2.4 0.0116  7 2.2 0.0118 
 
Tab. 6.11: distribution of haplogroup H1 in all the 11 countries. The frequencies and the Standard Error 
(SE) are reported. 
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Fig. 6.14: H1 distribution for cases and controls in all countries. 
 
The same rationale has been used for J2 haplogroup distribution (Tab. 6.12 and 
Fig. 6.15) and the same Pearson's Chi-squared test was conducted, showing that J2 is 
associated with male controls belonging to Calabria (p=0.008151) and Greece 
(p=0.02535), which surprisingly represent the South Europe. As the distribution of this 
haplogroup evidences, J2 is not represented among 90+ subjects in Calabria and Greece 
but only among controls subjects. The absence of association of mtDNA haplogroup J 
with longevity in southern Italian population was previously observed (De Benedictis et 
al, 1999 and Dato et al, 2004). 
 90+  controls 
 N % SE  N % SE 
Belfast 1 2.6 0.0120  3 5.3 0.0181 
Belgium 2 5.1 0.0167  2 3.5 0.0149 
Bologna 3 7.7 0.0202  5 8.8 0.0229 
Calabria 0 0.0 0.0000  7 12.3 0.0266 
Denmark 9 23.1 0.0319  12 21.1 0.0331 
Finland 3 7.7 0.0202  5 8.8 0.0229 
Germany 4 10.3 0.0230  1 1.8 0.0106 
Greece 0 0.0 0.0000  5 8.8 0.0229 
Montpellier 4 10.3 0.0230  6 10.5 0.0249 
Netherland 2 5.1 0.0167  4 7.0 0.0207 
Newcastle 2 5.1 0.0167  1 1.8 0.0106 
Poland 3 7.7 0.0202  2 3.5 0.0149 
Roma 1 2.6 0.0120  0 0.0 0.0000 
Sassari 4 10.3 0.0230  3 5.3 0.0181 
Ukraina 1 2.6 0.0120  1 1.8 0.0106 
 
Tab. 6.12: distribution of haplogroup J2 in all the 11 countries. We reported the frequencies and the 
Standard Error (SE). 
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As we can observe from the distribution of J2 in each country, the distribution of 
this subhaplogroup, not considering Calabria and Greece, is nearly balanced (for a total 
of 39 J2 cases and 45 J2 controls), but when considering also these two areas, J2 seems 
to be more prevalent in controls. We conclude that Calabria and Greece determined this 
difference. The frequency in Calabria and Greece is high (respectively 4.6% and 4.8%) 
considering that J2 represents only 2% of the entire distribution (2.6% in controls and 
1.8% in siblings).  
 
 
Fig. 6.15: Distribution of J2 in all the 11 countries adherent to the Project. 
 
Also, if we stratify for gender, we could better appreciate the association between 
J2 and male controls but the number of samples belonging to this haplogroup is not 
enough to conduct exhaustive statistical analysis. 
 
5. How subhaplogroups can influence associations? 
Furthermore, we have studied the distribution of all subhaplogroups of H1 (H1a, 
H1a1, H1a2, H1a3, H1b, H1c, H1c1, H1e, H1f, H1n) in order to verify which 
subhaplogroup, if present, could influence the association (Fig. 6.16). The analysis was 
conducted only taking into account the complete sequences. In fact, simply analyzing the 
Dlopp sequences we are not able to assign the subhaplogroups of H1. Only by 
sequencing the entire sequence we can go more deeply in the analysis. 
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Fig. 6.16: distribution of all H1 subhaplogroups. None of the subhaplogroups resulted significant. 
 
The calculation of p value for all  the subhaplogroups, taking into account 
male/female and case/control, reported no significant data. 
Furthermore, we have studied the distribution of the subhaplogroups J2a and J2b, 
and we observed that only J2a is really significant (X-squared = 5.6958, p-value = 
0.01701) rather than J2b subhaplogroup (X-squared = 1.1722, p-value = 0.2789). If we 
consider the distribution in male and females (Fig. 6.17 and Fig. 6.18), among males 
about 80% are controls, confirming the J2 haplogroup trend. This analysis was 
conducted both on complete sequences and on d-loop sequences. 
 
 
Fig. 6.17: distribution of J2a among gender.  
 
 
 84 
This fact suggests that the higher frequency of haplogroup J2 in male controls is 
attributable to an increase in subcluster J2a, rather than to J2b. 
 
 
Fig. 6.18: distribution of J2b among gender. 
 
These data are in contrast with data reported by literature. The fact that J2 has a 
higher frequency in male controls is not supported by previous studies conducted in 
North Italy and in Finland (De Benedictis, 1999, Niemi et al. 2003). Other studies are in 
contrast with the findings of De Benedictis et al. (1999). The study conducted by Ross et 
al. (2001) on Irish failed to show any J haplogroup association with either age and 
gender. We found the association between H1 and male controls, and with a highly 
significance, J2 with male controls. 
It is very interesting to note that in general J2 haplogroup appears to be slightly 
more frequent in 90+ females than in control females, even thought this data is not 
significant. But analyzing J2a and J2b subhaplogroups, we can see an opposite trend: J2a 
seems to be more frequent in cases while J2b in controls. 
 
6. Analysis of quartiles 
A quartile is one of the three values that divide a range of data into four equal 
parts. The first quartile (also defined “lower quartile”) is the number below which lies 
the 25 percent of the bottom data. The second quartile (the 'median') divides the range 
in the middle and has 50 percent of the data below it. The third quartile (also called 
'upper quartile') has 75 percent of the data below it and the top 25 percent of the data 
above it.  
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We tried to analyze our 90+ subjects samples using quartiles in order to discover 
association never seen. For men, we identified different values: the I quartile is 
represented by samples with age below 92 years, the II quartile by subjects with 92 and 
93 years, the III quartile by samples with 94 and 95 years and the IV quartile by subjects 
with age higher than 96 years (to 103 years). For women, the I quartile groups samples 
with age below 93 years, the II quartile is represented by subjects with 93 years, the III 
quartile by samples with 94 and 95 years (Median value is 94) and the IV quartile by 
subjects with age higher than 96 years (to 107 years). The values of median, lower 
quartile and upper quartile are as follows: 
 
  Male Female 
Median 94 94 
Lower quartile 92 93 
Upper quartile 96 96 
 
We wanted to study the association between J2 and subjects with more than 96 
years (the upper quartile value) and eventually apply the same association study to all 
other haplogroups.  
Firstly we analyzed J haplogroup in a case/control study, taking into account the 
gender. By applying a Fisher exact test, J1 subhaplogroup seems to be no significantly 
associated with this group of subjects (OR=0.78, 95%CI 0.39-1.51, p=0.5337), J2 is again 
significant and associated with male controls (OR=0.24, 95%CI 0.041-0.96, p=0.03302), 
in fact among males, 88% is represented by controls, as Fig. 6.19 shows.  
 
 
Fig. 6.19: distribution of males and females to J2 haplogroup in cases and controls. 88% of males are 
controls. 
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By extending this analysis on this restricted group to all haplogroups in this 
restricted group (over 96 years), also T2 haplogroup resulted significant (OR=0.566, 
95%CI 0.30-1.02, p=0.05) as Fig. 6.20 shows. Among cases, 76% are females while 
males are only 23%. T2 is tendentially more represented in females both cases and 
controls. In T2 subjects younger than 96 years old no significant association is observed. 
Instead, H1 is now not significant (p=0.09).  
 
 
Fig. 6.20: distribution of males and females belonging to T2 haplogroup in cases and controls. 69% of 
males are represented by controls. 
 
 
7. Analysis of mutations in complete sequences 
  
7.1 J2 haplogroup and complete sequencing 
In order to identify whether the association of J2 with longevity could be attributed 
to specific mutations, the complete sequences of Finland and Denmark samples were 
analyzed. The Operative Unit of Bologna has sequenced all mtDNAs from Calabria and 
Greece but J2 is not represented among sibs, while among controls there were only two 
sequences for Greece and one for Calabria, not sufficient for statistical analysis or more 
simply for a comparison. The Chinese Partner has sequenced mtDNAs from Finland and 
Denmark and we have used these data in order to verify whether could exist a mutation 
or mutations more frequent in 90+ subjects than controls or viceversa. In order to assess 
if the J2 background of the patients harboured mutations responsible for the longevity 
phenotype, we investigated the complete sequences of J2 haplogroup subjects 
(compared to controls). The result of the sequence analysis is summarized in Table 
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6.13. A total of 110 mutated positions relative to the reference sequence of Cambridge 
were detected and analyzed. Overall 23 of the total mutations (underlined and in italics) 
were not previously reported in either MITOMAP (www.mitomap.org) or mtDB 
(www.genpat.uu.se/mtDB) and each mutation was observed only in a single J2 mtDNA. 
Nucleotide 
position 
Locus Nucleotide 
Change 
Aminoacid 
Change 
90+ subjects 
N=12 (%) 
Controls 
N=17 (%) 
73 D-loop (HVSII) A>G  non coding 12 (100) 17 (100) 
146 D-loop (HVSII) T>C  non coding 1 (8,3) 0 (0) 
150 D-loop (HVSII) C>T  non coding 12 (100) 17 (100) 
152 D-loop (HVSII) T>C  non coding 12 (100) 17 (100) 
189 D-loop (HVSII) A>G  non coding 1 (8,3) 3 (17,6) 
195 D-loop (HVSII) T>C  non coding 9 (75) 13 (76,5) 
203 D-loop (HVSII) G>A  non coding 1 (8,3) 0 (0) 
215 D-loop (HVSII) A>G  non coding 9 (75) 12 (70,6) 
295 D-loop (HVSII) C>T  non coding 12 (100) 17 (100) 
319 D-loop (HVSII) T>C  non coding 9 (75) 13 (76,5) 
430 D-loop T>C  non coding 0 (0) 2 (11,8) 
489 D-loop (HVSIII) T>C  non coding 12 (100) 17 (100) 
513 D-loop (HVSIII) G>A  non coding 9 (75) 13 (76,5) 
569 D-loop (HVSIII) C>T  non coding 1 (8,3) 0 (0) 
709 rRNA 12S G>A  - 1 (8,3) 1 (5,9) 
750 rRNA 12S A>G  - 12 (100) 17 (100) 
1438 rRNA 12S A>G  - 12 (100) 17 (100) 
1850 rRNA 16S T>C  - 9 (75) 13 (76,5) 
2706 rRNA 16S A>G  - 12 (100) 17 (100) 
2824 rRNA 16S C>G  - 1 (8,3) 0 (0) 
3447 NADH dehydrogenase subunit 1 A>G  synonymous 4 (33,3) 5 (29,4) 
3915 NADH dehydrogenase subunit 1 G>A  synonymous 1 (8,3) 0 (0) 
3930 NADH dehydrogenase subunit 1 C>T  synonymous 0 (0) 1 (5,9) 
4216 NADH dehydrogenase subunit 1 T>C  Tyr Y > His H 12 (100) 17 (100) 
4232 NADH dehydrogenase subunit 1 T>C  Ile I > Thr T 0 (0) 1 (5,9) 
4769 tRNa isoleucine A>G  - 12 (100) 17 (100) 
5290 NADH dehydrogenase subunit 2 A>G  Asn N > Ser S 0 (0) 1 (5,9) 
5307 NADH dehydrogenase subunit 2 A>G  Thr T > Ala A 0 (0) 1 (5,9) 
5585 - G>A  - 2 (16,7) 0 (0) 
5633 tRNa alanine C>T  - 3 (25) 4 (23,5) 
5936 Cytochrome c oxidase subunit I  C>A  Asn N > Lys K 0 (0) 1 (5,9) 
6019 Cytochrome c oxidase subunit I  C>G  Ala A > Gly G 0 (0) 1 (5,9) 
6020 Cytochrome c oxidase subunit I  C>G  synonymous 0 (0) 1 (5,9) 
6024 Cytochrome c oxidase subunit I  C>A  Leu L > Met M 0 (0) 1 (5,9) 
6025 Cytochrome c oxidase subunit I  T>A  Leu L > Gln Q 0 (0) 1 (5,9) 
6026 Cytochrome c oxidase subunit I  G>A  synonymous 0 (0) 1 (5,9) 
6027 Cytochrome c oxidase subunit I  G>A  Gly G > Ser S 0 (0) 1 (5,9) 
6029 Cytochrome c oxidase subunit I  C>A  synonymous 0 (0) 1 (5,9) 
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6378 Cytochrome c oxidase subunit I  T>C  synonymous 1 (8,3) 0 (0) 
6447 Cytochrome c oxidase subunit I  C>T  Pro P > Ser S 0 (0) 1 (5,9) 
6448 Cytochrome c oxidase subunit I  C>A  Pro P > His H 0 (0) 1 (5,9) 
6731 Cytochrome c oxidase subunit I  T>C  synonymous 1 (8,3) 0 (0) 
7028 Cytochrome c oxidase subunit I  C>T  synonymous 12 (100) 16 (94,1) 
7302 Cytochrome c oxidase subunit I  T>C  synonymous 1 (8,3) 0 (0) 
7476 tRNA serine C>T  - 12 (100) 17 (100) 
7501 tRNA serine T>C  - 2 (16,7) 2 (11,8) 
7690 Cytochrome c oxidase subunit II C>T  synonymous 0 (0) 1 (5,9) 
7789 Cytochrome c oxidase subunit II G>A  synonymous 9 (75) 12 (70,6) 
7960 Cytochrome c oxidase subunit II A>G  synonymous 1 (8,3) 0 (0) 
8245 Cytochrome c oxidase subunit II A>G  synonymous 1 (8,3) 0 (0) 
8860 ATP synthase F0 subunit 6  A>G  Thr T > Ala A 12 (100) 17 (100) 
8904 ATP synthase F0 subunit 6  C>T  synonymous 0 (0) 1 (5,9) 
9145 ATP synthase F0 subunit 6  G>A  Ala A> Thr T 1 (8,3) 0 (0) 
9344 Cytochrome c oxidase subunit III C>T  synonymous 0 (0) 1 (5,9) 
9477 Cytochrome c oxidase subunit III G>A  Val V> Ile I 1 (8,3) 0 (0) 
9788 Cytochrome c oxidase subunit III C>G  synonymous 1 (8,3) 0 (0) 
9791 Cytochrome c oxidase subunit III A>T  synonymous 2 (16,7) 0 (0) 
9856 Cytochrome c oxidase subunit III T>G  Ile I > Ser S 0 (0) 1 (5,9) 
9857 Cytochrome c oxidase subunit III C>G  Ile I > Met M  0 (0) 1 (5,9) 
9861 Cytochrome c oxidase subunit III T>C  Phe F > Leu L 0 (0) 1 (5,9) 
10172 NADH dehydrogenase subunit 3  G>A  synonymous 3 (25) 4 (23,5) 
10237 NADH dehydrogenase subunit 4 T>C  Ile I > Thr T 1 (8,3) 3 (17,6) 
10398 NADH dehydrogenase subunit 5 A>G  Thr T > Ala A 12 (100) 17 (100) 
10448 tRNA arginine T>C  - 1 (8,3) 0 (0) 
10499 NADH dehydrogenase subunit 4L  A>G  synonymous 9 (75) 13 (76,5) 
10801 NADH dehydrogenase subunit 4  G>A  synonymous 0 (0) 1 (5,9) 
10961 NADH dehydrogenase subunit 4  C>T  synonymous 1 (8,3) 0 (0) 
10966 NADH dehydrogenase subunit 4  T>C  synonymous 1 (8,3) 0 (0) 
11251 NADH dehydrogenase subunit 4  A>G  synonymous 12 (100) 17 (100) 
11377 NADH dehydrogenase subunit 4  G>A  synonymous 9 (75) 13 (76,5) 
11719 NADH dehydrogenase subunit 4  G>A  synonymous 12 (100) 17 (100) 
11900 NADH dehydrogenase subunit 4  G>A  Val V > Met M 1 (8,3) 0 (0) 
12528 NADH dehydrogenase subunit 5  G>A  synonymous 12 (100) 17 (100) 
12612 NADH dehydrogenase subunit 5  A>G  synonymous 12 (100) 17 (100) 
13026 NADH dehydrogenase subunit 5  C>T  synonymous 1 (8,3) 0 (0) 
13708 NADH dehydrogenase subunit 5  G>A  Ala A> Thr T 12 (100) 17 (100) 
13722 NADH dehydrogenase subunit 5  A>G  synonymous 9 (75) 13 (76,5) 
14133 NADH dehydrogenase subunit 5  A>G  synonymous 9 (75) 13 (76,5) 
14180 NADH dehydrogenase subunit 6 T>C  synonymous 0 (0) 1 (5,9) 
14194 NADH dehydrogenase subunit 6 C>T  synonymous 1 (8,3) 0 (0) 
14759 cytochrome b C>A  Arg R> Gly G 0 (0) 1 (5,9) 
14766 cytochrome b C>T  Ile I > Thr T 12 (100) 17 (100) 
15014 cytochrome b T>C  Phe F > Leu L 1 (8,3) 0 (0) 
15191 cytochrome b T>C  Leu L > Met M 1 (8,3) 3 (17,6) 
15213 cytochrome b T>C  Ile I > Thr T 0 (0) 1 (5,9) 
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15217 cytochrome b G>A  synonymous 2 (16,7) 0 (0) 
15257 cytochrome b G>A  Asp D > Asn N 12 (100) 17 (100) 
15326 cytochrome b A>G  Thr T > Ala A 12 (100) 17 (100) 
15452 cytochrome b C>A  Leu L > Ile I 12 (100) 17 (100) 
15613 cytochrome b A>G  synonymous 0 (0) 1 (5,9) 
15812 cytochrome b G>A  Val V > Met M 3 (25) 4 (23,5) 
15930 tRNA threonine G>A  - 1 (8,3) 0 (0) 
15983 tRNA proline T>C  - 1 (8,3) 0 (0) 
16037 D-loop A>G  non coding 0 (0) 1 (5,9) 
16069 D-loop (HVS I) C>T  non coding 12 (100) 17 (100) 
16086 D-loop (HVS I) T>C  non coding 1 (8,3) 0 (0) 
16126 D-loop (HVS I) T>C  non coding 12 (100) 17 (100) 
16145 D-loop (HVS I) G>A  non coding 9 (75) 13 (76,5) 
16168 D-loop (HVS I) C>T  non coding 0 (0) 1 (5,9) 
16172 D-loop (HVS I) T>C  non coding 1 (8,3) 3 (17,6) 
16193 D-loop (HVS I) C>T  non coding 3 (25) 4 (23,5) 
16220 D-loop (HVS I) A>G  non coding 0 (0) 1 (5,9) 
16231 D-loop (HVS I) T>C  non coding 9 (75) 13 (76,5) 
16261 D-loop (HVS I) C>T  non coding 9 (75) 13 (76,5) 
16278 D-loop (HVS I) C>T  non coding 3 (25) 3 (17,6) 
16299 D-loop (HVS I) A>G  non coding 0 (0) 1 (5,9) 
16301 D-loop (HVS I) C>T  non coding 1 (8,3) 1 (5,9) 
16311 D-loop (HVS I) T>C  non coding 0 (0) 1 (5,9) 
16355 D-loop (HVS I) C>T  non coding 0 (0) 2 (11,8) 
16519 D-loop T>C  non coding 0 (0) 3 (17,6) 
 
Tab. 6.13: Novel mutation are underlined and in italics, mutations resulting in an amino acid change are 
in bold. 
 
In the table above, we can identify mutations which were previously observed to 
be connected to longevity. In particular T489C, G13708A and A14133G were associated 
to longevity by a study conducted by Bilal et al. (2008) and the mutation A10398G by 
Tanaka et al. (2002), even though they are all characteristic polymorphisms of J2 
haplogroup. 
We also analyzed the novel mutations and we found that there are eight new 
mutation in old subjects (two of them modify the aminoacid) and fifteen are in controls 
(ten of them imply an aminoacid modification) but we haven’t found nothing of 
significative. 
We have tried to compare the number of mutations along mtDNA molecule by 
mtDNA regions (Tab. 6.14) and we found that the accumulation of mutations in the 
Dloop is significantly higher in controls than in cases (p=0.0001). 
 90 
J2 
mtDNA region 
N. mutations in 
90+ 
N. mutations in 
controls 
D-loop 160 235 
ND1 17 24 
ND2 0 2 
ND3 3 4 
ND4L 9 13 
ND4 39 51 
ND5 55 78 
ND6 1 1 
COI 15 26 
COII 11 13 
COIII 4 4 
ATPase6 13 18 
ATPase8 0 0 
cyt b 55 78 
rRNA total 47 65 
tRNA total 32 40 
 
Tab. 6.14: Number of mutations found along the mtDNA molecule regions in 90+ subjects and younger 
controls. 
 
In general, there are more mutation in controls than in 90+ subjects and in 
particular in COI, which is a part of IV complex, even when we consider the frequency of 
mutation in each mitochondrial gene. 
As regard sporadic mutations (showing up in one sample only), they are observed 
in 23 mtDNAs positions in 90+ subjects while they are observed in 30 positions in 
controls subjects. Even though this difference between cases and controls is not 
significant (X-squared = 0.9245, p-value = 0.3363), it is very interesting to notice how 
mutations accumulate in each group. In general, In controls there are much more 
mutations than in nonagenarians (Fig. 6.21). These could mean that there are more 
deleterious mutations wich lead to a further decreasing of the performance. In fact 
controls have 5 non coding mutations, 10 synonymous mutations and 15 aminoacid 
changes. These mutations which change the aminoacid sequence hit NADH 
dehydrogenase subunits (I, II and VI), cytochrome c (subunit I and III) and cytochrome 
b. At the same time we found also among cases some 90+ subjects belonging to J2 
haplogroup. First of all they have different mutations in different positions (ATP 
synthase F0 subunit VI, Cytochrome c oxidase subunit III, NADH dehydrogenase subunit 
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IV and cytochrome b), 4 non coding mutations and 11 synonymous mutations. 
Intringuingly, we notice that 90+ subjects’ mtDNAs have 4 sporadic mutations hitting 
tRNA and rRNA genes, absolutely absent in the control subjects.  
 
 
 
 
 
We verified the significance of this finding by comparing the number of the tRNA + 
rRNA mutations with the number of mutations falling in the remaining of coding region 
(23 in siblings and 30 in controls). The χ2 test showed a strong significance (p=0.017). 
 
Fig.6.21: List of sporadic mutations found in controls and 90+ subjects. For details see the text 
above. 
 
We then analyzed the non-synonymous mutations that affect subjects belonging to 
haplogroup J2, and we observed that the frequency of these mutations (the number of 
mutations in a given complex divided by the total number of only non-synonymous 
mutations) is larger and is statistically significant in the respiratory chain complex IV of 
the control subjects. In the other complexes it appears that the non synonymous 
mutations accumulate more among the nineties, even though there are not significant 
differences. But at what subunits of the respiratory chain the significance is due to? The 
significance is attributable to cytochrome c subunit I, which is significant with a p value 
= 0.0081 (Fig. 6.22). 
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Fig. 6.22: distribution of non synonymous mutations in each gene. ND1, ND2, ND4, ND5 belong to 
complex I, cyt b to complex III, cyt c I and cyt c III to complex IV and ATP6 to complex V. 
 
7.2 T2 haplogroup and complete sequencing 
In order to assess if the T2 background of the patients harboured mutations 
responsible for the longevity phenotype, we investigated the complete sequences of T2 
haplogroup subjects (compared to controls). The same analysis of J2 was performed for 
T2 haplogroup. The result of the sequence analysis are summarized in Tab. 6.15. 
A total of 251 mutated positions relative to the reference sequence of Cambridge 
were detected and analyzed.  Overall 46 of the total mutations (underlined and in italics) 
were not previously reported in either MITOMAP (www.mitomap.org) or mtDB 
(www.genpat.uu.se/mtDB). The majority of mutations were observed in a single mtDNA 
(or in 90+ subjects or in controls). There are other mutations that were detected both in 
90+ and in controls (position 5322, 8492, 9788, 9790, 9791, 10496, 12363, 16236, 
16276), other mutations are present only in 90+ subjects and other in controls (see 
beyond in sporadic mutations). This could explain how the increasing of mutation 
numbers in 90+ subjects is a favourable aspect and it is genetically positive.  
Among all mutations observed in the 86 T2 mtDNA sequences, the mutation in 
position 189 was observed in 17.3% in 90+ subjects and in 2.9% in controls subjects and 
this difference is slightly significant (p=0.046). Also mutation in position 195 was 
observed only in 23.6% of controls subjects (p=0.011) and mutation C150T already 
associated to longevity (Rose et al. 2007) is present only in mtDNAs of 90+ subjects than 
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controls even if it is not resulted significant. Also mutation in position 189 is present in 
eight mtDNAs of sibling and only in one of controls (p=0.01141). All these mutations hit 
the dloop region. There is another mutation in position 3350 (ND1 subunit) which is 
present only in four mtDNAs of 90+ subjects, it does not change an amino acid and hence 
is not considered a candidate mutation even if it could have a functional role.   
Nucleotide 
position 
 
Locus Nucleotide 
Change 
Aminoacid 
Change 
90+ subjects 
N=52 (%) 
Controls 
N=34 (%) 
41 D-loop C>T  non coding 0 (0) 1 (2,9) 
57 D-loop (HVSII) T>C  non coding 1 (1,9) 0 (0) 
61 D-loop (HVSII) C>T  non coding 2 (3,8) 1 (2,9) 
64 D-loop (HVSII) C>T  non coding 1 (1,9) 1 (2,9) 
73 D-loop (HVSII) A>G  non coding 52 (100) 33 (97,0) 
93 D-loop (HVSII) A>G  non coding 1 (1,9) 1 (2,9) 
95 D-loop (HVSII) A>C  non coding 1 (1,9) 1 (2,9) 
146 D-loop (HVSII) T>C  non coding 8 (15,3) 4 (11,8) 
150 D-loop (HVSII) C>T  non coding 3 (5,8) 0 (0) 
151 D-loop (HVSII) C>T  non coding 1 (1,9) 0 (0) 
152 D-loop (HVSII) T>C  non coding 5 (9,6) 8 (23,6) 
153 D-loop (HVSII) A>G  non coding 2 (3,8) 0 (0) 
189 D-loop (HVSII) A>G  non coding 9 (17,3) 1 (2,9) 
195 D-loop (HVSII) T>C  non coding 0 (0) 8 (23,6) 
198 D-loop (HVSII) C>T  non coding 3 (5,8) 1 (2,9) 
204 D-loop (HVSII) T>C  non coding 1 (1,9) 0 (0) 
215 D-loop (HVSII) A>G  non coding 3 (5,8) 1 (2,9) 
225 D-loop (HVSII) G>A  non coding 1 (1,9) 0 (0) 
227 D-loop (HVSII) A>G  non coding 1 (1,9) 0 (0) 
279 D-loop (HVSII) T>C  non coding 4 (7,7) 3 (8,8) 
297 D-loop (HVSII) A>C  non coding 0 (0) 1 (2,9) 
310 D-loop (HVSII) T>C  non coding 0 (0) 1 (2,9) 
316 D-loop (HVSII) G>A  non coding 1 (1,9) 1 (2,9) 
316 D-loop (HVSII) G>C  non coding 1 (1,9) 1 (2,9) 
321 D-loop (HVSII) T>C  non coding 1 (1,9) 0 (0) 
324 D-loop (HVSII) C>G  non coding 0 (0) 1 (2,9) 
330 D-loop (HVSII) C>A  non coding 0 (0) 1 (2,9) 
350 D-loop (HVSII) A>C  non coding 0 (0) 1 (2,9) 
385 D-loop A>G  non coding 1 (1,9) 0 (0) 
389 D-loop G>A  non coding 2 (3,8) 0 (0) 
513 D-loop (HVSIII) G>A  non coding 1 (1,9) 0 (0) 
709 rRNA 12S G>A  - 52 (100) 34 (100) 
750 rRNA 12S A>G  - 52 (100) 34 (100) 
930 rRNA 12S G>A  - 28 (53,8) 14 (41,2) 
1420 rRNA 12S T>C  - 1 (1,9) 0 (0) 
1438 rRNA 12S A>G  - 52 (100) 34 (100) 
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1530 rRNA 12S A>G  - 1 (1,9) 0 (0) 
1625 tRNA valine  A>G  - 1 (1,9) 0 (0) 
1888 rRNA 16S G>A - 52 (100) 34 (100) 
2141 rRNA 16S T>C  - 6 (11,5) 2 (5,9) 
2412 rRNA 16S A>G  - 1 (1,9) 0 (0) 
2706 rRNA 16S A>G  - 52 (100) 34 (100) 
2707 rRNA 16S A>G  - 1 (1,9) 0 (0) 
2780 rRNA 16S C>G  - 1 (1,9) 0 (0) 
2850 rRNA 16S T>C  - 1 (1,9) 3 (8,8) 
3010 rRNA 16S G>A  - 1 (1,9) 0 (0) 
3105 rRNA 16S A>G  - 1 (1,9) 0 (0) 
3335 NADH dehydrogenase subunit 1 T>C  synonymous 1 (1,9) 0 (0) 
3338 NADH dehydrogenase subunit 1 T>C  synonymous 1 (1,9) 1 (2,9) 
3350 NADH dehydrogenase subunit 1 T>C  synonymous 4 (7,7) 0 (0) 
3394 NADH dehydrogenase subunit 1 T>C  Tyr Y> His H 0 (0) 1 (2,9) 
3398 NADH dehydrogenase subunit 1 T>C  Met M > Thr T 1 (1,9) 0 (0) 
3511 NADH dehydrogenase subunit 1 A>G  Thr T > Ala A 1 (1,9) 0 (0) 
3549 NADH dehydrogenase subunit 1 C>T  synonymous 0 (0) 1 (2,9) 
3552 NADH dehydrogenase subunit 1 T>C  synonymous 1 (1,9) 0 (0) 
3633 NADH dehydrogenase subunit 1 T>C  synonymous 0 (0) 1 (2,9) 
3826 NADH dehydrogenase subunit 1 T>C  synonymous 0 (0) 3 (8,8) 
3867 NADH dehydrogenase subunit 1 C>T  synonymous 0 (0) 1 (2,9) 
4216 NADH dehydrogenase subunit 1 T>C  Tyr Y > His H 52 (100) 34 (100) 
4246 NADH dehydrogenase subunit 1 A>C  Ile I > Leu L 1 (1,9) 0 (0) 
4491 NADH dehydrogenase subunit 2 G>A  Val V > Ile I 1 (1,9) 1 (2,9) 
4688 NADH dehydrogenase subunit 2 T>C  synonymous 1 (1,9) 1 (2,9) 
4769 NADH dehydrogenase subunit 2 A>G  synonymous 52 (100) 34 (100) 
4859 NADH dehydrogenase subunit 2 T>C  synonymous 1 (1,9) 1 (2,9) 
4913 NADH dehydrogenase subunit 2 A>C  synonymous 0 (0) 1 (2,9) 
4917 NADH dehydrogenase subunit 2 A>G  Asn N-Asp D 52 (100) 34 (100) 
4924 NADH dehydrogenase subunit 2 G>C  Ser S > Thr T 1 (1,9) 0 (0) 
4961 NADH dehydrogenase subunit 2 A>G  synonymous 1 (1,9) 0 (0) 
5147 NADH dehydrogenase subunit 2 G>A  synonymous 24 (46,1) 13 (38,2) 
5187 NADH dehydrogenase subunit 2 C>T  synonymous 4 (7,7) 3 (8,8) 
5277 NADH dehydrogenase subunit 2 T>C  Phe F > Leu L 2 (3,8) 5 (14,7) 
5319 NADH dehydrogenase subunit 2 A>G  Thr T > Ala A 1 (1,9) 1 (2,9) 
5322 NADH dehydrogenase subunit 2 A>C  synonymous 2 (3,8) 1 (2,9) 
5426 NADH dehydrogenase subunit 2 T>C  synonymous 2 (3,8) 5 (14,7) 
5480 NADH dehydrogenase subunit 2 A>G  Ala A > Thr T 1 (1,9) 0 (0) 
5527 tRNA tryptophan  A>G  - 1 (1,9) 0 (0) 
5567 tRNA tryptophan  T>C  - 0 (0) 1 (2,9) 
5580 - T>C  - 2 (3,8) 0 (0) 
6249 Cytochrome c oxidase subunit I  G>A  Ala A > Thr T 1 (1,9) 0 (0) 
6261 Cytochrome c oxidase subunit I  G>A  Ala A > Thr T 4 (7,7) 3 (8,8) 
6293 Cytochrome c oxidase subunit I  T>C  synonymous 0 (0) 1 (2,9) 
6489 Cytochrome c oxidase subunit I  C>A  Leu L>Ile I 2 (3,8) 5 (14,7) 
6524 Cytochrome c oxidase subunit I  T>C  synonymous 1 (1,9) 0 (0) 
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6899 Cytochrome c oxidase subunit I  G>A  synonymous 1 (1,9) 0 (0) 
7022 Cytochrome c oxidase subunit I  T>C  synonymous 1 (1,9) 3 (8,8) 
7028 Cytochrome c oxidase subunit I  C>T  synonymous 52 (100) 34 (100) 
7041 Cytochrome c oxidase subunit I  G>A  Val V > Ile I 1 (1,9) 0 (0) 
7076 Cytochrome c oxidase subunit I  A>G  synonymous 0 (0) 1 (2,9) 
7100 Cytochrome c oxidase subunit I  A>G  synonymous 1 (1,9) 0 (0) 
7268 Cytochrome c oxidase subunit I  T>C  synonymous 0 (0) 1 (2,9) 
7684 Cytochrome c oxidase subunit II T>C  synonymous 1 (1,9) 0 (0) 
7685 Cytochrome c oxidase subunit II A>G  Ile I > Val V 1 (1,9) 0 (0) 
7853 Cytochrome c oxidase subunit II G>A  Val V > Ile I 1 (1,9) 0 (0) 
7873 Cytochrome c oxidase subunit II C>T  synonymous 4 (7,7) 3 (8,8) 
7891 Cytochrome c oxidase subunit II C>T  synonymous 1 (1,9) 1 (2,9) 
7979 Cytochrome c oxidase subunit II G>A  Asp D > Asp N 0 (0) 1 (2,9) 
8041 Cytochrome c oxidase subunit II A>G  Met M > Val V 1 (1,9) 1 (2,9) 
8256 Cytochrome c oxidase subunit II T>C  Val V > Ala A 2 (3,8) 0 (0) 
8270 - C>T  - 1 (1,9) 0 (0) 
8416 ATP synthase F0 subunit 8  C>T  synonymous 0 (0) 1 (2,9) 
8492 ATP synthase F0 subunit 8  A>G  Lys K > Asp D 1 (1,9) 1 (2,9) 
8572 ATP synthase F0 subunit 8  G>C  synonymous 0 (0) 2 (5,9) 
8697 ATP synthase F0 subunit 6  G>A  synonymous 52 (100) 34 (100) 
8860 ATP synthase F0 subunit 6  A>G  Thr T > Ala A 52 (100) 34 (100) 
8944 ATP synthase F0 subunit 6  A>G  Met M > Val V 1 (1,9) 1 (2,9) 
9053 ATP synthase F0 subunit 6  G>A  Ser S > Asn N 1 (1,9) 0 (0) 
9117 ATP synthase F0 subunit 6  T>C  synonymous 6 (11,5) 2 (5,9) 
9254 Cytochrome c oxidase subunit III A>G  synonymous 6 (11,5) 4 (11,8) 
9719 Cytochrome c oxidase subunit III C>A  synonymous 1 (1,9) 0 (0) 
9788 Cytochrome c oxidase subunit III C>G  synonymous 1 (1,9) 2 (5,9) 
9790 Cytochrome c oxidase subunit III C>T  Ser S > Stop 1 (1,9) 2 (5,9) 
9791 Cytochrome c oxidase subunit III A>T  synonymous 1 (1,9) 2 (5,9) 
9843 Cytochrome c oxidase subunit III A>G  Thr T > Ala A 0 (0) 1 (2,9) 
10000 tRNA glycine  G>T  - 1 (1,9) 0 (0) 
10005 tRNA glycine  A>G  - 1 (1,9) 0 (0) 
10111 NADH dehydrogenase subunit 3  T>A  Met M > Lys K 2 (3,8) 0 (0) 
10116 NADH dehydrogenase subunit 3  A>G  Ile I > Val V 1 (1,9) 0 (0) 
10243 NADH dehydrogenase subunit 3  T>C  Phe F > Ser S 0 (0) 1 (2,9) 
10403 NADH dehydrogenase subunit 3  A>G  synonymous 1 (1,9) 0 (0) 
10463 tRNA arginine T>C  - 52 (100) 34 (100) 
10496 NADH dehydrogenase subunit 4L  A>G  synonymous 1 (1,9) 1 (2,9) 
10559 NADH dehydrogenase subunit 4L  A>G  synonymous 2 (3,8) 0 (0) 
10589 NADH dehydrogenase subunit 4L  G>A  synonymous 1 (1,9) 0 (0) 
10746 NADH dehydrogenase subunit 4L  C>T  synonymous 0 (0) 1 (2,9) 
10750 NADH dehydrogenase subunit 4L  A>G  Asn N > Ser S 2 (3,8) 3 (8,8) 
10822 NADH dehydrogenase subunit 4  C>T  synonymous 4 (7,7) 3 (8,8) 
10876 NADH dehydrogenase subunit 4  A>G  synonymous 0 (0) 1 (2,9) 
10879 NADH dehydrogenase subunit 4 A>C  synonymous 0 (0) 1 (2,9) 
10993 NADH dehydrogenase subunit 4 G>A  synonymous 0 (0) 1 (2,9) 
10997 NADH dehydrogenase subunit 4 A>C  Ser S > Arg R 1 (1,9) 0 (0) 
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11016 NADH dehydrogenase subunit 4 G>A  Ser S > Asn N 0 (0) 1 (2,9) 
11020 NADH dehydrogenase subunit 4 A>G  synonymous 1 (1,9) 0 (0) 
11176 NADH dehydrogenase subunit 4 G>A  synonymous 2 (3,8) 0 (0) 
11251 NADH dehydrogenase subunit 4 A>G  synonymous 52 (100) 34 (100) 
11260 NADH dehydrogenase subunit 4 T>C  synonymous 1 (1,9) 0 (0) 
11290 NADH dehydrogenase subunit 4 A>G  synonymous 1 (1,9) 0 (0) 
11344 NADH dehydrogenase subunit 4 A>G  synonymous 0 (0) 1 (2,9) 
11395 NADH dehydrogenase subunit 4 C>T  synonymous 0 (0) 1 (2,9) 
11719 NADH dehydrogenase subunit 4 G>A  synonymous 52 (100) 34 (100) 
11812 NADH dehydrogenase subunit 4 A>G  synonymous 52 (100) 34 (100) 
11914 NADH dehydrogenase subunit 4 G>A  synonymous 5 (9,6) 3 (8,8) 
11944 NADH dehydrogenase subunit 4 T>C  synonymous 0 (0) 3 (8,8) 
12172 tRNA histidine  A>G  - 0 (0) 2 (5,9) 
12341 NADH dehydrogenase subunit 5  C>T  Thr T > Ile I 2 (3,8) 0 (0) 
12358 NADH dehydrogenase subunit 5  A>G  Thr T > Ala A 1 (1,9) 0 (0) 
12363 NADH dehydrogenase subunit 5 C>T  synonymous 3 (5,8) 2 (5,9) 
12397 NADH dehydrogenase subunit 5 A>G  Thr T > Ala A 1 (1,9) 1 (2,9) 
12408 NADH dehydrogenase subunit 5 T>C  synonymous 1 (1,9) 0 (0) 
12481 NADH dehydrogenase subunit 5 T>A  Phe F > Ile I 1 (1,9) 0 (0) 
12501 NADH dehydrogenase subunit 5 G>A  synonymous 0 (0) 1 (2,9) 
12741 NADH dehydrogenase subunit 5 C>T  synonymous 5 (9,6) 1 (2,9) 
12771 NADH dehydrogenase subunit 5 G>A  synonymous 1 (1,9) 1 (2,9) 
13020 NADH dehydrogenase subunit 5 T>C  synonymous 3 (5,8) 1 (2,9) 
13050 NADH dehydrogenase subunit 5 A>G  synonymous 1 (1,9) 0 (0) 
13105 NADH dehydrogenase subunit 5 A>C  Ile I > Leu L 0 (0) 1 (2,9) 
13359 NADH dehydrogenase subunit 5 G>A  synonymous 0 (0) 1 (2,9) 
13368 NADH dehydrogenase subunit 5 G>A  synonymous 52 (100) 34 (100) 
13692 NADH dehydrogenase subunit 5 C>T  synonymous 1 (1,9) 1 (2,9) 
13722 NADH dehydrogenase subunit 5 A>G  synonymous 2 (3,8) 0 (0) 
13934 NADH dehydrogenase subunit 5 C>T  Thr T > Met M 1 (1,9) 0 (0) 
13965 NADH dehydrogenase subunit 5 T>C  synonymous 11 (21,1) 6 (17,6) 
13966 NADH dehydrogenase subunit 5 A>G  Thr T > Ala A 6 (11,5) 2 (5,9) 
13980 NADH dehydrogenase subunit 5 G>A  synonymous 1 (1,9) 0 (0) 
14097 NADH dehydrogenase subunit 5 C>T  synonymous 1 (1,9) 0 (0) 
14118 NADH dehydrogenase subunit 5 A>G  synonymous 2 (3,8) 1 (2,9) 
14233 NADH dehydrogenase subunit 6 A>G  synonymous 52 (100) 34 (100) 
14587 NADH dehydrogenase subunit 6 A>G  synonymous 1 (1,9) 0 (0) 
14687 NADH dehydrogenase subunit 6 A>G  synonymous 8 (15,3) 5 (14,7) 
14720 tRNA glutamic acid  C>G  - 1 (1,9) 0 (0) 
14722 tRNA glutamic acid  T>G  - 1 (1,9) 0 (0) 
14727 tRNA glutamic acid  T>C  - 2 (3,8) 0 (0) 
14759 cytochrome b C>A  Arg R > Ser S 1 (1,9) 0 (0) 
14762 cytochrome b A>G  Lys K > Glu E 2 (3,8) 0 (0) 
14766 cytochrome b C>T  synonymous 51 (98,1) 34 (100) 
14819 cytochrome b T>C  Ser S > Pro P 1 (1,9) 0 (0) 
14905 cytochrome b G>A  synonymous 52 (100) 34 (100) 
14954 cytochrome b A>G  Thr T > Ala A 0 (0) 1 (2,9) 
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15028 cytochrome b C>A  synonymous 2 (3,8) 5 (14,7) 
15043 cytochrome b G>A  synonymous 2 (3,8) 5 (14,7) 
15110 cytochrome b G>A  Ala A > Thr T 1 (1,9) 1 (2,9) 
15326 cytochrome b A>G  Thr T > Ala A 52 (100) 34 (100) 
15381 cytochrome b C>T  Thr T > Ile I 1 (1,9) 0 (0) 
15452 cytochrome b C>A  Leu L- Ile I  52 (100) 34 (100) 
15479 cytochrome b T>C  Phe F > Leu L 2 (3,8) 0 (0) 
15607 cytochrome b A>G  synonymous 52 (100) 34 (100) 
15608 cytochrome b C>G  Leu L > Val V 0 (0) 1 (2,9) 
15609 cytochrome b T>C  Leu L > Pro P 0 (0) 1 (2,9) 
15610 cytochrome b A>G  synonymous 0 (0) 1 (2,9) 
15758 cytochrome b A>G  Ile I > Val V 2 (3,8) 0 (0) 
15884 cytochrome b G>A  Ala A > Thr T 1 (1,9) 0 (0) 
15928 - G>A  - 52 (100) 34 (100) 
16037 D-loop (HVSI) A>G  non coding 0 (0) 1 (2,9) 
16126 D-loop (HVSI) T>C  non coding 52 (100) 34 (100) 
16129 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16140 D-loop (HVSI) T>C  non coding 1 (1,9) 0 (0) 
16153 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16172 D-loop (HVSI) T>C  non coding 5 (9,6) 3 (8,8) 
16182 D-loop (HVSI) A>C  non coding 2 (3,8) 5 (14,7) 
16183 D-loop (HVSI) A>C  non coding 3 (5,8) 6 (17,6) 
16184 D-loop (HVSI) C>T  non coding 0 (0) 1 (2,9) 
16189 D-loop (HVSI) T>C  non coding 7 (13,4) 7 (20,6) 
16194 D-loop (HVSI) A>C  non coding 1 (1,9) 0 (0) 
16195 D-loop (HVSI) T>G  non coding 0 (0) 1 (2,9) 
16197 D-loop (HVSI) C>G  non coding 1 (1,9) 0 (0) 
16201 D-loop (HVSI) C>A  non coding 1 (1,9) 0 (0) 
16204 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16205 D-loop (HVSI) C>A  non coding 1 (1,9) 0 (0) 
16208 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16209 D-loop (HVSI) T>A  non coding 1 (1,9) 0 (0) 
16211 D-loop (HVSI) C>A  non coding 1 (1,9) 0 (0) 
16213 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16214 D-loop (HVSI) C>A  non coding 1 (1,9) 1 (2,9) 
16218 D-loop (HVSI) C>A  non coding 0 (0) 1 (2,9) 
16224 D-loop (HVSI) T>C  non coding 1 (1,9) 0 (0) 
16228 D-loop (HVSI) C>A  non coding 0 (0) 1 (2,9) 
16228 D-loop (HVSI) C>T  non coding 1 (1,9) 0 (0) 
16232 D-loop (HVSI) C>A  non coding 1 (1,9) 0 (0) 
16234 D-loop (HVSI) C>A  non coding 0 (0) 1 (2,9) 
16236 D-loop (HVSI) C>A  non coding 1 (1,9) 1 (2,9) 
16245 D-loop (HVSI) C>G  non coding 2 (3,8) 1 (2,9) 
16245 D-loop (HVSI) C>T  non coding 2 (3,8) 1 (2,9) 
16247 D-loop (HVSI) A>G  non coding 1 (1,9) 0 (0) 
16255 D-loop (HVSI) G>A  non coding 1 (1,9) 0 (0) 
16258 D-loop (HVSI) A>C  non coding 1 (1,9) 1 (2,9) 
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16261 D-loop (HVSI) C>T  non coding 1 (1,9) 0 (0) 
16263 D-loop (HVSI) T>C  non coding 2 (3,8) 0 (0) 
16265 D-loop (HVSI) A>C  non coding 1 (1,9) 1 (2,9) 
16266 D-loop (HVSI) C>T  non coding 1 (1,9) 0 (0) 
16269 D-loop (HVSI) A>C  non coding 1 (1,9) 1 (2,9) 
16276 D-loop (HVSI) T>A  non coding 1 (1,9) 1 (2,9) 
16282 D-loop (HVSI) C>A  non coding 1 (1,9) 1 (2,9) 
16291 D-loop (HVSI) C>T  non coding 0 (0) 1 (2,9) 
16292 D-loop (HVSI) C>T  non coding 5 (9,6) 4 (11,8) 
16294 D-loop (HVSI) C>T  non coding 52 (100) 34 (100) 
16295 D-loop (HVSI) C>T  non coding 0 (0) 1 (2,9) 
16296 D-loop (HVSI) C>T  non coding 33 (63,5) 20 (58,8) 
16297 D-loop (HVSI) T>C  non coding 0 (0) 1 (2,9) 
16298 D-loop (HVSI) T>C  non coding 2 (3,8) 5 (14,7) 
16299 D-loop (HVSI) A>G  non coding 1 (1,9) 1 (2,9) 
16304 D-loop (HVSI) T>C  non coding 27 (51,9) 14 (41,2) 
16308 D-loop (HVSI) T>A  non coding 0 (0) 1 (2,9) 
16310 D-loop (HVSI) G>T  non coding 0 (0) 1 (2,9) 
16311 D-loop (HVSI) T>C  non coding 1 (1,9) 0 (0) 
16313 D-loop (HVSI) C>A  non coding 0 (0) 1 (2,9) 
16315 D-loop (HVSI) T>A  non coding 0 (0) 1 (2,9) 
16320 D-loop (HVSI) C>T  non coding 2 (3,8) 0 (0) 
16322 D-loop (HVSI) A>T  non coding 0 (0) 1 (2,9) 
16324 D-loop (HVSI) T>C  non coding 7 (13,4) 3 (8,8) 
16368 D-loop T>C  non coding 1 (1,9) 0 (0) 
16519 D-loop T>C  non coding 45 (86,5) 30 (88,2) 
 
Tab. 6.15: Novel mutation are underlined and in italics, mutations resulting in an amino acid change are 
in bold. 
 
We noticed that among all mutations listed in the above Tab.6.15, some of them 
were previously associated with longevity. In particular the mutation G3010A was 
connected to longevity by Tanaka et al (2002) an Bilal et al. (2008), such as for 
G15043A, G16129A and T16297C. They are all sporadic mutation present only in 90+ 
subjects except for the mutation T16297C, present in one control sequence. 
We also tried to compare the number of mutations along mtDNA molecule by 
mtDNA regions (Tab. 6.16) and we did not find any statistical significant result. The 
complete re-sequencing of the 86 mtDNAs belonging to T2 revealed that 90+ subjects 
showed a trend towards a higher number of mutations in all genes when compared with 
controls. But if we consider the total number of mutations, the frequency of mutations in 
each region is higher in controls than in our cases. 
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T2 
mtDNA 
region N. mutations in 90+ N. mutations in controls 
D-loop 380 258 
ND1 62 42 
ND2 121 87 
ND3 4 1 
ND4L 6 5 
ND4 171 117 
ND5 96 53 
ND6 61 39 
COI 64 48 
COII 11 6 
COIII 10 11 
ATPase6 112 71 
ATPase8 1 4 
cyt b 274 151 
rRNA total 302 189 
tRNA total 60 37 
Tab. 6.16: Number of mutations found along the mtDNA molecule regions in 90+ subjects and younger 
controls. 
 
Subsequently, we searched for groups of singleton mutations falling in specific 
mtDNA regions that may be associated with longevity. They are observed in 79 mtDNAs 
positions in 90+ subjects while they are observed in 47 positions in controls subjects. 
This difference between cases and controls is strongly significant (X-squared = 8.127, df 
= 1, p-value = 0.004361) and it is very interesting to notice how mutations accumulate in 
each group. In general, taking into account simply absolut numbers it appears that 
mutations seem to accumulate much more in cases than in controls, but if frequency is 
considered, the trend is opposite. In other words, mutations accumulate with higher 
frequency in controls than in cases, reflecting the same pathway of J2 haplogroup 
mutations. As figure 6.23 shows, 29 non coding mutations, 18 synonymous mutations 
and 19 mutations which cause the aminoacid changes accumulate in 90+ subjects, 
whereas 20 non coding mutations, 17 synonymous mutations and 9 mutations changing 
the sequence of aminoacids accumulate in controls. As for the analysis of entire 
sequences resulting J2, also here we assist to a high accumulations of mutations in tRNA 
and rRNA genes in 90+ subjects. 
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Fig.6.23: List of sporadic mutations found in controls and 90+ subjects. For details see the text 
above. 
 
We found that 13 sporadic mutations (single occurrences) were present in tRNA 
and rRNA genes from 90+ subjects mtDNAs and only one sporadic mutation in controls. 
 
SPORADIC MUTATIONS 
 90+ controls 
tRNA 6 1 
rRNA 7 0 
   
 
We verified the significance of this finding by comparing the number of the 
tRNA+rRNA mutations with the number of mutations falling in the remaining of coding 
region (79 in siblings and 47 in controls). The χ2 test showed a strong significance 
(p=0.014). 
Finally, we have investigated the non-synonymous mutations that affect persons 
belonging haplogroup T2, and we discovered that the frequency of these mutations, as 
well as already performed for J2, is larger, but not significant, in the respiratory chain 
complex IV of the control subjects. Also in this haplogroup frequency of non-
synonymous mutations in other genes seem to accumulate more in the nineties. In 
particular, once again there are more mutations in genes cyt c I and cyt c III but nothing 
is statistically significant (Fig. 6.24). 
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Fig. 6.24: distribution of non synonymous mutations in each gene. ND1, ND2, ND3, ND4, ND4L and ND5 
belong to the complex I, cyt b to complex III, cyt c I, II and III to complex IV and ATP6 and ATP8 to complex 
V. 
 
8. Cluster analysis 
Cluster analysis or clustering (introduced by Robert Tryon in 1939) or group 
analysis, is the assignment of a set of observations into subsets (called clusters) so that 
observations in the same cluster are similar in some sense. All the clustering techniques 
calculate the distance between two elements based on Euclidean distance, or more 
simply the geometric distance in the multidimensional space. The good quality of 
analysis depends on how the distance is calculated. Clustering algorithms group 
together elements on the strength of their mutual distance, thus depends on how much 
the element is distant from the set. 
We have applied this cluster analysis to our samples taking into account all 
subhaplogroups frequency distribution in different geographic areas (Fig. 6.25). To 
justify the countries aggregations, it has been conducted a similarity study among 
countries and parameters were haplogroups frequencies in cases and controls. 
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Fig. 6.25: Cluster analysis of all 15 geographic areas. On the left the first group includes Italian regions 
and Central Europe, on the right the second group includes North European countries, and the unexpected 
Greece. 
 
More precisely, this aggregation has been built recording for each nation 
differences among frequencies related to cases and controls for all the haplogroups, 
except for N1, OTHER and R0A because too less numerous. 
The analysis resulted in the two groups of samples, using a Chi-squared test to try 
out the significativity of cases/controls vs. haplogroups. In detail, we have obtained the 
following results. The first group includes Sassari, all Italian regions (Calabria, Bologna 
and Roma) and Central Europe countries (Denmark, Germany, Montpellier and 
Belgium). Sassari is the only geographic area that distance itself from the others, 
Bologna and Roma on one hand and Denmark and Montpellier on the other hand result 
similar. The distribution of this first group results significative (X-squared = 17.6093, p-
value = 0.01386). 
The only anomaly in the distribution of the second group is Greece which is 
thought to be more associated to Mediterranean countries (in particular to Calabria, 
representative of the South Europe) than to North European countries. Also in this case 
the distribution is statistically significative (X-squared = 19.513, p-value = 0.006723). In 
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order to conduct the same cluster analysis, we have forced the analysis by dividing the 
11 countries into three  groups, each representative of a single geographic area, as 
follows: 
1. Finland 
2. Europe: Denmark, Belfast, Newcastle, Netherland, Belgium, Germany, France, 
Poland, Ukraine 
3. Mediterraneo: Bologna, Roma, Calabria, Sassari, Greece. 
We decided to set Finland alone on the basis of a study conducted by Perola in 
2008 on GEHA nuclear data. According to this study, Finland may distance itself from the 
other countries, as Fig. 6.26: 
 
 
 
Fig. 6.26: PCA analysis on the 15 geographic areas (11 countries adherent to the Project) on the nuclear 
DNA. As we immediately notice Finland distance itself from other countries (red squared), while Greece is 
similar to Calabria, Sassari, Rome and Bologna (in the left side of the figure). We do not know the 
parameters used. 
 
Then, we have obtained a matrix of distances in which value change from 0 (maximum 
similarity) to 1 (no similarity). 
 Finland  Europe Mediterranean area 
Finland 0.000 0.083 0.115 
Europe 0.083 0.000 0.030 
Mediterranean area 0.115 0.030 0.000 
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As we expected, Finland is the country with the maximum divergence rate (red 
value) and whose haplogroup distribution differ from the rest of the analyzed countries. 
The Mediterranean area (included Greece) is deeply divergent from Finland (value 
in orange), while the rest of Europe has an intermediate trend between Finland and 
Mediterranean area. 
 
9. MDS – Multidimensional scaling 
Multidimensional scaling (MDS) allows to explain observed similarities or 
dissimilarities (distances) between the investigated objects, by analyzing any kind of 
similarity or dissimilarity matrix, in addition to correlation matrices.  In order to 
compare the distribution of haplotype variability in our samples and to confirm the 
genetic similarity between Finland and Greece,  we calculated the genetic distances. 
Distance matrix was represented with not metric MDS using MASS library of R. 
Fig. 6.27 reports the distribution of all countries in controls subjects. We report 
only controls distribution because the high number of samples is more statistically 
significant than 90+ subjects. 
All the dissimilarities were calculated using Hellinger distance, which is used to 
quantify the similarity between two probability distributions and it is defined in term of  
the “Hellinger integral”. It considers the relative frequencies of control haplogroups 
related to the two compared countries. 
We can notice that all countries are well distributed in a homogeneous cluster. All 
the Northern countries are in the middle of the graph, near among them. Belfast samples 
seems to be more different than other countries because it shows a high grade of 
isolation, such as Finland. In this MDS, again Greece is the nearest country to Finland, 
confirming our similarity between these two countries. 
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Fig. 6.27: MDS constructed on the basis of distance matrix of all our controls subjects belonging to all 
European areas. 
 
10. Network of J haplogroup 
The overall phylogenetic network, based on 281 J haplogroup females (137 sibs 
and 144 controls), 112 J haplogroup males (46 sibs and 66 controls) and their 
corresponding haplotypes is shown in Fig. 6.28 (females) and Fig. 6.31 (males). In 
order to analyze the different haplotype distribution among nations, a median-joining 
network was also constructed for the HVS-I and HVS-II sequence data (16080-300 
segment region) of all samples resulted J.  
Each node and solid edge could be labeled, but even with a small font the labels 
may detract from the overall presentation. Above on the left the legend has been 
reported.  
A phylogenetic network for the variation scored in the 393 haplogroup J mtDNAs is 
shown. 
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Figure 6.28: The J phylogenetic network (unlabelled) of all sibs and controls females. Circles are 
proportional to lineage frequencies. The red circle is the median vector 8, which connects the two 
phylogenetic branch of J2a and J2b. The area of each circle is proportional to the number of mtDNAs in the 
total sample harboring the corresponding haplotype. Lines represent one mutational step and red dots 
are hypothetical missing intermediates (median vectors). 
 
The node corresponding to mv3 (median vector3 in red, Fig. 6.28) has been 
evidenced to emphasize that it is the point at which the network connects the two 
phylogenetic branch of J2a and J2b. In particular J2 is characterize by 150 and 152 
mutations, J2a is defined by polymorphisms 195, 215, 16145, 16231 and 16261, J2b by 
16193. With the red line under mutations in Fig. 6.29, there are typical polimorphisms 
of J. With the blue circle we indicate the median vector 9, which really divides J2a from 
J2b (also visible and clear in Fig. 6.30). 
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Fig. 6.29: The J phylogenetic network (unlabelled) of all sibs and controls females. Circles are 
proportional to lineage frequencies. The red circle is the median vector 3, which represent the start point 
of J haplogroup. The blue circle indicates the median vector 8, which divides J2a from J2b branch. The red 
lines under mutations are  ancient polymorphisms typical of haplogroup J. The area of each circle is 
proportional to the number of mtDNAs in the total sample harboring the corresponding haplotype. Lines 
represent one mutational step and red dots are hypothetical missing intermediates. 
 
 
Fig. 6.30: J2 haplogroup branch and typical polymorphisms. 
 
There are several obvious features of the phylogenetic network for the haplogroup. 
One of the most apparent is the subgroups J1 and J2 dominating the haplogroup. In 
female network (Fig. 6.28) subhaplogroup J2a, J2b and J1b take the form of star-like 
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clusters, whereas J1c do not exhibit the pattern of a dominant central node with more 
than one node, radiating out from it. The star-like shape of network indicates population 
expansion. 
The network analysis has allowed us not only to revise and correct wrong 
haplogroups but also to collocate samples, whose haplogroup were general, in specific 
cluster (in our case, samples defined as J1 were collocated by Network in J1b 
subcluster). Another striking aspect of the network is that it is not a tree, but instead it 
contains many cycles or reticulations. A closer inspection of the edges in the network 
reveals that several of these cycles contain edges that correspond to mutations at 
nucleotide 228, typical of J1c.  
As regard male network (Fig. 6.31), we observed that only J2a and J1b have a star-
like cluster, J1c has different central nodes, as in females network, while J2b do not 
present a specific cluster. It is interesting to notice that in J2b cluster different cycles are 
present and in particular the most recurring mutation is 16261, representative of this 
haplogroup. 
 
 
Fig. 6.31: The J phylogenetic network (unlabelled) of all sibs and controls males. Circles are proportional 
to lineage frequencies. The area of each circle is proportional to the number of mtDNAs in the total sample 
harboring the corresponding haplotype. Lines represent one mutational step and red dots are 
hypothetical missing intermediates. 
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The node corresponding to mv10 (median vector10, Fig. 6.32) has been evidenced 
to emphasize that it is the point at which the network connects the two phylogenetic 
branch of J2a and J2b. As for female network, J2 is characterized by 150 and 152 
mutations, J2a is defined in this case by polymorphisms 195, 16145 and 16261, J2b by 
16193. With the red line under mutations, there are typical polimorphisms of J.  
 
 
Fig. 6.32: The J phylogenetic network (unlabelled) of males. Circles are proportional to lineage 
frequencies. The red circle is the median vector 10, which connects the two phylogenetic branch of J2a and 
J2b. The red lines under mutations are  ancient polymorphisms typical of haplogroup J.The area of each 
circle is proportional to the number of mtDNAs in the total sample harboring the corresponding 
haplotype. Lines represent one mutational step and red dots are hypothetical missing intermediates. 
 
We have also tried to focus on geographical distribution in J network, in order to 
evidence a particular trend of Finland in females and males (Fig. 6.33 and Fig. 6.34). 
The distribution of countries haplotypes in the European-wide minimum 
spanning-network suggests multiple independent colonization events. Multiple 
unrelated founding events is one possible explanation for this pattern. In particular 
Finland seems to localize in the external branches, suggesting the fact that Finland is an 
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isolated country both in females and male networks. Instead Denmark is represented 
with higher frequency more than other countries in J2a and J1c in both gender. The star-
like shape of the European-wide haplotype network strongly suggest sudden expansion. 
 
 
Fig. 6.33: The geographic representation of J females. Circles are proportional to lineage 
frequencies. 
 
 
Fig. 6.34: The geographic representation of J males. Circles are proportional to lineage frequencies. 
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Chapter 6 
 
DISCUSSION 
 
Much evidence has accumulated on the association between mitochondrial DNA 
and the aging process. It is known that somatic mutations accumulate with aging 
suggesting a possible pathophysiology role for mtDNA in aging and senescence. On the 
other hand, several data demonstrate that the inherited mtDNA variability plays a role in 
longevity. 
The present study is part of the European Project GEHA – GEnetic of Healthy Aging 
– whose the most important aim is to identify genes involved in healthy aging and 
longevity, which allows individuals to reach advanced old age in good cognitive and 
physical conditions, without the major age-related diseases.  The GEHA Project 
represents the strongest and the most competitive consortium ever realized in Europe 
to investigate genetic bases of human aging process, capable of reaching results that is 
impossible to obtain in a single European country. The aim of the Project GEHA is to 
identify genes involved in healthy aging and longevity, allowing individuals to survive to 
advanced old age in good cognitive and physical function and in the absence of major 
age-related diseases, such as type II diabetes, neurodegenerative diseases, 
cardiovascular diseases and osteoporosis. 
In the present study, we investigate the association of haplogroups, mitochondrial 
polymorphisms and mutation with longevity.  
 
1. Haplogroups and association with male controls 
In this study it has been applied a high resolution analysis, through the complete 
sequencing, the D-loop region sequencing and the restriction analysis of specific 
markers in the coding region of mtDNA. We determined and analyzed the haplogroup of 
a large cohort of 90+ subjects (N=2,086) and controls (N=2158) comparable for 
ethnicity and sex from 11 European countries, adherent to the GEHA Project and we 
wanted to test whether the analysis of mtDNA haplogroups is able to reveal any 
association between mtDNA inherited variability and longevity. The approach was a 
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comparative analysis between mtDNA of healthy 90+ subjects and younger controls 
matched for sex and geographic area, avoiding possible bias related to a founder effect 
or population heterogeneity. 
From a descriptive analysis, we can observe that recruited females are in general 
more numerous than males in all countries except for Greece where the number of 
males is incredibly higher than females, both in cases and controls. We can say that the 
distribution is balanced among recruitment centre. The approach was a comparative 
analysis between our cases (90+ subjects) and the younger controls, matched for sex 
and geographic area. 
Then we wanted to test whether the analysis of mtDNA haplogroups is able to 
reveal any association between mtDNA inherited variability and longevity.  
The mitochondrial theory of aging proposes that the accumulation of mutations in 
mtDNA, caused by ROS (Reactive Species of Oxygen), is the mayor contributor to the 
cellular deterioration, leading to the aging process (Kowald and Kirkwood, 2000). 
Consistent with this theory is the enormous number of data in literature identifying 
mutations occurring with age. The fact that there is a possibility to inherit mtDNA 
polymorphisms which may predispose certain individuals to become nonagenarians or 
centenarians is supported by some studies. In fact the question of whether unusual 
longevity is linked to certain genetic markers has sparked much interest and resulted in 
a sizeable literature. From an evolutionary view, if there is a clear genetic component to 
longevity, and if longevity benefits fitness, long-lived individuals should have an 
evolutionary advantage, and their genes should be expected to become more frequent in 
a population across several generations. 
Previous reviews (Madrigal et al, 2008; Capri et al, 2006) on candidate genes, 
which may result in unusual longevity, conclude that there is a consistent association 
between longevity and some apolipoprotein genes, genes involved in stress-response, 
and mtDNA. Of these, mitochondrial DNA has been the most frequently researched 
system. The hypothesis that longevity is associated with advantageous mtDNA markers 
has been tested mainly in individuals with unusual longevity, taken to mean individuals 
who live over 90 years of age (although a few studies focus on centenarians). 
Specifically, three mutations (mt5178A, mt8414T, mt3010A) were found in 
significantly higher frequencies in Japanese centenarians (Tanaka et al, 1998; Alexe et al, 
2007), while another variant (mt9055A) was found to be significantly more frequent in 
French centenarians (Ivanova et al, 1998).  
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Other studies have shown that centenarians from Northern Italy have a 
significantly different frequency of the J haplogroup than do younger controls (20 vs. 
about 2%) (De Benedictis et al, 1999). A higher frequency of the J haplogroup and a 
significantly high frequency of three mtDNA polymorphisms (150T, 489C, 10398G) has 
also been reported in Finnish long-lived subjects (Niemi et al, 2003). 
Lastly, other studies report a significantly higher frequency of the 150T mutation 
in aged individuals in comparison with younger subjects in Finnish (Niemi et al, 2003), 
Japanese (Zhang et al, 2003) and Italian subjects (De Benedictis et al, 1999), although 
this association was not replicated by a study with Ashkenazi Jews (Shlush et al, 2008 ), 
who is a homogeneous population, due to a strong founder effect, followed by a rapid 
population expansions and characterized by high levels of consanguinity and endogamy.  
  The fact that both Finnish as well as the northern Italian study found an 
association of longevity, with the same mtDNA haplogroup J, certainly motivates further 
investigation. Several of these associations were not replicated in other studies (Iwata et 
al, 2007, Castri et al, 2009) suggesting that the association between mitochondrial DNA 
variants and longevity could be population-dependent (Dato et al, 2003). In this regard, 
Dominguez-Garrido et al (2009) found that J2 was overrepresented in elderly people in 
Pyrenees but not in people coming from the Ebro’s Valley in Spain and they discovered 
that the former population have a lower mtDNA damage. It means that environmental 
condition can have a phenotypic survival advantage or disadvantage on population in 
study, demonstrating that the geographical altitude (Pyrenees Mountains), causing a 
lower oxygen pressure, determines lesser ROS production and reduces levels of mtDNA 
damage than in Valley one.  
Our data demonstrates that there is not an increased frequency of haplogroup J 
within the aged population. In fact, in contrast to the findings of De Benedictis et al. who 
found that the J haplogroup was significantly associated with male centenarians of 
northern Italy, our study failed to show this association, even though we found that H1 
and J2 significantly increased in the control males, thus representing a risk factor.  
Among all males, H1 is more represented in controls than cases (p=0.0427), while 
among females the frequency is the same. As regard J2 haplogroup, it is resulted 
significant (p=0.0214). If we take into account gender considering the distribution 
among males, more than 80% are cases, as Fig.16 reports, while among females the 
frequency is equally distributed. These percentages mean that haplogroup J2 has an 
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higher frequency among male controls than cases and that J2 is not associated with 
female gender. 
Furthermore, we have studied the distribution of H1 and J2 subhaplogroups in 
order to verify which subhaplogroup, if present, could influence the association. We 
studied H1 subhaplogroups (H1a, H1a1, H1a2, H1a3, H1b, H1c, H1c1, H1e, H1f, H1n) but 
we found no significant data. What about J2, we have studied the distribution of the 
subhaplogroups J2a and J2b, and we observed that only J2a is highly significant (p-value 
= 0.01701) rather than J2b subhaplogroup (p-value = 0.2789) and in particular among 
males about 80% are controls, confirming the J2 haplogroup trend. This fact suggests 
that the higher frequency of haplogroup J2 in male controls is attributable to an increase 
in subcluster J2a, rather than to J2b. 
As these results demonstrates, it is very important to conduct a high resolution 
analysis by stratifying in subhaplogroups and for gender. For example, haplogroup H, 
the most common in Europe with a frequency of  30%-50%, is divided in numerous 
subhaplogroups, whose frequency is geographic-specific. Such a diversity could explain 
how differences in European countries are effectively noticed in association studies. 
Also, the strategy to collect subhaplogroups phylogenetically related, could be statistical 
informative, but not sufficiently biological exhaustive. 
Therefore, we investigated the relationship between haplogroups and aging 
through the analysis of age quartile, which has directed us to study subjects with an age 
superior to 96 years. For men, we identified 94 years as median, 92 years is the lower 
quartile value and 96 years is the upper quartile value. For women, we identified 94 
years as median, 93 years is the lower quartile value and 96 years is the upper quartile 
value. We decided to analyze the association between haplogroups and all 96+ years old 
subjects.  
Firstly we verified the association of this group of individuals with J2 haplogroup. 
By applying a Fisher exact test, J1 seems to be no significantly associated with this group 
of subjects (p=0.5337), J2 is again significant and associated with male controls 
(p=0.03302), in fact among males, 88% is represented by controls.  
Secondly, we calculated the significance for all subhaplogroups and also T2 
haplogroup resulted slightly significant (p=0.05). T2 is more represented in male 
controls than females even though it is tendentially over-represented in females either 
cases and controls. In T2 subjects younger than 96 years old no significant association 
was observed. Instead, H1 is now not significant (p=0.09).  
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This finding is almost expected because in the overall phylogenetic tree, 
haplogroup T is closest to haplogroup J, which is characterised by the HVR1 motif 
16069–16126 (Torroni et al. 1994; Richards et al. 1996) as well as coding region 
mutations at 4216, 10398, 11251, 12612, 13708, and 15452 (Torroni et al. 1994; 
Macaulay et al. 1999; Finnilä and Majamaa 2001). When considering HVR1 mutations, it 
is therefore the additional mutation at 16294 that defines haplogroup T, whereas 
haplogroup J is distinguished by the mutation at 16069. 
As we can see from these data, age is a strong limit and this interaction suggests 
that age 96, corresponding to upper quartile of our samples, could be considered as a 
threshold. These data allowed us to identify the subgroup of 90+ subjects (older than 96 
years of age) where J2 and T2 haplogroup has a stronger effect. 
 
2. Analysis of H1 and J2 in all European countries  
Therefore, we analyzed the distribution of H1 and J2 haplogroup in the 11 
European countries in order to discover, where it is possible, an association with one or 
more countries. By applying a Pearson's Chi-squared test to each country in the H1 
distribution, without taking into account gender, we verified that H1 is significantly 
associated with control  belonging to Greece (p=0.0455), Poland (p=0.01631) and highly 
associated with Newcastle (p=0.00604). But H1 inverts its trend in Belfast, Belgium, 
Montpellier, Finland and Sassari (being more represented in 90+ subjects of different 
countries than controls) even if they are not significant. If we stratify for gender, we 
could find that H1 is significantly associated with male controls confirming this 
association (data not reported). 
The same analysis has been used for J2 haplogroup distribution showing that J2 is 
associated with male controls belonging to Calabria (p=0.008151) and Greece 
(p=0.02535), which surprisingly represent the South Europe. As the distribution of this 
haplogroup evidences, J2 is not represented among 90+ subjects in Calabria and Greece 
but only among controls subjects. Even discarding Calabria and Greece, the distribution 
of J2 haplogroup is nearly balanced (for a total of 39 J2 cases and 45 J2 controls), but 
when considering these two areas, J2 seems to be more prevalent in controls. We 
conclude that Calabria and Greece determined this difference. The frequency in Calabria 
and Greece is high (respectively 4.6% and 4.8%) considering that J2 represents only 2% 
of the entire distribution (2.6% in controls and 1.8% in siblings). 
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The absence of association of mtDNA haplogroup J with longevity in southern 
Italian population (in Calabria) was in keeping with a study on southern Italian 
population (Dato et al. 2004) which revealed the absence of association of mtDNA 
haplogroup J with longevity in a southern Italian population. After that this association 
has been reported in three independent studies in northern Europeans, suggesting that 
the influence of mtDNA variability on longevity is population specific. Sequencing of 
HVS-I in Italian centenarians and controls has not revealed any clustering into a specific 
haplotype within haplogroup J (Rose et al. 2001). These data suggest that the association 
between mtDNA variants and longevity could be highly geographically or population 
dependent, as could be seen from other genetic studies on longevity (Franceschi et al. 
2005).  
Similarly, in the Japanese population, the C5178A transversion (characteristic of 
haplogroup D), was reported to be associated with longevity, being more frequent in 
centenarians than in a control group of younger subjects. But the same study confirmed 
an absence of association of haplogroup D with southern Chinese. This is likely to be due 
to the absence of old persons in the Chinese sample (the maximum age was 75 years 
old), but it is true that an association between haplogroup D and longevity exists and is 
specific of the Japanese population and thus absent in the Chinese group. 
 
3. The analysis of complete sequences 
Most of the pathological mtDNA mutations identified so far were probably the 
easiest to evidence at first, but according to many,they are only the most extreme 
fraction of a much larger group mutations that although "natural" are not necessarily 
"neutral". In recent years, for many other diseases and phenotypes, which lack a clear 
pattern of transmission, has been postulated a role for sequence variation in the 
"natural" sequence of the mtDNA and it was assumed that the "natural "forms of mtDNA, 
which can be very different from each other because of the high evolutionary rate of 
mtDNA, may modulate the expression not only of pathological mtDNA mutations, but 
also of nuclear genotypes. It is generally accepted that mtDNAs should be entirely 
sequenced. It is believed, in fact, that the entire sequence can hide non-functional 
polymorphisms that may be associated with a particular character and whose D-loop 
sequencing data does not give enough clarification on SNPs that characterize the 
genomic sequence. 
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The entire sequence also allows to identify all the polymorphisms, searching those 
really functional, and to identify any new mutations that may play a role in longevity and 
aging. 
Finally, the entire sequence, although much more expensive and laborious, allow a 
better resolution of haplogroups’ phylogeographic trees, which were widely 
documented (Torroni et al, 2006).  
In order to assess whether J2 and T2 haplogroups harboured mutations involved 
in longevity, we investigated the complete mtDNA sequences of our J2 and T2 subjects 
among complete sequences. Since J2 and T2 are not present among 90+ subjects of 
Greece and Calabria, we cannot analyze them. We focused on the complete sequences of 
Denmark and Finland, sequenced by Chinese Partner, and more numerous than our 
samples. We did not find any particular mutation in J2, while in T2 we found some 
mutated position hitting the control region. In particular the mutation A189G is 
observed in 17.3% of siblings and in 2.9% controls and this difference is slightly 
statistically significant (p=0.046). It has been reported that CR mutation A189G 
accumulates with age in skeletal muscle (Wang et al. 2001, Zhang et al. 2003) and is 
germline transmitted polymorphism associated with specific mtDNA haplogroups (in 
this case with haplogroup T). Thus, it appears that each tissue may accumulate its own 
unique somatic mtDNA CR mutations with age, but some of these same variants might 
also be inherited. 
Two additional mtDNA CR mutations has been detected, T195C and C150T. The 
first was observed only in mtDNAs controls in a percentage of 23.6% (p=0.011), the 
second is present only in mtDNAs of 90+ subjects and not in controls even if this 
distribution is not significant. The story of C150T is a bit complicated; it accumulates 
with age in skin fibroblasts, but is also present in the blood cell lymphocytes of 
centenarians and twins. Rose et al. (2007) reported the association of the C150T 
mutation with centenarians (and in particular the high level of heteroplasmy) 
suggesting to the authors that the C150T imparts resistance to stress and thus promotes 
longevity. Yet, this mutation has also been reported to be an inherited polymorphism in 
some instances. 
We have compared the number of mutations along mtDNA molecule by mtDNA 
regions for J2 and T2 haplogroups. We found that the percentage of mutations in the D-
loop of subjects resulted in J2 is significantly higher in controls than in cases (p=0.0001). 
In almost all regions, mutations seem to be more numerous in controls than cases. In 
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particular, ND1 and ND2 show a slightly higher percentage of mutation in controls than 
in cases, as well as the COI region shows a similar trend (4.29% vs controls. 3.50% in 
cases). While for T2 the frequency of mutation accumulation in each region is quite 
similar both in cases and controls. As for J2, we do not notice any significant difference 
between cases and controls in the regions of ND1 and ND2, while the percentage of 
mutations in the COI is higher (3.99% vs. 3.0%), once again, in controls than in cases. 
These data are not statistically significant but a trend that favors mutations in controls 
compared to cases is clear.  
ND1 is thought that, if hit by mutations, it is able to bypass the “obstacle” or 
preventing the onset of OXPHOS itself, or using other mechanisms. The situation is quite 
different for the COI, which belongs to complex IV. If the COI is affected by many 
mutations, it is unable to cope with this situation and to bypass the site of damage. The 
OXPHOS crashes and this leads to an event even more dangerous with further 
accumulation of ROS. 
In addition we found that sporadic mutations are more numerous in controls than 
in cases both in J2 and T2. As regard J2 complete sequences, 23 sporadic mutations are 
observed in in 90+ subjects while 30 in controls. This fact could mean that there are 
more deleterious mutations which could lead to a further decreasing of the performance 
in a very negative way. Controls have 5 non coding mutations, 9 synonymou mutations 
and 16 amminoacid changes. But we have found that there are 90+ subjects belonging to 
J2 haplogroup. Why? We investigated tha mutations which lead to amminoacid change 
and we discovered that they hit different genes. Intringuingly, we notice that 90+ 
subjects’ mtDNAs have 4 sporadic mutations hitting tRNA and rRNA genes, totally 
absent in the control subjects. We already know that J2 haplogroup is characterized by a 
low OXPHOS performance and by a low ROS production as a consequence, as previously 
anticipated, and we hypotize that these mutations in tRNA and rRNAs could lead to a 
further decreasing of ROS production. This advantageous situation could compense the 
disadvantageous effect of J2. We investigated the accumulation of non-synonymous 
mutations both in nonagenarians and control subjects and we discovered that there is 
an higher number of these mutations in controls than in nonagenarians in complex IV 
and in particular in cyt c subunitI. The same was observed for T2 even though this data 
is not significant. 
As regard T2 sporadic mutations’ accumulation, we found the same trend as seen 
in J2. A number of 13 sporadic mutations tRNA plus rRNA genes from 90+ subjects 
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mtDNAs and only one sporadic mutation in controls. The same mechanisms can be 
hypotized for T2 haplogroup. 
So the complete re-sequencing revealed that 90+ subjects showed a trend towards 
a higher number of sporadic mutations in tRNA and rRNA genes when compared with 
controls. 
 
4. Final consideration on the association study 
We have found an association between H1, J2 and T2 haplogroups and male 
controls.  
Each of the mtDNA haplogroups is determined by a few ancient polymorphism, 
even though they harbour a great number of other nucleotide variants. Polymorphisms 
in mtDNA may be mildly deleterious, causing a subtle decrease in OXPHOS activity and 
an increase in the frequency of somatic mtDNA mutations. The differences in mtDNA 
haplogroup frequencies between the present 90+ group subjects and the controls 
suggest either a contribution from mildly deleterious polymorphisms that shorten the 
life span in the younger age groups or from advantageous polymorphisms that lengthen 
the life span in the elderly. Our data appear to favour the presence of disadvantageous 
polymorphisms and support a role for mitochondria and mtDNA in the degenerative 
processes involved in ageing. 
It has been proposed that J haplogroup represents a paradox (Rose et al, 2001) 
because it is associated with longevity on one hand, but on the other hand it shows 
similar characteristic to that found in association with several complex diseases, for 
example the Leber Hereditary Optic Neuropathy (LHON). In fact, it has been found that 
haplogroup J seems to boost the effect of mutations causing this disease and thus 
contributing to optic neuritis in multiple sclerosis patients. Indeed, a relationship 
between OXPHOS performance and haplogroups exists. 
Haplogroup J seems to have a border line status because a low OXPHOS 
performance could lead to a reducing in the production of ROS (through an increase in 
detoxifying enzymes, due to nuclear genes). In this way, a low OXPHOS performance 
may not necessarily be detrimental  for the cell. On the other hand, this situation could 
put the cell in a vulnerable situation where a further single mutation (for example 11778 
in LHON) would be even more damaging (see paragraph 8 of Chapter 2).  
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Intriguingly, haplogroup T shows a significantly less efficient OXPHOS respect to H 
(Ruiz-Pesini et al, 2000). Also the mutations defining the haplogroup J hit particularly 
the complex I protein subunits and partly share with haplogroup T.  
It seems that there is a strong similarity between these two haplogroups, in fact we 
found that both are significantly associated with male controls. 
But why were these phenomena not observed in females? Different findings 
support the difference in gene/aging  association studies in males and females (Ivanova 
et al 1998). Longevity is a multifactorial trait in which a phenotypic effect of a gene 
depends on the physiological background where the gene is expressed. The effect of 
mtDNA variability on successful aging could vary between sexes, since males and 
females have a different physiological aspect. It is known that life expectancy is 
significantly higher in females than in males for a gender effect and probably for this 
reason we have found the association of J2, as risk factor, with male controls. 
Another question is: why have not we found J2 represented in Southern Europe? 
The mitochondrial genome is highly variable and a continent-specific haplogroup may 
include mtDNA mutations that only occur in a specific ethnic group. Also genetic and 
environmental background can influence the effect of mtDNA mutations on a complex 
trait, such as longevity. It is extremely important to remember that the mtDNA 
haplogroup J, which is believed to have entered Europe about 10 000 years ago from the 
Near East, is characterized by a low efficiency of oxidative phosphorylation. This may 
favors the onset of either complex diseases or longevity, according to the genetic 
background of the carriers. It has been proposed that a low efficiency of oxidative 
phosphorylation leads to a waste of heat which represents an advantage in the cold 
climate of northern Europe; on turn, the cold climate of northern Europe seems to have 
favored the accumulation of further mutations emphasizing this feature of the J 
molecules. Therefore, the population-specific association of mtDNA haplogroup J with 
longevity may be due to population-specific genetic backgrounds, to particular 
interactions between haplogroup J and different environments, and/or to diversity of 
the J molecules between northern and southern European populations. In this regard, it 
is important to continue to have rapid and cheap genetic markers, such as haplogroups, 
to test the role of mtDNA on longevity in various populations from various geographical 
areas. For example, the Mt5178A mutation found in Japanese centenarians (Tanaka et al, 
2000) and postulated to decelerate the accumulation of mtDNA mutations in somatic 
cells with advancing age, is included in the M haplogroup, but virtually absent in Europe. 
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Similarly, it is important to point out that any specific nucleotide, or haplogroup 
defining, mtDNA polymorphism associated with aging, may not directly involved but 
simply acting as a marker for other tightly linked polymorphisms occurring elsewhere in 
the mtDNA genome that directly could affect longevity. 
 
5. The cluster analysis and MDS analysis 
In this thesis, we have also conducted a cluster analysis on the differences of all 
haplogroups frequencies in all countries. In general the calculation of cluster analysis is 
based on the distance between two elements based on Euclidean distance, or more 
simply the geometric distance in the multidimensional space. The good quality of 
analysis depends on how the distance is calculated.  
More precisely, this aggregation has been built recording for each nation 
differences among frequencies related to cases and controls for all the haplogroups, 
except for N1, OTHER and R0A because too less numerous. The cluster analysis 
evidenced two groups, both statistical significative: one including all Calabria, Bologna, 
Roma and Sassari belonging to Italy, Germany, Montpellier and Belgium belonging to 
Central Europe and Denmark (p=0.01386), the second including all the northern 
European countries plus Greece, which might have been collocated in the first group, 
near to Calabria and Mediterranean area (p-value=0.006723). 
Perola et al. (2008, data not yet published) conducted the same analysis on the 
nuclear genome of GEHA samples and found that Finland may distance itself from the 
other countries. On the basis of this result, we decided to force our analysis by grouping 
countries into three clusters: Finland, Europe (including Denmark, Belfast, Newcastle, 
Netherland, Belgium, Germany, France, Poland, Ukraine) and Mediterranean area 
(Bologna, Roma, Calabria, Sassari, Greece). As expected, Finland is the country with the 
maximum divergence rate, it means that its overall haplogroup distributions deeply 
differ from that of the rest of countries. The same result was obtained by conducting a 
MDS  (Multidimensional scaling) analysis. Again Finland is isolated from other countries, 
while all the Northern countries are in the middle of the graph, near among them. Also 
Mediterranean area countries are close by each other. Greece is one more time the 
nearest country to Finland.  
Why Finland is so isolated? It is known that geographical and cultural isolation has 
greatly shaped Finnish gene pool towards homogeneity, as can be seen for example in 
certain recessive diseases which are infrequent elsewhere (Norio et al. 1973). The 
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oldest settlement in Finland dates back approximately 9,000 years and a second wave of 
settlers arrived in the southern parts of Finland around 5,500 years ago. Permanent 
settlement extended across southern Finland and along the coast and riversides of 
Ostrobothnia in the 16th century (Norio et al. 1973). About 40% of the Finns belong to 
haplogroup H, which is the most common haplogroup in Europe but rare among Asians 
(Torroni et al. 1996, Richards et al. 1998). Also haplogroup U (16-28%), J (4.5-14%), W 
(4.1-9.2%) and T (2.5-6.1%) are frequent among Finns. The remaining European 
haplogroups, I, K, V and X, are less common, as in other parts of Europe, each with 
frequency below 5.5% in both studies.  
This means that Finland has different haplogroup frequencies from other 
European countries, for examples, haplogroup J in Finland has a frequency of 8%, in Italy 
about 2%.  
From the cluster analysis and MDS analysis we have noticed that the nearest 
country to Finland was Greece. Why? There are not scientific evidences or literature 
supporting this similarity, but an emerging theory could explain it. About the historical 
studious Felice Vinci, the Achaeans would have lived in the early II millennium B.C. on 
the Baltic coast and in the middle of the millennium, following a tightening of the 
climate, as identified in this age by paleoclimatology, they would have moved southward 
along the Dnepr river reaching the Black Sea and the Aegean. The newcomers have 
founded the Mycenaean City and they would have given to the new places the same 
names of northern cities, but they are not fully responsive to their original geographical 
location, due to differences in conformation of the two regions. The main argument is 
represented by inconsistencies detected by Vinci between the geography described by 
Homer in his Iliad and Odyssey and the conformation on the Mediterranean lands, 
already noticed by Strabo. Also the climate description in Homeric poems would better 
adapt to Baltic region rather than Mediterranean. 
This is only a theory since we have no scientific support to our observation. 
 
6. The network analysis 
The haplogroup J network based on sequence variation in the control region could 
be divided into two subclusters that confirmed the subdivision proposed previously 
(Torroni et al. 1997). 
The overall phylogenetic network was based on 281 J haplogroup females (137 
sibs and 144 controls) and 112 J haplogroup males (46 sibs and 66 controls). In order to 
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analyze the different haplotype distribution among nations, a median-joining network 
was also constructed for the HVS-I and HVS-II sequence data (16080-300 segment 
region) of all J samples. We have individuate the median vectors in female and male 
network representing a branch point between J2a and J2b. In particular in female 
network we have identified the median vector 3 from which we found the ancient 
polymorphisms 150 and 152, then the median vector 9 which divides J2a from J2b. J2a is 
defined by polymorphisms 195, 215, 16145, 16231 and 16261, J2b by 16193. In male 
network we see that median vector 10 is responsible of the division between J2a and 
J2b.  As for female network, J2 is characterize by 150 and 152 mutations, J2a is defined 
in this case by polymorphisms 195, 16145 and 16261, J2b by 16193. 
There are several obvious features of the phylogenetic network for the haplogroup 
J. In female network subhaplogroup J2a, J2b and J1b take the form of star-like clusters, 
whereas J1c do not exhibit the pattern of a dominant central node with more than one 
node, radiating out from it. The star-like shape of network indicates population 
expansion. 
As regard male network (figure 28), we observed that only J2a and J1b have a star-
like cluster, J1c has different central nodes, as in females network, while J2b do not 
present a specific cluster. It is interesting to notice that in J2b cluster different cycles are 
present and in particular the most recurring mutation is 16261, representative of this 
haplogroup. 
Another striking aspect of these networks is that there are areas with a form 
different from tree branch, rather they contain reticulations. This kind of conformation 
is more frequent in males than in females, in fact a closer inspection of the edges in the 
male network reveals that several of these cycles contain edges that correspond to 
mutations at nucleotide 228, typical of J1c.  
At the end, we tried to focus on geographical distribution of J haplogroup in all the 
European countries, members of the European Project GEHA. We cannot observe any 
particular distribution; we only can this nation, as previously reported (Finnila et al. 
2000). 
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Chapter 7 
 
CONCLUSIONS 
 
It can be concluded that the studies of associations between haplogroups and 
longevity or healthy aging is still an open field of research. 
The development of high-throughput genotyping technologies has greatly 
increased the feasibility of comprehensive associatin studies of the mitochondrial 
genome. 
Stratifing by sex, significant differences were found between controls and 90+ 
subjects and we found the association of J2 with males controls. Even when we consider 
the age and particularly subjects with an age over 96 years, in addition to J2, whose 
significance was confirmed,  T2 was significant. 
In general, we can confirm that the association of J2 is population dependent and 
that the population-specific association of mtDNA haplogroup J with longevity may be 
due to population-specific genetic backgrounds, to particular interactions between 
haplogroup J and different environments, and/or to diversity of the J molecules between 
northern and southern European populations. 
These observation were possible because the number of recruited samples were 
too high that it allowed to obtain sufficient data for statistical analysis; this is defined as 
the power of GEHA. 
We also analyzed the entire sequences in oder to understand if there were any 
particular mutations in the coding region which can justify such associations. In fact, 
from this analysis we observed a higher percentage of mutations in controls compared 
with sibs, which could have a negative role and could justify the association of J2 with 
the controls as a risk factor. The fact that a higher percentage of mutations in tRNA and 
rRNA accumulate only in sibs, might have a beneficial effect on them. 
Finally, the GEHA project has planned the collection of phenotypic data of each 
patient (BMI, handgrip, cognitive and functional Activities, hypercholesterolemia, 
diseases, etc. ..). It would be interesting to stratify for these data because there could be a 
hidden association between haplogroups and a particular phenotype. 
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APPENDIX 
 
 
TBE 5X (TRIS BORATO EDTA) 1L 
 
54 gr TRIS BASE 
27,5 gr boric acid 
20 ml  EDTA 0,5X pH=8 
 
TBE 0,5X 1L 
100 ml TBE 5X 
900 ml distilled H2O  
 
AGAROSE GEL 1,5% IN TBE 0.5X 250 ML 
 
250 ml TBE 0,5X 
3,75 gr agarose 1.5% 
12,5 ml Ethidium Bromide (5 μl in 100 ml) 
 
EDTA 
 
P.M.=372.24 g/mol 
A final volume of 50 ml at concentration 125 mM: 
Moles=0.125M·0.050 l= 0.00625 moles 
Grams: 0.00625·372.24=2.33g 
 
NaAc 
 
P.M.=82.03 g/moli 
A final concetration of 3M pH=4.6. 
Moles= 3M·0.2 l=0.6 moles 
Grams= 0.6 moli·82.03 g/moles=49.218g 
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90+ sibpair (n=2,086)   controls (n=2,153) 
sub-haplogroups N % SE  sub-haplogroups N % SE 
H* 366 17,55 0,0083   H* 357 16,58 0,0080 
H1 292 14,00 0,0076  H1 325 15,10 0,0077 
H2 42 2,01 0,0031   H2 23 1,07 0,0022 
H3 71 3,40 0,0040  H3 85 3,95 0,0042 
H4 5 0,24 0,0011   H4 9 0,42 0,0014 
H5 68 3,26 0,0039  H5 63 2,93 0,0036 
H6 52 2,49 0,0034   H6 47 2,18 0,0031 
H7 18 0,86 0,0020  H7 10 0,46 0,0015 
H8 4 0,19 0,0010   H8 0 0,00 0,0000 
H9 9 0,43 0,0014  H9 5 0,23 0,0010 
HV0a 13 0,62 0,0017   HV0a 6 0,28 0,0011 
HV0* 70 3,36 0,0039  HV0* 62 2,88 0,0036 
HV1 4 0,19 0,0010   HV1 5 0,23 0,0010 
HV2 1 0,05 0,0005  HV2 0 0,00 0,0000 
HV* 42 2,01 0,0031   HV* 50 2,32 0,0032 
V 27 1,29 0,0025  V 33 1,53 0,0026 
I 25 1,20 0,0024   I 21 0,98 0,0021 
I1 9 0,43 0,0014  I1 12 0,56 0,0016 
I3 12 0,58 0,0017   I3 11 0,51 0,0015 
J1 9 0,43 0,0014  J1 8 0,37 0,0013 
J1b 25 1,20 0,0024   J1b 27 1,25 0,0024 
J1c 109 5,23 0,0049  J1c 117 5,43 0,0049 
J1d 1 0,05 0,0005   J1d 1 0,05 0,0005 
J2 2 0,10 0,0007  J2 7 0,33 0,0012 
J2a 25 1,20 0,0024   J2a 32 1,49 0,0026 
J2b 12 0,58 0,0017  J2b 18 0,84 0,0020 
K 13 0,62 0,0017   K 15 0,70 0,0018 
K1 13 0,62 0,0017  K1 12 0,56 0,0016 
K1a 79 3,79 0,0042   K1a 91 4,23 0,0043 
K1b 0 0,00 0,0000  K1b 1 0,05 0,0005 
K1c 25 1,20 0,0024   K1c 36 1,67 0,0028 
K2 7 0,34 0,0013  K2 6 0,28 0,0011 
N1a 8 0,38 0,0014   N1a 5 0,23 0,0010 
N1b 12 0,58 0,0017  N1b 15 0,70 0,0018 
N1c 2 0,10 0,0007   N1c 3 0,14 0,0008 
N9a 2 0,10 0,0007  N9a 1 0,05 0,0005 
R0 3 0,14 0,0008   R0 3 0,14 0,0008 
R0a 12 0,58 0,0017  R0a 10 0,46 0,0015 
R1a 1 0,05 0,0005   R1a 1 0,05 0,0005 
R2 0 0,00 0,0000  R2 4 0,19 0,0009 
T 6 0,29 0,0012   T 6 0,28 0,0011 
T1 4 0,19 0,0010  T1 5 0,23 0,0010 
T1a 38 1,82 0,0029   T1a 44 2,04 0,0030 
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T1b 1 0,05 0,0005  T1b 4 0,19 0,0009 
T2 50 2,40 0,0033   T2 44 2,04 0,0030 
T2a 7 0,34 0,0013  T2a 2 0,09 0,0007 
T2b 104 4,99 0,0048   T2b 94 4,37 0,0044 
T2c 7 0,34 0,0013  T2c 5 0,23 0,0010 
T2e 6 0,29 0,0012   T2e 6 0,28 0,0011 
T2f 0 0,00 0,0000  T2f 1 0,05 0,0005 
U 2 0,10 0,0007   U 4 0,19 0,0009 
U1 4 0,19 0,0010  U1 3 0,14 0,0008 
U1a 4 0,19 0,0010   U1a 11 0,51 0,0015 
U1b 2 0,10 0,0007  U1b 0 0,00 0,0000 
U1c 0 0,00 0,0000   U1c 1 0,05 0,0005 
U2 13 0,62 0,0017  U2 13 0,60 0,0017 
U2d 1 0,05 0,0005   U2d 0 0,00 0,0000 
U2e 24 1,15 0,0023  U2e 26 1,21 0,0024 
U3 11 0,53 0,0016   U3 5 0,23 0,0010 
U3a 11 0,53 0,0016  U3a 7 0,33 0,0012 
U3b 0 0,00 0,0000   U3b 1 0,05 0,0005 
U4 14 0,67 0,0018  U4 21 0,98 0,0021 
U4a 15 0,72 0,0018   U4a 17 0,79 0,0019 
U4b 5 0,24 0,0011  U4b 10 0,46 0,0015 
U5 0 0,00 0,0000   U5 3 0,14 0,0008 
U5a 90 4,31 0,0044  U5a 109 5,06 0,0047 
U5b 51 2,44 0,0034   U5b 56 2,60 0,0034 
U6a 6 0,29 0,0012  U6a 11 0,51 0,0015 
U7 7 0,34 0,0013   U7 3 0,14 0,0008 
U8 3 0,14 0,0008  U8 3 0,14 0,0008 
U8a 4 0,19 0,0010   U8a 1 0,05 0,0005 
U8b 4 0,19 0,0010  U8b 8 0,37 0,0013 
U9 1 0,05 0,0005   U9 0 0,00 0,0000 
W 29 1,39 0,0026  W 26 1,21 0,0024 
W1 1 0,05 0,0005   W1 1 0,05 0,0005 
W4 13 0,62 0,0017  W4 1 0,05 0,0005 
W5 6 0,29 0,0012   W5 3 0,14 0,0008 
W6 2 0,10 0,0007  W6 8 0,37 0,0013 
X 12 0,58 0,0017   X 13 0,60 0,0017 
X1 0 0,00 0,0000  X1 2 0,09 0,0007 
X2 11 0,53 0,0016   X2 6 0,28 0,0011 
X2a 2 0,10 0,0007  X2a 0 0,00 0,0000 
X2b 15 0,72 0,0018   X2b 12 0,56 0,0016 
X2c 2 0,10 0,0007  X2c 8 0,37 0,0013 
OTHER 8 0,38 0,0014   OTHER 12 0,56 0,0016 
Tab. 1: Frequencies of all mtDNA sub-haplogroups in 2,086 90+ sibpairs and 2,153 controls from all over 
Europe.  
 
 128 
 
Fig. 1: Graphical distribution of all 90+ and controls subhaplogroups. 
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